
<html lang="en"     class="pb-page"  data-request-id="4b63753f-1bc9-430b-810b-0ccdd952b378"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-2;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01153;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models" /></meta><meta name="dc.Creator" content="Jianjun  Cheng" /></meta><meta name="dc.Creator" content="Patrick M.  Giguere" /></meta><meta name="dc.Creator" content="Claire M.  Schmerberg" /></meta><meta name="dc.Creator" content="Vladimir M.  Pogorelov" /></meta><meta name="dc.Creator" content="Ramona M.  Rodriguiz" /></meta><meta name="dc.Creator" content="Xi-Ping  Huang" /></meta><meta name="dc.Creator" content="Hu  Zhu" /></meta><meta name="dc.Creator" content="John D.  McCorvy" /></meta><meta name="dc.Creator" content="William C.  Wetsel" /></meta><meta name="dc.Creator" content="Bryan L.  Roth" /></meta><meta name="dc.Creator" content="Alan P.  Kozikowski" /></meta><meta name="dc.Description" content="A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonis..." /></meta><meta name="Description" content="A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonis..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 13, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01153" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01153" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01153" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01153" /></link>
        
    
    

<title>Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01153" /></meta><meta property="og:title" content="Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0009.jpeg" /></meta><meta property="og:description" content="A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors. ADMET assays showed that compound (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile. Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol. These data support the further development of (+)-22a as a drug candidate for the treatment of schizophrenia." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01153"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01153">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01153&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01153&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01153&amp;href=/doi/10.1021/acs.jmedchem.5b01153" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 578-591</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01092" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01369" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Cheng">Jianjun Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+M.++Giguere">Patrick M. Giguere</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claire+M.++Schmerberg">Claire M. Schmerberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vladimir+M.++Pogorelov">Vladimir M. Pogorelov</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramona+M.++Rodriguiz">Ramona M. Rodriguiz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xi-Ping++Huang">Xi-Ping Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hu++Zhu">Hu Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++McCorvy">John D. McCorvy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+C.++Wetsel">William C. Wetsel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+L.++Roth">Bryan L. Roth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+P.++Kozikowski">Alan P. Kozikowski</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">National Institute of Mental Health Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine Analysis Core Facility, Duke University Medical Center, Durham, North Carolina 27710, United States</span></div><div class="corresp-info"><strong>*</strong>Telephone: +1 312 996-7577. E-mail: <a href="/cdn-cgi/l/email-protection#9bf0f4e1f2f0f4ecfadbeef2f8b5feffee"><span class="__cf_email__" data-cfemail="7c1713061517130b1d3c09151f52191809">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01153&amp;href=/doi/10.1021%2Facs.jmedchem.5b01153" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 578–591</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 24, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 July 2015</li><li><span class="item_label"><b>Published</b> online</span>13 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01153</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D578%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJianjun%2BCheng%252C%2BPatrick%2BM.%2BGiguere%252C%2BClaire%2BM.%2BSchmerberg%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D2%26contentID%3Dacs.jmedchem.5b01153%26title%3DFurther%2BAdvances%2Bin%2BOptimizing%2B%25282-Phenylcyclopropyl%2529methylamines%2Bas%2BNovel%2BSerotonin%2B2C%2BAgonists%253A%2BEffects%2Bon%2BHyperlocomotion%252C%2BPrepulse%2BInhibition%252C%2Band%2BCognition%2BModels%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D591%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01153"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1485</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01153" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;M. Giguere&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;M. Schmerberg&quot;},{&quot;first_name&quot;:&quot;Vladimir&quot;,&quot;last_name&quot;:&quot;M. Pogorelov&quot;},{&quot;first_name&quot;:&quot;Ramona&quot;,&quot;last_name&quot;:&quot;M. Rodriguiz&quot;},{&quot;first_name&quot;:&quot;Xi-Ping&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Hu&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. McCorvy&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;C. Wetsel&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;L. Roth&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;P. Kozikowski&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;578-591&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01153&quot;},&quot;abstract&quot;:&quot;A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT2C agonists. Compound (+)-22a was identified as a potent 5-HT2C receptor agonist, with good selectivity against the 5-HT2B and the 5-HT2A receptors. ADMET assays showed that compound (+)-22a possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile. Evaluation of (+)-22a in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced d-amphetamine-stimulated hyperlocomotion in the open field test, it restored d-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol. These data support the further development of (+)-22a as a drug candidate f&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01153&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01153" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01153&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01153" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01153&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01153" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01153&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01153&amp;href=/doi/10.1021/acs.jmedchem.5b01153" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01153" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01153" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01153%26sid%3Dliteratum%253Aachs%26pmid%3D26704965%26genre%3Darticle%26aulast%3DCheng%26date%3D2016%26atitle%3DFurther%2BAdvances%2Bin%2BOptimizing%2B%25282-Phenylcyclopropyl%2529methylamines%2Bas%2BNovel%2BSerotonin%2B2C%2BAgonists%253A%2BEffects%2Bon%2BHyperlocomotion%252C%2BPrepulse%2BInhibition%252C%2Band%2BCognition%2BModels%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D2%26spage%3D578%26epage%3D591%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/jmcmar.2016.59.issue-2/20160128/jmcmar.2016.59.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of novel compounds with two halogen substituents have been designed and synthesized to further optimize the 2-phenylcyclopropylmethylamine scaffold in the quest for drug-like 5-HT<sub>2C</sub> agonists. Compound (+)-<b>22a</b> was identified as a potent 5-HT<sub>2C</sub> receptor agonist, with good selectivity against the 5-HT<sub>2B</sub> and the 5-HT<sub>2A</sub> receptors. ADMET assays showed that compound (+)-<b>22a</b> possessed desirable properties in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain penetration profile. Evaluation of (+)-<b>22a</b> in animal models of schizophrenia-related behaviors revealed that it had a desirable activity profile, as it reduced <i>d</i>-amphetamine-stimulated hyperlocomotion in the open field test, it restored <i>d</i>-amphetamine-disrupted prepulse inhibition, it induced cognitive improvements in the novel object recognition memory test in NR1-KD animals, and it produced very little catalepsy relative to haloperidol. These data support the further development of (+)-<b>22a</b> as a drug candidate for the treatment of schizophrenia.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Schizophrenia is a severe mental disease that affects 1% of the population in the US and more than 21 million people worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is a disease of complex etiology with likely more than 100 genetic loci and unspecified nongenetic contributing factors.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> At least three types of symptoms exemplify schizophrenia: positive, negative, and cognitive. The available antipsychotic drugs are effective against positive symptoms while having minimal effects on cognitive and negative symptoms.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a></div><div class="NLM_p">The 5-HT<sub>2C</sub> receptor has recently been identified as a promising drug target for the treatment of a variety of central nervous system (CNS) disorders, including obesity, schizophrenia, and substance abuse.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Lorcaserin (<b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and vabicaserin (<b>2</b>) are two representative 5-HT<sub>2C</sub> agonists that have been developed and studied in clinical trials for these indications. Lorcaserin is the first-in-class 5-HT<sub>2C</sub> agonist that has won FDA approval in 2012 for the treatment of obesity, and a clinical trial to evaluate its use in smoking cessation has also been completed, with the results remaining to be disclosed.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Vabicaserin was studied in clinical trials for the treatment of acute schizophrenia, in which it demonstrated significant therapeutic effects and achieved a proof-of-concept, but it failed to meet the primary efficacy objective.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> For many years it has been appreciated that 5-HT<sub>2C</sub> receptor function might be altered in schizophrenia and that the 5-HT<sub>2C</sub> antagonist activity of certain atypical antipsychotic drugs might be associated with weight gain and adverse metabolic consequences.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11-14)</a> Advantages of the 5-HT<sub>2C</sub> receptor as a drug target for treating schizophrenia and related disorders include the following: (1) activation of 5-HT<sub>2C</sub> receptors specifically decreases mesolimbic dopamine release without affecting nigrostriatal dopamine;<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> thus, it is predicted to have antipsychotic efficacy while causing few extrapyramidal symptoms (EPS); (2) 5-HT<sub>2C</sub> agonists are known to induce weight loss, and thus such drugs should lack the undesired side effect of weight gain and related metabolic disorders, which have been associated with most current antipsychotic drugs.<a onclick="showRef(event, 'ref14 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref16">(14, 16)</a> Additionally, activation of the 5-HT<sub>2C</sub> receptor has been demonstrated to counter cognitive deficits induced by <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) antagonism,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> as well as to overcome cognitive deficits in animals bearing the human tryptophan hydroxylase 2 (Tph2) loss of function mutation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Therefore, developing safe 5-HT<sub>2C</sub> agonists for the treatment of schizophrenia could potentially address the cognitive deficits associated with this disease with fewer EPS and a lower risk of causing weight gain.</div><div class="NLM_p">The greatest challenge for developing 5-HT<sub>2C</sub> receptor agonists is their selectivity against the other two related receptors of the 5-HT<sub>2</sub> subfamily, namely 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>. Activation of 5-HT<sub>2A</sub> receptors in the CNS has been reported to be associated with hallucinogenic effects,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> while activation of 5-HT<sub>2B</sub> receptors in the periphery produces valvulopathy and pulmonary hypertension as has been observed with the use of dexfenfluramine.<a onclick="showRef(event, 'ref7 ref20'); return false;" href="javascript:void(0);" class="ref ref7 ref20">(7, 20)</a> The FDA-approved drug lorcaserin was reported to have 100-fold selectivity for 5-HT<sub>2C</sub> relative to the 5-HT<sub>2B</sub> subtype; however, it possesses full agonist activity at 5-HT<sub>2B</sub> with moderate potency (EC<sub>50</sub> = 943 ± 90 nM, <i>E</i><sub>max</sub> = 100%),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and lorcaserin was reported to cause a higher incidence of cardiac valve disorders in clinical trials compared to the placebo group.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We previously reported on a series of novel compounds that have excellent selectivity for 5-HT<sub>2C</sub> receptors which are composed of a 2-phenylcyclopropylmethylamine scaffold.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23-26)</a> Among the reported compounds, analogues <b>3</b>–<b>6</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) were identified to possess moderate to excellent pharmacological profiles, and they are now undergoing further evaluation in preclinical models.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of lorcaserin (<b>1</b>), vabicaserin (<b>2</b>), and compounds <b>3</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to the relatively small structural scaffold of the 2-phenylcyclopropylmethylamines and the very strict steric limitations applying to these compounds as revealed by previous structure–activity relationship (SAR) studies, adding a second halogen atom to the benzene ring appeared to offer a practical approach to further enhancing ligand potency and possibly metabolic stability. Decoration of the aromatic ring of a drug candidate with halogen atoms, especially fluorine and chlorine, has been used extensively in medicinal chemistry.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The role of halogen substituents in enhancing ligand potency as well as in optimizing pharmacokinetic properties is well-known. The incorporation of multihalogen atoms is exemplified by drugs not only for peripheral diseases such as sitagliptin (<b>7</b>)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and crizotinib (<b>8</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> but also for CNS drugs such as aripiprazole (<b>9</b>)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Moreover, the role of halogen binding in protein–ligand interactions has been studied recently,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and halogen bonds have been proposed to provide molecular interactions orthogonal to hydrogen bonds.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The lipophilicity of halogen atoms, which enhances the LogP values of small molecules, might also improve the blood–brain barrier (BBB) permeability of compounds designed for CNS indications.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative drugs having a multihalogen substitution pattern and the general structure of new 2-phenylcyclopropylmethylamines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by the promising results that had been achieved for the monohalogenated compounds,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and the possible beneficial effect of a second halogen, we synthesized a new series of compounds containing two halogen substituents on the benzene ring, as depicted by the general structure <b>10</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The synthesis and SAR results are described herein, along with the ADMET evaluation and efficacy study of a key compound in four different schizophrenia-related animal behavioral models.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Chemical Synthesis and Pharmacological Profiling</h3><div class="NLM_p">The synthesis of the dihalogenated compounds was achieved employing methods similar to those reported by us previously, starting from the corresponding benzaldehydes. Thus, various dihalogenated benzaldehydes <b>11a</b>–<b>g</b> were purchased or prepared according to literature methods (for details, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, the benzaldehydes <b>11a</b>–<b>g</b> were converted to the corresponding acrylamides <b>12a</b>–<b>g</b>, with the double bond in the <i>E</i> configuration, using the commercially available Wittig reagent <i>N</i>-methoxy-<i>N</i>-methyl(triphenylphosphoranylidene)acetamide. This reagent was preferred over ethyl 2-(triphenylphosphoranylidene)acetate due to the facts that better or complete <i>E</i> selectivity was observed for the newly formed double bond and that the subsequent cyclopropanation step proceeds more efficiently with α,β-unsaturated Weinreb amides than with esters.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> The acrylamides <b>12a</b>–<b>g</b> were then subjected to the Corey–Chaykovsky cyclopropanation reaction to generate the cyclopropanes <b>13a</b>–<b>g</b> as their trans isomers, using the sulfur ylide generated from trimethylsulfoxonium iodide by treatment with sodium hydride. Next, sequential reduction using DIBAL-H followed by sodium borohydride provided alcohols <b>14a</b>–<b>g</b> in good yields. Mitsunobu reactions of <b>14a</b>–<b>g</b> with phthalimide produced the phthalimides <b>15a</b>–<b>g</b> in excellent yields. Deprotection of these imides with hydrazine hydrate afforded the primary amines, which were protected as their Boc intermediates <b>16a</b>–<b>g</b>. Demethylation of intermediates <b>16a</b>–<b>g</b> with BBr<sub>3</sub> in dichloromethane afforded the phenol intermediates <b>17a</b>–<b>g</b>. In our previous SAR studies,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> the analogues containing 2-fluoroethyl and allyl ether moieties were found to provide compounds with the best pharmacological profiles. Thus, the phenols <b>17a</b>–<b>g</b> were converted to the 2-fluoroethyl ethers <b>18a</b>–<b>g</b> using Mitsunobu conditions while alkylation of <b>17a</b>–<b>g</b> with allyl bromide afforded allyl ethers <b>19a</b>–<b>g</b>. The racemic compounds <b>16a</b>–<b>g</b>, <b>18a</b>–<b>g</b>, and <b>19a</b>–<b>g</b> were then resolved by chiral preparative-HPLC to provide both the (−)- and (+)-enantiomers, which were then deprotected with HCl in ether to afford both enantiomers of compounds <b>20a</b>–<b>g</b>, <b>21a</b>–<b>g</b>, and <b>22a</b>–<b>g</b> as their HCl salts.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>20a</b>–<b>g</b>, <b>21a</b>–<b>g</b>, and <b>22a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>P═CHC(O)N(OMe)Me, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (b) Me<sub>3</sub>S<sup>+</sup>(O)I<sup>–</sup>, NaH, DMSO, rt, overnight; (c) DIBAL-H, THF, –78 °C, 2 h; then NaBH<sub>4</sub>, MeOH, 0 °C to rt, 0.5 h; (d) phthalimide, PPh<sub>3</sub>, DEAD, THF, rt, overnight; (e) N<sub>2</sub>H<sub>4</sub>–H<sub>2</sub>O, EtOH, reflux, 3 h; then Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5 h; (f) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, – 78 °C to rt, 3 h; then Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5 h; (g) 2-fluoroethanol, Ph<sub>3</sub>P, DEAD, THF, 0 to 60 °C (microwave), 1 h; (h) allyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C (microwave), 0.5–1 h; (i) (1) chiral preparative-HPLC; (2) 2 M HCl in Et<sub>2</sub>O, rt, 24–48 h. <b>11</b>–<b>22a</b>: 4,5-diF; <b>11</b>–<b>22b</b>: 5,6-diF; <b>11–22c</b>: 4-F, 5-Cl; <b>11</b>–<b>22d</b>: 5-Cl, 6-F; <b>11</b>–<b>22e</b>: 4,5-diCl; <b>11</b>–<b>22f</b>: 5,6-diCl; <b>11</b>–<b>22g</b>: 5-F, 6-Cl.</p></p></figure><div class="NLM_p">All compounds were screened in functional assays at the 5-HT<sub>2C</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2A</sub> receptors. Data were acquired using recombinant, stably expressed human 5-HT<sub>2</sub> receptors in the HEK-293 cell line, using a fluorescence imaging plate reader (FLIPR) assay as described previously.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, a 2-methoxy substituent provides analogues with good potency but poor selectivity for 5-HT<sub>2C</sub>, while the 2-fluoroethoxy and allyloxy substituents afford compounds with sometimes reduced but in other cases preserved 5-HT<sub>2C</sub> potency and improved selectivity.</div><div class="NLM_p">Compared to compounds bearing a single fluorine or chlorine group at position 5,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> those with an additional fluorine atom at position 4 or 6 exhibited slightly modified pharmacological profiles. In comparison to the 5,6-difluorinated compounds, the 4,5-difluoro substitution pattern led to better potency, as shown by the pairs (+)-<b>20a</b> vs (+)-<b>20b</b>, (+)-<b>21a</b> vs (+)-<b>21b</b>, and (+)-<b>22a</b> vs (+)-<b>22b</b>, wherein an approximately 3-fold difference can be observed within each pair. Importantly, the 2-fluoroethyl and allyl ethers provided improved subtype selectivity due to loss of potency at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors. Thus, compounds (+)-<b>21a</b>, (+)-<b>22a</b>, (+)-<b>21b</b>, and (+)-<b>22b</b> showed moderate to excellent profiles as selective 5-HT<sub>2C</sub> agonists. Notably, compound (+)-<b>22a</b> represents the best of this series, exhibiting an EC<sub>50</sub> value of 8.7 nM at the 5-HT<sub>2C</sub> receptors, with >200-fold selectivity over 5-HT<sub>2B</sub> and >50-fold selectivity over 5-HT<sub>2A</sub>. Given the fact that this compound displayed very weak activation of both the 5-HT<sub>2B</sub> receptors (<i>E</i><sub>max</sub> = 35%) and 5-HT<sub>2A</sub> receptors (<i>E</i><sub>max</sub> = 21%), (+)-<b>22a</b> is a good candidate for further studies. Considering that the 5-monofluoro analogue of (+)-<b>22a</b> showed greater 5-HT<sub>2A</sub> agonist efficacy, the superiority of compound (+)-<b>22a</b> over its 5-monofluoro analogue relies on its very weak 5-HT<sub>2A</sub> activity, as the latter showed greater activation of the same receptor (EC<sub>50</sub> = 374 nM, <i>E</i><sub>max</sub> = 56%).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">Similarly, the 4-fluoro-5-chloro-substituted analogues provided an advantage with respect to potency compared to the 5-chloro-6-fluoro scaffold, which is illustrated by comparisons of (+)-<b>20c</b> vs (+)-<b>20d</b>, (+)-<b>21c</b> vs (+)-<b>21d</b>, and (+)-<b>22c</b> vs (+)-<b>22d</b>. Compound (+)-<b>22c</b> displayed an EC<sub>50</sub> of 42 nM at 5-HT<sub>2C</sub>, no activity at 5-HT<sub>2A</sub>, and good selectivity over 5-HT<sub>2B</sub> (EC<sub>50</sub> = 1001 nM, <i>E</i><sub>max</sub> = 34%).</div><div class="NLM_p">The introduction of a second chlorine atom which is significantly larger than fluorine, into the 5-monochloro compound, led to a notable change in potency and selectivity. Compound (−)-<b>20e</b>, bearing a 4,5-dichloro substitution pattern, showed midnanomolar potency at the 5-HT<sub>2C</sub> receptor (EC<sub>50</sub> = 14 nM) and no activity at 5-HT<sub>2B</sub> but only moderate selectivity over 5-HT<sub>2A</sub> (EC<sub>50</sub> = 84 nM). Compound (+)-<b>21e</b>, with a 2-fluoroethoxy group at position 2, displayed an EC<sub>50</sub> of 18 nM and excellent selectivity against 5-HT<sub>2B</sub> but only moderate selectivity against 5-HT<sub>2A</sub>.</div><div class="NLM_p">Most of the compounds above displayed the same enantiomer preference as we had described previously,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> with the (+)-enantiomer showing greater potency. However, the introduction of a chlorine atom at position 6, as in the compound <b>20f</b>, led to the reversal of this preference. (−)-<b>20f</b> showed excellent 5-HT<sub>2C</sub> potency (EC<sub>50</sub> = 0.95 nM), 31-fold selectivity over 5-HT<sub>2B</sub>, and 40-fold selectivity over 5-HT<sub>2A</sub>, while its enantiomer (+)-<b>20f</b> was 22-fold weaker (EC<sub>50</sub> = 21 nM) at the 5-HT<sub>2C</sub> receptor. The introduction of a slightly larger 2-alkoxy group led to a decrease in potency, as shown by compounds <b>21f</b> and <b>22f</b>. With the combination of a 5-fluoro and 6-chloro group, similar enantiomer preference was observed for compound <b>20g</b>, with the (−)-enantiomer showing higher potency (EC<sub>50</sub> = 3.2 nM). Although (+)-<b>20g</b> is 7.5-fold weaker (EC<sub>50</sub> = 24 nM) compared to (−)-<b>20g</b>, it showed better selectivity against 5-HT<sub>2B</sub> (no activity) and 5-HT<sub>2A</sub> (EC<sub>50</sub> = 769 nM, 32-fold). Compounds (−)-<b>21g</b> and (−)-<b>22g</b> showed only midnanomolar potency at 5-HT<sub>2C</sub> but good selectivity against both 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In earlier work, based on the support of good internal consistency of our potency data, we tacitly assumed that enantiomers with the same sign of optical rotation as their parents devoid of substituents on the benzene ring had the same absolute configuration as those parents.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> An independent determination of the any of the new compounds’ absolute configuration has not yet been carried out, but the observed switch of the eutomer from the (+)- to the (−)-isomer in the two compounds mentioned above may as well result from the sign of optical rotation for a given absolute configuration having changed in response to the change in the substitution pattern, as from the eutomer possessing the opposite absolute configuration in those cases.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmacological Profiles of Dihalogenated Compounds at 5-HT<sub>2</sub> Receptors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0011.gif" alt="" id="GRAPHIC-d330e1152-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Data were acquired with recombinant, stably expressed human 5-HT<sub>2</sub> receptors in the HEK-293 cell line, using a fluorescence imaging plate reader (FLIPR) assay; pEC<sub>50</sub> and <i>E</i><sub>max</sub> values are shown as mean ± SEM (<i>n</i> ≥ 2); EC<sub>50</sub>s are calculated from mean pEC<sub>50</sub> values; “NA”, no activity (<i>E</i><sub>max</sub> < 15%) at 10 μM.</p></div></div><div></div></div><div class="NLM_p">The SAR results of the above dihalogenated ligands further demonstrate the strict steric limitations that apply to these 2-phenylcyclopropylmethylamine-based 5-HT<sub>2C</sub> ligands. As an example of these steric limitations, one can consider (−)-<b>20f</b> and the effect of increasing the size of its ether group from methoxy to allyloxy as in compound (−)-<b>22f</b>. This modification leads to a ∼100-fold decrease in potency (108 nM vs 0.95 nM). Also, a ∼200-fold loss in potency was observed for the 2-fluoroethoxy-containing compound (−)-<b>21f</b> (224 nM vs 0.95 nM). In fact, a decrease of greater than 2-fold in potency was observed across all of the dihalogen-substituted compounds when the 2-alkoxy group was changed from methoxy to allyloxy or 2-fluoroethoxy. However, this loss in potency was accompanied by an improvement in selectivity in most cases.</div><div class="NLM_p">(+)-<b>22a</b> is the best compound in this series with respect to its 5-HT<sub>2C</sub> potency and selectivity against the 5-HT<sub>2B</sub> (>200-fold) and 5-HT<sub>2A</sub> receptors (>50-fold). It was 3-fold weaker than lorcaserin (EC<sub>50</sub> = 2.7 nM) at 5-HT<sub>2C</sub> receptors in our assay, but lorcaserin showed much greater activation of both 5-HT<sub>2B</sub> (EC<sub>50</sub> = 328 nM, <i>E</i><sub>max</sub> = 80%) and 5-HT<sub>2A</sub> receptors (EC<sub>50</sub> = 258 nM, <i>E</i><sub>max</sub> = 67%). The low <i>E</i><sub>max</sub> values of compound (+)-<b>22a</b> at both 5-HT<sub>2B</sub> and 5-HT<sub>2A</sub> receptors make it unlikely to cause side-effects associated with the activation of those receptors. To determine its off-target activity, compound (+)-<b>22a</b> was screened against a panel of 46 targets including serotonin receptors, dopamine receptors, adrenergic receptors, monoamine transporters, and other common CNS targets (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> Table S1).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Among these, 17 targets showed greater than 50% binding at 10 μM; thus, <i>K</i><sub>i</sub> values were determined. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, compound (+)-<b>22a</b> binds to 5-HT<sub>2C</sub> receptors with a <i>K</i><sub>i</sub> value of 29 nM, while exhibiting excellent selectivity over most other targets. Notably, compound (+)-<b>22a</b> binds to 5-HT<sub>2B</sub> with a <i>K</i><sub>i</sub> = 68 nM, which indicates that the selectivity reported above is “functional”, namely the compound binds to this receptor but its intrinsic activity is very low (EC<sub>50</sub> = 1745 nM, <i>E</i><sub>max</sub> = 35%). Interestingly, compound (+)-<b>22a</b> also binds to the 5-HT<sub>6</sub> receptor with a low <i>K</i><sub>i</sub> value (111 nM). Because both 5-HT<sub>6</sub> agonists and antagonists have been shown to represent potential therapeutics for treating cognitive deficits such as those observed in Alzheimer’s disease (AD),<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> the affinity of (+)-<b>22a</b> for this receptor may be a desirable feature rather than represent an undesirable side effect. We thus selected (+)-<b>22a</b> for further studies of its ADMET properties and in vivo efficacy in animal behavioral models.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Binding Affinity of Compound (+)-<b>22a</b> at Selected Targets<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center" char="±">p<i>K</i><sub>i</sub></th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>i</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.03 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">750</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2A</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.80 ± 0.16</td><td class="colsep0 rowsep0" align="char" char=".">1573</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2B</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.16 ± 0.12</td><td class="colsep0 rowsep0" align="char" char=".">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2C</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.57 ± 0.05</td><td class="colsep0 rowsep0" align="char" char=".">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.94 ± 0.08</td><td class="colsep0 rowsep0" align="char" char=".">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.99 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">1274</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SERT</td><td class="colsep0 rowsep0" align="char" char="±">5.90 ± 0.10</td><td class="colsep0 rowsep0" align="char" char=".">1259</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.31 ± 0.11</td><td class="colsep0 rowsep0" align="char" char=".">4898</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.71 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">201</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D<sub>4</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.77 ± 0.17</td><td class="colsep0 rowsep0" align="char" char=".">1685</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α<sub>2A</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.78 ± 0.31</td><td class="colsep0 rowsep0" align="char" char=".">661</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α<sub>2B</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.42 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">1549</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α<sub>2C</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.56 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">278</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.09 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">807</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.47 ± 0.22</td><td class="colsep0 rowsep0" align="char" char=".">3388</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M<sub>5</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.55 ± 0.07</td><td class="colsep0 rowsep0" align="char" char=".">2840</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">σ<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.68 ± 0.25</td><td class="colsep0 rowsep0" align="char" char=".">2113</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Binding profiles were tested by the National Institute of Mental Health’s Psychoactive Drug Screening Program (NIMH PDSP). Each value of p<i>K</i><sub>i</sub> is shown as mean ± SEM (<i>n</i> = 2–5); <i>K</i><sub>i</sub> presents the value calculated from mean p<i>K</i><sub>i</sub>.</p></div></div></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> ADMET Study of Compound (+)-<b>22a</b></h3><div class="NLM_p">The liver microsomal stability of (+)-<b>22a</b> using both human and mouse microsomes was assayed, and the data are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Better stability was observed in the mouse liver microsomes in the absence of NADPH, indicating that oxidative mechanisms are likely involved in the metabolism of this compound. In the presence of NADPH, only 32.4% of (+)-<b>22a</b> remained after 2 h. In contrast, the compound’s stability in the presence of human liver microsomes is much better, with 70.5% of the parent compound remaining under the same conditions. Thus, good metabolic stability is anticipated in humans.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Liver Microsomal Stability of Compound (+)-<b>22a</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">remaining percentage (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">HLM</th><th class="rowsep1 colsep0" colspan="3" align="center">MLM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay format</th><th class="colsep0 rowsep0" align="center">0 min</th><th class="colsep0 rowsep0" align="center">30 min</th><th class="colsep0 rowsep0" align="center">120 min</th><th class="colsep0 rowsep0" align="center">0 min</th><th class="colsep0 rowsep0" align="center">30 min</th><th class="colsep0 rowsep0" align="center">120 min</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">+ NADPH</td><td class="colsep0 rowsep0" align="left">100.0</td><td class="colsep0 rowsep0" align="left">91.9</td><td class="colsep0 rowsep0" align="left">70.5</td><td class="colsep0 rowsep0" align="left">100.0</td><td class="colsep0 rowsep0" align="left">68.1</td><td class="colsep0 rowsep0" align="left">32.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">– NADPH</td><td class="colsep0 rowsep0" align="left">100.0</td><td class="colsep0 rowsep0" align="left">94.7</td><td class="colsep0 rowsep0" align="left">81.9</td><td class="colsep0 rowsep0" align="left">100.0</td><td class="colsep0 rowsep0" align="left">97.8</td><td class="colsep0 rowsep0" align="left">79.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Concentration of liver microsomes was 0.5 mg/mL and (+)-<b>22a</b> was tested at a concentration of 2 μM; HLM = human liver microsomes; MLM = mouse liver microsomes.</p></div></div></div><div class="NLM_p">A frequently confronted challenge in developing CNS-targeted drugs is insufficient blood-brain barrier (BBB) penetration. Thus, compound (+)-<b>22a</b> was tested in mice to verify its CNS exposure. The compound was administered intraperitoneally (ip) to CD1 mice at a dose of 10 mg/kg, and both brain and plasma concentrations were assayed at the 0.5 and 2 h time-points (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Excellent brain penetration was observed for compound (+)-<b>22a</b>, with brain/plasma concentration ratios of 29.9 and 45.0 at 0.5 and 2.0 h, respectively. The high brain penetrance of this compound should thus maximize its exposure in the CNS, allowing for robust activation of central 5-HT<sub>2C</sub> receptors, while at the same time minimizing possible side effects due to compound interactions with peripheral systems.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Brain Penetration Study of Compound (+)-<b>22a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center">time (h)</th><th class="colsep0 rowsep0" align="center">animal ID</th><th class="colsep0 rowsep0" align="center" char=".">brain (ng/g)</th><th class="colsep0 rowsep0" align="center" char=".">plasma (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">ratio (brain/ plasma)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">mean</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ip 10 mg/kg</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">10120</td><td class="colsep0 rowsep0" align="char" char=".">321</td><td class="colsep0 rowsep0" align="char" char=".">31.5</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">29.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">8480</td><td class="colsep0 rowsep0" align="char" char=".">300</td><td class="colsep0 rowsep0" align="char" char=".">28.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">3948</td><td class="colsep0 rowsep0" align="char" char=".">96.4</td><td class="colsep0 rowsep0" align="char" char=".">41.0</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">45.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">2228</td><td class="colsep0 rowsep0" align="char" char=".">45.4</td><td class="colsep0 rowsep0" align="char" char=".">49.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Density of brain tissue is calculated as 1.0 g/mL.</p></div></div></div><div class="NLM_p">The inhibition of the cytochrome P450 enzymes by (+)-<b>22a</b> was tested at five different isoforms, and the data are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. Although a high inhibition of CYP 1A2 (86%) was observed with (+)-<b>22a</b> when it was tested at a concentration of 10 μM, low inhibition was observed for the other, more abundant isoforms, especially CYP 3A4 (3.4% inhibition at 10 μM). Furthermore, inhibition of the human Ether-à-go-go related gene (hERG) channel was also tested, and (+)-<b>22a</b> displayed a dose-dependent inhibition of hERG, with an IC<sub>50</sub> value of 9.1 μM. This was not unexpected, as the structure of (+)-<b>22a</b> falls into the common templates which are known to cause hERG inhibition.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, the high brain/plasma concentration ratios found for this compound should minimize the possible cardiac toxicity associated with hERG inhibition.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Cytochrome P450 Inhibition by Compound (+)-<b>22a</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CYP isoform (substrate)</th><th class="colsep0 rowsep0" align="center" char="±">inhibition (%) ± SEM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1A2 (phenacetin)</td><td class="colsep0 rowsep0" align="char" char="±">86.0 ± 0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C9 (tolbutamide)</td><td class="colsep0 rowsep0" align="char" char="±">29.2 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2C19 (mephenytoin)</td><td class="colsep0 rowsep0" align="char" char="±">32.0 ± 5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2D6 (dextromethorphan)</td><td class="colsep0 rowsep0" align="char" char="±">43.5 ± 3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3A4 (midazolam)</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 1.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Compound (+)-<b>20a</b> was tested at 10 μM (<i>n</i> = 2); concentration of human liver microsomes was 0.2 mg/mL; concentrations of phenacetin, tolbutamide, mephenytoin, dextromethorphan, and midazolam were 40, 200, 50, 10, and 5 μM, respectively.</p></div></div></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Efficacy Study of Compound (+)-<b>22a</b> in Animal Models of Schizophrenia-Like Behaviors</h3><div class="NLM_p">To explore the possible use of (+)-<b>22a</b> in the treatment of schizophrenia, this compound was tested in four different animal behavioral paradigms. The open field test was used to evaluate the ability of the compound to decrease hyperlocomotion using <i>d</i>-amphetamine (AMPH) as the stimulant, whereas the AMPH-disrupted prepulse inhibition (PPI) test was used to analyze possible compound effects on abnormalities in sensorimotor gating.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> The well-known novel object recognition memory (NORM) test using transgenic <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor NR1-knockdown (KD) mice was conducted to assess the ability of the compound to improve cognition.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Lastly, the ability of (+)-<b>22a</b> to induce catalepsy was evaluated and compared to haloperidol. These data are detailed below.</div><div id="sec1_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Open Field Activity</h4><div class="NLM_p">The baseline activity of the mice was assessed for 15 min before the administration of AMPH (3 mg/kg, ip). During this period, only those mice from the 30 mg/kg (+)-<b>22a</b> + AMPH group showed a small, albeit significant (<i>p</i> < 0.040), reduction in locomotion compared to the Veh + AMPH group; all other groups had similar levels of baseline activities (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,B). Administration of AMPH induced a significant increase in locomotor activity, as shown by the comparison of the Veh + AMPH group with the Veh + Veh group (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,C). Animals given (+)-<b>22a</b> showed a dose-dependent suppression of AMPH-stimulated hyperlocomotion; the 2 mg/kg dose showed no significant efficacy while 5, 10, 20, and 30 mg/kg significantly reduced the hyperactivity compared to the Veh + AMPH group. Notably, locomotor activities of mice treated with 20 or 30 mg/kg (+)-<b>22a</b> + AMPH did not significantly differ from animals in the 20 mg/kg (+)-<b>22a</b> + Veh or the Veh + Veh control groups which had similar activity levels. Thus, a dose of 20 or 30 mg/kg of (+)-<b>22a</b> reduced the animals’ activities to normal levels.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound (+)-<b>22a</b> on <i>d</i>-amphetamine (AMPH)-stimulated hyperlocomotion in the open field. (A) Locomotor activity in the open field in 5 min blocks reflecting baseline responses (0–15 min) and AMPH-stimulated activity with its reduction by (+)-<b>22a</b> (15–120 min). (B) Cumulative baseline locomotor activities (0–15 min). (C) Cumulative AMPH-stimulated activities and reductions in activity with (+)-<b>22a</b> (15–90 min). <i>N</i> = 7–10 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh group; #, <i>p</i> < 0.05, compared to the Veh + AMPH group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Prepulse Inhibition (PPI)</h4><div class="NLM_p">The Veh + AMPH group showed a marked suppression of PPI compared to Veh + Veh controls (<i>p</i> < 0.007) and a loss of prepulse dependency at the 8 and 12 dB prepulse intensities (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). The suppression was reversed by both 0.5 (<i>p</i> < 0.01) and 1 mg/kg (<i>p</i> < 0.05) doses of (+)-<b>22a</b>, and the PPI was restored in both groups. Mice treated with the 1 mg/kg dose + AMPH showed full prepulse dependency of the PPI response, with the percentages of the PPI at 4, 8, and 12 dB being significantly distinguished from each other (<i>p</i> < 0.010). Although 2 mg/kg (+)-<b>22a</b> increased AMPH-disrupted PPI, this effect was not significantly different from the Veh + AMPH group. Mice in the 4 mg/kg (+)-<b>22a</b> + Veh group exhibited PPI levels which were indistinguishable from the Veh + Veh group. However, the 4 mg/kg dose failed to increase AMPH-disrupted PPI.</div><div class="NLM_p">The startle or “pulse-only” responses to the 120 dB acoustic stimulus (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B) were similar among the Veh + Veh, 4 mg/kg (+)-<b>22a</b> + Veh, Veh + AMPH, and 4 mg/kg (+)-<b>22a</b> + AMPH groups. In contrast, the 0.5, 1, and 2 mg/kg doses of this compound decreased startle activities, with the 0.5 mg/kg dose significantly reducing this response relative to the Veh + Veh, 4 mg/kg (+)-<b>22a</b> + Veh, Veh + AMPH, and 4 mg/kg (+)-<b>22a</b> + AMPH groups (<i>p</i>s < 0.035). Null activities were not distinguished across treatment conditions, with activities averaging 10.60 ± 0.53 AU across all animals, which accounted for less than 4% of the average pulse-only response. Together, these data demonstrate that (+)-<b>22a</b> can normalize AMPH-disrupted PPI and restore the prepulse dependency of the response, with 1 mg/kg showing the best efficacy.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound (+)-<b>22a</b> restores <i>d</i>-amphetamine (AMPH)-disrupted PPI in C57BL/6J mice. (A) Mice treated with vehicle–vehicle (Veh + Veh) showed prepulse dependency in PPI. Four mg/kg (+)-<b>22a</b> alone did not affect PPI relative to the Veh + Veh controls. Mice administered Veh + AMPH had a marked reduction in PPI. Treatment with 0.5, 1, or 2 mg/kg (+)-<b>22a</b> restored overall AMPH-disrupted PPI to the levels of the Veh + Veh group, with 1 mg/kg fully rescuing the prepulse dependency of the response. Mice given the 4 mg/kg dose + AMPH showed a reduction in PPI similar to that found in Veh + AMPH animals. <i>N</i> = 8–11 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh control; #, <i>p</i> < 0.05, compared to the Veh + AMPH group; ‡,<i>p</i> < 0.05, within treatment for 8 or 12 dB compared to the 4 dB response; §, <i>p</i> < 0.05, within treatment for 12 dB compared to the 8 dB response. (B) Pulse-only responses during PPI testing were not affected by treatment in the (+)-<b>22a</b> + Veh or the Veh + AMPH groups, but when (+)-<b>22a</b> was given before AMPH, the startle-only response was attenuated in the 0.5 and 2 mg/kg (+)-<b>22a</b> groups. <i>N</i> = 8–11 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh control; #, <i>p</i> < 0.05, compared to the Veh + AMPH group; + , <i>p</i> < 0.05 compared to 4 mg/kg (+)-<b>22a</b> + Veh treatment; †, <i>p</i> < 0.05, compared to the 4 mg/kg (+)-<b>22a</b> + AMPH treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Novel Object Recognition Memory (NORM)</h4><div class="NLM_p">This task in rodents is considered similar to testing declarative memory in humans, and individuals with schizophrenia are deficient on declarative memory tasks.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> We used the transgenic NR1-KD mice since these mice represent a hypoglutamatergic model of schizophrenia and are deficient on the NORM test.<a onclick="showRef(event, 'ref41 ref40'); return false;" href="javascript:void(0);" class="ref ref41 ref40">(41, 40)</a></div><div class="NLM_p">As expected, vehicle-treated wild-type (WT) mice displayed a preference for the novel object at testing, whereas the NR1-KD animals showed no preference for either object (<i>p</i> < 0.001; <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Administration of 1 mg/kg (+)-<b>22a</b> attenuated NORM in WT animals (<i>p</i> < 0.010). By comparison, the 0.5 and 1 mg/kg doses increased novel object preference in NR1-KD mice, and 1 mg/kg (+)-<b>22a</b> significantly enhanced this preference relative to the vehicle-treated NR1-KD animals (<i>p</i> < 0.002) to a level that was indistinguishable from the WT vehicle control. Hence, the 1 mg/kg dose decreased NORM in WT mice, but augmented it in the hypoglutamatergic NR1-KD animals.</div><div class="NLM_p">To determine whether the differences in responses between the genotypes or among the doses of (+)-<b>22a</b> could be attributed to neophobia, total object exploration times were examined both at training and at testing for long-term memory (LTM). The vehicle-treated NR1-KD mice were observed to spend more time exploring objects than WT controls at both training (<i>p</i> < 0.006; <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B) and testing (<i>p</i> < 0.032; <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C). By contrast, following administration of 0.5 or 1 mg/kg (+)-<b>22a</b>, object exploration was similar between genotypes during training and testing. Hence, the rescue of NORM in NR1-KD mice cannot be attributed to neophobia in these mutants.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound (+)-<b>22a</b> rescues novel object recognition memory in NR1-KD mice. Mice were given vehicle (Veh) or 0.5 or 1 mg/kg (+)-<b>22a</b> 30 min before training or at testing for long-term memory (LTM). (A) At testing for LTM, Veh-treated wild-type (WT) controls displayed a preference for the novel object, whereas NR1-KD mice showed no preference for either object. In contrast, 1 mg/kg (+)-<b>22a</b> rescued this deficit in the mutants while producing some deficiency in the WT animals. (B, C) As a control, the duration of object exploration was examined during (B) training and (C) LTM testing. At training and at testing, Veh-treated NR1-KD mice spent more time exploring the objects than WT mice, while (+)-<b>22a</b> reduced this exploration time to levels that were not significantly different from the WT controls. <i>N</i> = 9–10 mice/genotype/treatment; *, <i>p</i> < 0.05, (+)-<b>22a</b> compared to the Veh within genotype; <sup>x</sup>, <i>p</i> < 0.05, NR1-KD compared to the WT vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Catalepsy</h4><div class="NLM_p">We next determined whether compound (+)-<b>22a</b> had any cataleptic activity as compared with the vehicle and haloperidol responses. Catalepsy at baseline prior to injection (time 0) was similar for all groups with time in catalepsy ≤1 s (data not shown). One hour after injection, catalepsy was very low in all groups given 0.01 to 30 mg/kg (+)-<b>22a</b> and this result was not significantly different from that of the vehicle control (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). In contrast, catalepsy was observed to increase in a dose-dependent fashion with haloperidol, such that responses at the 1 and 10 mg/kg doses were significantly higher than those for all groups given (+)-<b>22a</b> as well as that for the vehicle control (<i>p</i><i>s</i> < 0.001). These findings demonstrate that the cataleptic potential of (+)-<b>22a</b> is extremely low.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of catalepsy induced by haloperidol and (+)-<b>22a</b> in C57BL/6J mice with the horizontal bar test. Separate groups of mice were injected with vehicle (Veh), or 0.01, 0.1, 1, or 10 mg/kg haloperidol (Hal), or 0.01, 0.1, 1, 10, or 30 mg/kg compound (+)-<b>22a</b> and evaluated for catalepsy 60 min later. <i>N</i> = 8–10 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh control; <sup>V</sup>, <i>p</i> < 0.05, compared to all other groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A new series of cyclopropylmethylamine-based 5-HT<sub>2C</sub> ligands bearing two halogen substituents on the phenyl ring have been designed and synthesized to further optimize this class of molecules. Compound (+)-<b>22a</b> was identified as a potent 5-HT<sub>2C</sub> receptor agonist (EC<sub>50</sub> = 8.7 nM, <i>E</i><sub>max</sub> = 97%), with good selectivity against the 5-HT<sub>2B</sub> (EC<sub>50</sub> = 1745 nM, <i>E</i><sub>max</sub> = 35%) and 5-HT<sub>2A</sub> receptors (EC<sub>50</sub> = 491 nM, <i>E</i><sub>max</sub> = 21%). Improved selectivity over the 5-HT<sub>2A</sub> receptor has been achieved in comparison to the analogue containing a single fluorine substituent, which showed moderate potency at the 5-HT<sub>2A</sub> receptor as well as higher efficacy (EC<sub>50</sub> = 374 nM, <i>E</i><sub>max</sub> = 56%).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In ADMET tests, compound (+)-<b>22a</b> displayed good stability in the liver microsome assays and low inhibition of the most abundant CYP isoforms. It inhibits the hERG channel with moderate potency (IC<sub>50</sub> = 9.1 μM). However, a brain penetration study in mice indicated high brain concentration/plasma concentration ratios at 0.5 h (29.9) and 2.0 h (45.0), respectively.</div><div class="NLM_p last">Compound (+)-<b>22a</b> showed efficacy in schizophrenia-related behavioral models. In the hyperdopaminergic model, it suppressed AMPH-induced hyperlocomotion in the open field in a dose-dependent manner, and it normalized the AMPH-disrupted PPI. Furthermore, it rescued NORM in the NR1-KD mice in the hypoglutamatergic model. Catalepsy was very low with compound (+)-<b>22a</b>, as it showed effects similar to that of the vehicle control and was significantly lower than that for haloperidol. Although species differences at the 5-HT<sub>2A</sub> receptor have been reported to influence the in vivo translation of 5-HT<sub>2C</sub> selective agonists,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> ultimately we are interested in the human species 5-HT<sub>2</sub> receptor selectivity. Considering that 5-HT<sub>2A</sub> agonists disrupt rather than normalize PPI and that 5-HT<sub>2A</sub> antagonists rather than agonists suppress AMPH-induced hyperlocomotion,<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> our results with compound (+)-<b>22a</b> likely do not reflect 5-HT<sub>2A</sub> activation resulting from species differences in rodent models of schizophrenia. Taken together, these data support the further development of compound (+)-<b>22a</b> as a potential drug candidate for the treatment of schizophrenia. This agent may cause fewer side effects while improving cognition and avoiding weight gain in schizophrenia patients based upon its 5-HT<sub>2C</sub>-directed mechanism of action.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General</h3><div class="NLM_p">All chemicals and solvents were purchased from Sigma-Aldrich or Fisher Scientific and were used as obtained without further purification. Microwave reactions were run in a Biotage Initiator microwave reactor. Synthetic intermediates were purified by CombiFlash flash chromatography on 230–400 mesh silica gel. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on Bruker DPX-400 or AVANCE-400 spectrometers, at 400 and 100 MHz, respectively. NMR chemical shifts were reported in δ (ppm) using residual solvent peaks as standard (CDCl<sub>3</sub> 7.26 (H), 77.23 (C); CD<sub>3</sub>OD 3.31 (H), 49.15 (C); DMSO-<i>d</i><sub>6</sub> 2.50 (H), 39.52 (C)). Mass spectra were measured using ESI with an LCMS-IT-TOF (Shimadzu). Purity of all final compounds (greater than 95%) was determined by analytical HPLC (ACE 3AQ C<sub>18</sub> column (150 × 4.6 mm, particle size 3 μM); 0.05% TFA in H<sub>2</sub>O/0.05% TFA in MeOH gradient eluting system; flow rate = 1.0 mL/min). Optical rotation values were recorded on a Rudolph Research Autopol IV automatic polarimeter.</div><div class="NLM_p last">Compounds <b>16a</b>–<b>g</b>, <b>18a</b>–<b>g</b>, and <b>19a</b>–<b>g</b> were prepared according to the methods depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The synthetic procedures and characterization data of all intermediates can be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Methods</h3><div class="NLM_p">(1) Chiral HPLC separation of racemic <b>16a</b>–<b>g</b>, <b>18a</b>–<b>g</b>, and <b>19a</b>–<b>g</b>. Analytical conditions: RegisCell chiral column (25 cm × 4.6 mm, 10 μm particle size), 1.5–15% EtOH in <i>n-</i>hexane as the mobile phase; preparative conditions: RegisPack chiral column (25 cm × 21.1 mm, 10 μm particle size), 3.0–7.5% EtOH in <i>n-</i>hexane as the eluting system (isocratic eluent, stacked injections, flow rate =18 mL/min, λ = 254 and 280 nm). Optical purities of both enantiomers were determined with analytical HPLC after the separation, and a second separation was performed when necessary to guarantee an enantiomeric excess of >90%. (2) Both enantiomers of compounds <b>16a</b>–<b>g</b>, <b>19a</b>–<b>g</b>, and <b>21a</b>–<b>g</b> were dissolved in 2 M HCl in diethyl ether and stirred at room temperature for 24–48 h. The white solids formed were collected by filtration, washed with diethyl ether, and dried under vacuum to give compounds (−)-<b>20a</b>–<b>g</b>, (+)-<b>20a</b>–<b>g</b>, (−)-<b>21a</b>–<b>g</b>, (+)-<b>21a</b>–<b>g</b>, (−)-<b>22a</b>–<b>g</b>, and (+)-<b>22a</b>–<b>g</b> as HCl salts.</div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (−)-[2-(4,5-Difluoro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)<b>-20a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.94–6.88 (m, 2H), 3.87 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.93 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.09–2.03 (m, 1H), 1.27–1.23 (m, 1H), 1.13–1.08 (m, 1H), 1.04–1.00 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.2 (d, <i>J</i><sub>CF</sub> = 7.4 Hz), 150.2 (dd, <i>J</i><sub>CF</sub> = 242.7, 13.5 Hz), 145.5 (dd, <i>J</i><sub>CF</sub> = 236.5, 12.6 Hz), 127.1, 116.4 (d, <i>J</i><sub>CF</sub> = 19.2 Hz), 101.6 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 56.9, 45.1, 19.5, 17.8, 13.1; HRMS calcd for C<sub>11</sub>H<sub>14</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 214.1038, found: 214.1035; [α]<sub>D</sub><sup>20</sup> −7.9 (<i>c</i> 0.7, MeOH).</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (+)-[2-(4,5-Difluoro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)<b>-20a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.94–6.88 (m, 2H), 3.87 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.93 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.08–2.03 (m, 1H), 1.26–1.22 (m, 1H), 1.14–1.08 (m, 1H), 1.04–0.98 (m, 1H); HRMS calcd for C<sub>11</sub>H<sub>14</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 214.1038, found: 214.1030; [α]<sub>D</sub><sup>20</sup> +6.0 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (−)-[2-(2,3-Difluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20b</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.08 (q, <i>J</i> = 9.6 Hz, 1H), 6.74–6.71 (m, 1H), 3.86 (s, 3H), 3.13 (dd, <i>J</i> = 13.2, 6.8 Hz, 1H), 2.92 (dd, <i>J</i> = 13.2, 8.4 Hz, 1H), 1.85–1.79 (m, 1H), 1.54–1.47 (m, 1H), 1.27–1.21 (m, 1H), 1.11–1.05 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.7 (dd, <i>J</i><sub>CF</sub> = 5.8, 2.0 Hz), 151.3 (dd, <i>J</i><sub>CF</sub> = 243.3, 13.8 Hz), 146.7 (dd, <i>J</i><sub>CF</sub> = 237.2, 13.9 Hz), 119.3 (d, <i>J</i><sub>CF</sub> = 11.4 Hz), 115.6 (d, <i>J</i><sub>CF</sub> = 18.3 Hz), 106.8 (dd, <i>J</i><sub>CF</sub> = 6.4, 3.5 Hz), 56.8, 45.4, 18.3, 13.6, 12.9; HRMS calcd for C<sub>11</sub>H<sub>14</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 214.1038, found: 214.1044; [α]<sub>D</sub><sup>20</sup> −36.9 (<i>c</i> 0.7, MeOH).</div></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (+)-[2-(2,3-Difluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20b</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.08 (q, <i>J</i> = 9.6 Hz, 1H), 6.75–6.71 (m, 1H), 3.86 (s, 3H), 3.13 (dd, <i>J</i> = 12.8, 6.8 Hz, 1H), 2.91 (dd, <i>J</i> = 12.8, 8.4 Hz, 1H), 1.85–1.79 (m, 1H), 1.51–1.46 (m, 1H), 1.27–1.22 (m, 1H), 1.10–1.05 (m, 1H); HRMS calcd for C<sub>11</sub>H<sub>14</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 214.1038, found: 214.1041; [α]<sub>D</sub><sup>20</sup> +38.0 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (−)-[2-(5-Chloro-4-fluoro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.2%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 11.2 Hz, 1H), 3.89 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.93 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.06–2.00 (m, 1H), 1.29–1.21 (m, 1H), 1.13–1.08 (m, 1H), 1.04–0.98 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.8, 158.6 (d, <i>J</i><sub>CF</sub> = 235.0 Hz), 129.2, 128.0, 112.0 (d, <i>J</i><sub>CF</sub> = 17.9 Hz), 101.2 (d, <i>J</i><sub>CF</sub> = 25.4 Hz), 56.8, 45.1, 19.3, 17.7, 12.9; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0719; [α]<sub>D</sub><sup>20</sup> −37.4 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (+)-[2-(5-Chloro-4-fluoro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 11.2 Hz, 1H), 3.89 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.92 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.06–2.00 (m, 1H), 1.28–1.21 (m, 1H), 1.14–1.08 (m, 1H), 1.04–0.98 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.8, 158.6 (d, <i>J</i><sub>CF</sub> = 234.8 Hz), 129.2, 128.0, 112.1 (d, <i>J</i><sub>CF</sub> = 17.8 Hz), 101.2 (d, <i>J</i><sub>CF</sub> = 25.7 Hz), 56.8, 45.1, 19.3, 17.7, 12.9; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0724; [α]<sub>D</sub><sup>20</sup> +35.6 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (−)-[2-(3-Chloro-2-fluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20d</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.9%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.28 (t, <i>J</i> = 8.8 Hz, 1H), 6.79 (dd, <i>J</i> = 9.2, 1.6 Hz, 1H), 3.87 (s, 3H), 3.11 (dd, <i>J</i> = 13.2, 6.8 Hz, 1H), 2.90 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 1.82–1.76 (m, 1H), 1.48–1.43 (m, 1H), 1.23–1.18 (m, 1H), 1.09–1.03 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 160.1 (d, <i>J</i><sub>CF</sub> = 6.6 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 243.8 Hz), 129.6, 118.9 (d, <i>J</i><sub>CF</sub> = 20.1 Hz), 113.9 (d, <i>J</i><sub>CF</sub> = 19.3 Hz), 108.5, 56.8, 45.4, 18.4, 13.7, 13.1; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0740; [α]<sub>D</sub><sup>20</sup> −54.0 (<i>c</i> 0.15, MeOH).</div></div><div id="sec3_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (+)-[2-(3-Chloro-2-fluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20d</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.4%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.29 (t, <i>J</i> = 8.8 Hz, 1H), 6.79 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 3.88 (s, 3H), 3.11 (dd, <i>J</i> = 12.8, 6.4 Hz, 1H), 2.90 (dd, <i>J</i> = 12.8, 8.4 Hz, 1H), 1.82–1.77 (m, 1H), 1.48–1.44 (m, 1H), 1.24–1.18 (m, 1H), 1.09–1.04 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 160.1 (d, <i>J</i><sub>CF</sub> = 6.6 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 243.8 Hz), 129.6, 118.9 (d, <i>J</i><sub>CF</sub> = 20.1 Hz), 113.8 (d, <i>J</i><sub>CF</sub> = 19.3 Hz), 108.4, 56.8, 45.4, 18.4, 13.7, 13.0; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0744; [α]<sub>D</sub><sup>20</sup> +50.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (−)-[2-(4,5-Dichloro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.11 (s, 2H), 3.88 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.92 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.09–2.04 (m, 1H), 1.28–1.26 (m, 1H), 1.16–1.10 (m, 1H), 1.06–1.00 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.1, 131.6, 131.5 129.2, 124.5, 113.7, 56.8, 45.0, 19.5, 17.8, 13.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.0447, found: 246.0438; [α]<sub>D</sub><sup>20</sup> −37.4 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (+)-[2-(4,5-Dichloro-2-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.11 (s, 2H), 3.89 (s, 3H), 3.08 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 2.93 (dd, <i>J</i> = 12.8, 8.0 Hz, 1H), 2.09–2.04 (m, 1H), 1.29–1.26 (m, 1H), 1.15–1.10 (m, 1H), 1.06–1.02 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.1, 131.6, 131.5, 129.2, 124.5, 113.7, 56.8, 45.0, 19.5, 17.8, 13.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.0447, found: 246.0441; [α]<sub>D</sub><sup>20</sup> +37.7 (<i>c</i> 0.4, MeOH).</div></div><div id="sec3_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (−)-[2-(2,3-Dichloro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20f</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.9%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.40 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (d, <i>J</i> = 8.8 Hz, 1H), 3.88 (s, 3H), 3.06 (d, <i>J</i> = 7.2 Hz, 2H), 1.78–1.73 (m, 1H), 1.44–1.40 (m, 1H), 1.21–1.15 (m, 1H), 1.11–1.06 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.9, 135.9, 130.2, 129.6, 125.7, 111.7, 56.7, 45.4, 20.1, 18.3, 15.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.0447, found: 246.0449; [α]<sub>D</sub><sup>20</sup> −62.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (+)-[2-(2,3-Dichloro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20f</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.40 (d, <i>J</i> = 9.2 Hz, 1H), 6.96 (d, <i>J</i> = 9.2 Hz, 1H), 3.88 (s, 3H), 3.06 (d, <i>J</i> = 7.2 Hz, 2H), 1.77–1.74 (m, 1H), 1.44–1.42 (m, 1H), 1.21–1.15 (m, 1H), 1.09–1.05 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.9, 135.9, 130.2, 129.6, 125.7, 111.7, 56.7, 45.4, 20.1, 18.3, 15.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.0447, found: 246.0448; [α]<sub>D</sub><sup>20</sup> +69.0 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (−)-[2-(2-Chloro-3-fluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((−)-<b>20g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.10 (t, <i>J</i> = 8.8 Hz, 1H), 6.92 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 3.86 (s, 3H), 3.10–3.00 (m, 2H), 1.76–1.73 (m, 1H), 1.47–1.42 (m, 1H), 1.19–1.08 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 157.1, 154.2 (d, <i>J</i><sub>CF</sub> = 237.8 Hz), 129.1, 124.6 (d, <i>J</i><sub>CF</sub> = 18.2 Hz), 115.5 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 111.1 (d, <i>J</i><sub>CF</sub> = 8.5 Hz), 56.8, 45.4, 19.6, 17.5, 14.7; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0723; [α]<sub>D</sub><sup>20</sup> −66.4 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (+)-[2-(2-Chloro-3-fluoro-6-methoxyphenyl)cyclopropyl]methanamine Hydrochloride ((+)-<b>20g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.10 (t, <i>J</i> = 8.8 Hz, 1H), 6.92 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 3.86 (s, 3H), 3.10–3.00 (m, 2H), 1.76–1.73 (m, 1H), 1.47–1.43 (m, 1H), 1.19–1.07 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 157.1, 154.2 (d, <i>J</i><sub>CF</sub> = 237.9 Hz), 129.1, 124.6 (d, <i>J</i><sub>CF</sub> = 18.1 Hz), 115.5 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 111.1 (d, <i>J</i><sub>CF</sub> = 8.4 Hz), 56.8, 45.4, 19.6, 17.5, 14.7; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>14</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 230.0742, found: 230.0758; [α]<sub>D</sub><sup>20</sup> +69.4 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (−)-[2-[4,5-Difluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.99–6.93 (m, 2H), 4.88–4.74 (m, 2H), 4.32–4.22 (m, 2H), 3.03–3.00 (m, 2H), 2.11–2.08 (m, 1H), 1.25–1.15 (m, 2H), 1.05–1.01 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 155.0 (dd, <i>J</i><sub>CF</sub> = 7.4, 2.0 Hz), 150.1 (dd, <i>J</i><sub>CF</sub> = 243.0, 13.5 Hz), 145.8 (dd, <i>J</i><sub>CF</sub> = 237.3, 12.6 Hz), 127.6, 116.6 (d, <i>J</i><sub>CF</sub> = 19.5 Hz), 102.9 (d, <i>J</i><sub>CF</sub> = 21.4 Hz), 83.4 (d, <i>J</i><sub>CF</sub> = 166.9 Hz), 69.9 (d, <i>J</i><sub>CF</sub> = 18.8 Hz), 44.9, 19.7, 17.8, 12.8; HRMS calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.1100, found: 246.1106; [α]<sub>D</sub><sup>20</sup> −1.5 (<i>c</i> 0.4, MeOH).</div></div><div id="sec3_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (+)-[2-[4,5-Difluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.5%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.99–6.93 (m, 2H), 4.88–4.74 (m, 2H), 4.32–4.22 (m, 2H), 3.03–3.00 (m, 2H), 2.11–2.07 (m, 1H), 1.24–1.15 (m, 2H), 1.05–1.00 (m, 1H); HRMS calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.1100, found: 246.1086; [α]<sub>D</sub><sup>20</sup> +1.4 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (−)-[2-[2,3-Difluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21b</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.09 (q, <i>J</i> = 9.6 Hz, 1H), 6.77–6.73 (m, 1H), 4.88–4.86 (m, 1H), 4.77–4.74 (m, 1H), 4.31–4.20 (m, 2H), 3.10 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 2.99 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 1.89–1.84 (m, 1H), 1.56–1.53 (m, 1H), 1.35–1.31 (m, 1H), 1.12–1.07 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 155.6 (dd, <i>J</i><sub>CF</sub> = 5.6, 2.1 Hz), 151.4 (dd, <i>J</i><sub>CF</sub> = 243.7, 13.9 Hz), 147.0 (dd, <i>J</i><sub>CF</sub> = 238.0, 13.8 Hz), 119.9 (d, <i>J</i><sub>CF</sub> = 11.5 Hz), 115.6 (d, <i>J</i><sub>CF</sub> = 18.3 Hz), 108.2 (dd, <i>J</i><sub>CF</sub> = 3.6 Hz), 83.4 (d, <i>J</i><sub>CF</sub> = 167.1 Hz), 69.7 (d, <i>J</i><sub>CF</sub> = 18.9 Hz), 45.2, 18.4, 13.8, 12.9; HRMS calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.1100, found: 246.1099; [α]<sub>D</sub><sup>20</sup> −36.0 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (+)-[2-[2,3-Difluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21b</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.09 (q, <i>J</i> = 9.6 Hz, 1H), 6.77–6.73 (m, 1H), 4.88–4.85 (m, 1H), 4.76–4.74 (m, 1H), 4.31–4.20 (m, 2H), 3.09 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 2.99 (dd, <i>J</i> = 12.8, 7.6 Hz, 1H), 1.89–1.84 (m, 1H), 1.56–1.53 (m, 1H), 1.35–1.31 (m, 1H), 1.12–1.07 (m, 1H); HRMS calcd for C<sub>12</sub>H<sub>15</sub>F<sub>3</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 246.1100, found: 246.1088; [α]<sub>D</sub><sup>20</sup> +30.2 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (−)-[2-[5-Chloro-4-fluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.2%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.10 (d, <i>J</i> = 8.0 Hz, 1H), 6.96 (d, <i>J</i> = 11.2 Hz, 1H), 4.86–4.76 (m, 2H), 4.35–4.24 (m, 2H), 3.05–2.97 (m, 2H), 2.10–2.04 (m, 1H), 1.26–1.15 (m, 2H), 1.05–1.00 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.6, 158.5 (d, <i>J</i><sub>CF</sub> = 244.2 Hz), 129.5, 128.3, 112.7 (d, <i>J</i><sub>CF</sub> = 17.8 Hz), 102.3 (d, <i>J</i><sub>CF</sub> = 25.4 Hz), 83.3 (d, <i>J</i><sub>CF</sub> = 167.0 Hz), 69.7 (d, <i>J</i><sub>CF</sub> = 18.8 Hz), 45.0, 19.5, 17.8, 12.6; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 262.0782; [α]<sub>D</sub><sup>20</sup> −26.4 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (+)-[2-[5-Chloro-4-fluoro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 6.96 (d, <i>J</i> = 10.8 Hz, 1H), 4.86–4.75 (m, 2H), 4.34–4.24 (m, 2H), 3.04–2.98 (m, 2H), 2.09–2.04 (m, 1H), 1.25–1.15 (m, 2H), 1.05–1.00 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.6, 158.5 (d, <i>J</i><sub>CF</sub> = 243.9 Hz), 129.5, 128.3, 112.7 (d, <i>J</i><sub>CF</sub> = 17.5 Hz), 102.3 (d, <i>J</i><sub>CF</sub> = 25.5 Hz), 83.3 (d, <i>J</i><sub>CF</sub> = 167.1 Hz), 69.7 (d, <i>J</i><sub>CF</sub> = 19.0 Hz), 45.0, 19.5, 17.8, 12.6; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 262.0788; [α]<sub>D</sub><sup>20</sup> +28.4 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (−)-[2-[3-Chloro-2-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21d</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.29 (t, <i>J</i> = 8.8 Hz, 1H), 6.81 (d, <i>J</i> = 9.2 Hz, 1H), 4.88–4.83 (m, 1H), 4.77–4.75 (m, 1H), 4.35–4.21 (m, 2H), 3.09 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.98 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 1.88–1.83 (m, 1H), 1.55–1.51 (m, 1H), 1.32–1.28 (m, 1H), 1.12–1.06 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.0 (d, <i>J</i><sub>CF</sub> = 6.4 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 244.0 Hz), 129.5, 119.4 (d, <i>J</i><sub>CF</sub> = 14.7 Hz), 114.4 (d, <i>J</i><sub>CF</sub> = 19.2 Hz), 109.5, 83.3 (d, <i>J</i><sub>CF</sub> = 167.4 Hz), 69.6 (d, <i>J</i><sub>CF</sub> = 19.0 Hz), 45.3, 18.5, 13.9, 13.1; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 262.0791; [α]<sub>D</sub><sup>20</sup> −53.0 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (+)-[2-[3-Chloro-2-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21d</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.29 (t, <i>J</i> = 8.8 Hz, 1H), 6.81 (dd, <i>J</i> = 8.8, 1.4 Hz, 1H), 4.88–4.83 (m, 1H), 4.77–4.74 (m, 1H), 4.33–4.23 (m, 2H), 3.10 (dd, <i>J</i> = 12.8, 7.2 Hz, 1H), 2.98 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 1.88–1.83 (m, 1H), 1.55–1.51 (m, 1H), 1.32–1.28 (m, 1H), 1.12–1.06 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.0 (d, <i>J</i><sub>CF</sub> = 6.5 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 244.4 Hz), 129.5, 119.4 (d, <i>J</i><sub>CF</sub> = 14.7 Hz), 114.4 (d, <i>J</i><sub>CF</sub> = 19.3 Hz), 109.5, 83.3 (d, <i>J</i><sub>CF</sub> = 167.3 Hz), 69.6 (d, <i>J</i><sub>CF</sub> = 19.0 Hz), 45.3, 18.5, 13.9, 13.1; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 246.0793; [α]<sub>D</sub><sup>20</sup> +53.5 (<i>c</i> 0.4, MeOH).</div></div><div id="sec3_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (−)-[2-[4,5-Dichloro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.16 (s, 1H), 7.15 (s, 1H), 4.88–4.74 (m, 2H), 4.37–4.25 (m, 2H), 3.04–3.02 (m, 2H), 2.13–2.08 (m, 1H), 1.29–1.25 (m, 1H), 1.23–1.18 (m, 1H), 1.08–1.01 (m, 1H); HRMS calcd for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>FNO<sup>+</sup> ([M + H]<sup>+</sup>): 278.0509, found: 278.0496; [α]<sub>D</sub><sup>20</sup> −32.4 (<i>c</i> 0.25, MeOH).</div></div><div id="sec3_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (+)-[2-[4,5-Dichloro-2-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.4%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.16 (s, 1H), 7.15 (s, 1H), 4.88–4.75 (m, 2H), 4.36–4.24 (m, 2H), 3.04–3.01 (m, 2H), 2.13–2.08 (m, 1H), 1.29–1.26 (m, 1H), 1.23–1.19 (m, 1H), 1.08–1.03 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.1, 131.9, 131.6, 129.5, 125.1, 114.8, 83.3 (d, <i>J</i><sub>CF</sub> = 167.1 Hz), 69.7 (d, <i>J</i><sub>CF</sub> = 18.9 Hz), 44.9, 19.7, 17.9, 12.9; HRMS calcd for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>FNO<sup>+</sup> ([M + H]<sup>+</sup>): 278.0509, found: 278.0508; [α]<sub>D</sub><sup>20</sup> +30.2 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (−)-[2-[2,3-Dichloro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21f</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.09 (br, 3H), 7.48 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 4.90–4.73 (m, 2H), 4.32–4.22 (m, 2H), 3.26–3.22 (m, 1H), 2.64–2.59 (m, 1H), 1.78–1.73 (m, 1H), 1.45–1.41 (m, 1H), 1.18–1.12 (m, 1H), 1.04–1.00 (m, 1H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 157.1, 133.8, 128.8, 128.6, 123.5, 112.4, 82.2 (d, <i>J</i><sub>CF</sub> = 165.6 Hz), 68.1 (d, <i>J</i><sub>CF</sub> = 18.6 Hz), 42.7, 18.7, 16.9, 14.0; HRMS calcd for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>FNO<sup>+</sup> ([M + H]<sup>+</sup>): 278.0509, found: 278.0494; [α]<sub>D</sub><sup>20</sup> −96.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (+)-[2-[2,3-Dichloro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21f</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.0%; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.11 (br, 3H), 7.47 (d, <i>J</i> = 8.8 Hz, 1H), 7.03 (d, <i>J</i> = 8.8 Hz, 1H), 4.89–4.73 (m, 2H), 4.32–4.22 (m, 2H), 3.24 (dd, <i>J</i> = 12.4, 5.2 Hz, 1H), 2.64–2.59 (m, 1H), 1.78–1.73 (m, 1H), 1.45–1.41 (m, 1H), 1.18–1.13 (m, 1H), 1.04–1.00 (m, 1H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 157.0, 133.7, 128.8, 128.6, 123.5, 112.4, 82.2 (d, <i>J</i><sub>CF</sub> = 165.6 Hz), 68.1 (d, <i>J</i><sub>CF</sub> = 18.6 Hz), 42.7, 18.6, 16.9, 13.9; HRMS calcd for C<sub>12</sub>H<sub>15</sub>Cl<sub>2</sub>FNO<sup>+</sup> ([M + H]<sup>+</sup>): 278.0509, found: 278.0493; [α]<sub>D</sub><sup>20</sup> +70.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (−)-[2-[2-Chloro-3-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>21g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.1%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.11 (t, <i>J</i> = 8.8 Hz, 1H), 6.94 (dd, <i>J</i> = 9.0, 4.2 Hz, 1H), 4.88–4.85 (m, 1H), 4.77–4.74 (m, 1H), 4.32–4.20 (m, 2H), 3.34 (dd, <i>J</i> = 13.2, 6.4 Hz, 1H), 2.85 (dd, <i>J</i> = 13.2, 8.8 Hz, 1H), 1.85–1.79 (m, 1H), 1.56–1.50 (m, 1H), 1.23–1.18 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.0, 154.5 (d, <i>J</i><sub>CF</sub> = 238.6 Hz), 129.7, 124.7 (d, <i>J</i><sub>CF</sub> = 18.2 Hz), 115.5 (d, <i>J</i><sub>CF</sub> = 22.9 Hz), 112.6 (d, <i>J</i><sub>CF</sub> = 7.6 Hz), 83.4 (d, <i>J</i><sub>CF</sub> = 167.3 Hz), 69.8 (d, <i>J</i><sub>CF</sub> = 18.9 Hz), 45.3, 19.7, 17.7, 14.7; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 262.0801; [α]<sub>D</sub><sup>20</sup> −54.5 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (+)-[2-[2-Chloro-3-fluoro-6-(2-fluoroethoxy)phenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>21g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.2%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.11 (t, <i>J</i> = 8.8 Hz, 1H), 6.94 (dd, <i>J</i> = 9.0, 4.2 Hz, 1H), 4.88–4.85 (m, 1H), 4.78–4.74 (m, 1H), 4.33–4.20 (m, 2H), 3.34 (dd, <i>J</i> = 13.2, 8.8 Hz, 1H), 2.85 (dd, <i>J</i> = 13.2, 8.8 Hz, 1H), 1.85–1.79 (m, 1H), 1.56–1.52 (m, 1H), 1.24–1.17 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.0, 154.5 (d, <i>J</i><sub>CF</sub> = 238.6 Hz), 129.7, 124.7 (d, <i>J</i><sub>CF</sub> = 18.2 Hz), 115.5 (d, <i>J</i><sub>CF</sub> = 22.8 Hz), 112.6 (d, <i>J</i><sub>CF</sub> = 7.7 Hz), 83.4 (d, <i>J</i><sub>CF</sub> = 167.3 Hz), 69.8 (d, <i>J</i><sub>CF</sub> = 19.0 Hz), 45.3, 19.7, 17.7, 14.7; HRMS calcd for C<sub>12</sub>H<sub>15</sub>ClF<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 262.0805, found: 262.0807; [α]<sub>D</sub><sup>20</sup> +61.4 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (−)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.95–6.88 (m, 2H), 6.18–6.08 (m, 1H), 5.47 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.33 (dd, <i>J</i> = 10.4, 1.6 Hz, 1H), 4.60 (d, <i>J</i> = 5.2 Hz, 2H), 3.07 (dd, <i>J</i> = 12.8, 7.2 Hz, 1H), 2.98 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.17–2.09 (m, 1H), 1.33–1.29 (m, 1H), 1.13–1.02 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 155.0 (dd, <i>J</i><sub>CF</sub> = 7.6, 2.0 Hz), 150.0 (dd, <i>J</i><sub>CF</sub> = 242.8, 13.5 Hz), 145.7 (dd, <i>J</i><sub>CF</sub> = 236.9, 12.7 Hz), 134.5, 127.5, 118.6, 116.2 (d, <i>J</i><sub>CF</sub> = 19.2 Hz), 103.1 (d, <i>J</i><sub>CF</sub> = 21.3 Hz), 71.1, 45.1, 19.4, 18.0, 13.4; HRMS calcd for C<sub>13</sub>H<sub>16</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 240.1194, found: 240.1189; [α]<sub>D</sub><sup>20</sup> −14.0 (<i>c</i> 0.4, MeOH).</div></div><div id="sec3_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (+)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22a</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.4%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 6.94–6.89 (m, 2H), 6.18–6.08 (m, 1H), 5.47 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.33 (dd, <i>J</i> = 10.8, 1.6 Hz, 1H), 4.60 (d, <i>J</i> = 5.2 Hz, 2H), 3.06 (dd, <i>J</i> = 13.2, 7.2 Hz, 1H), 2.97 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 2.17–2.08 (m, 1H), 1.33–1.28 (m, 1H), 1.13–1.02 (m, 2H); HRMS calcd for C<sub>13</sub>H<sub>16</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 240.1194, found: 246.1192; [α]<sub>D</sub><sup>20</sup> +12.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (−)-[2-[6-(Allyloxy)-2,3-difluorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22b</b>)</h4><div class="NLM_p last">White solid. HPLC: 97.0%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.06 (q, <i>J</i> = 9.6 Hz, 1H), 6.75–6.71 (m, 1H), 6.16–6.09 (m, 1H), 5.46 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.32 (dd, <i>J</i> = 10.8, 1.6 Hz, 1H), 4.59 (d, <i>J</i> = 5.6 Hz, 2H), 3.08 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 3.01 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 1.91–1.86 (m, 1H), 1.61–1.56 (m, 1H), 1.31–1.27 (m, 1H), 1.12–1.08 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 155.7 (d, <i>J</i><sub>CF</sub> = 5.6 Hz), 151.3 (dd, <i>J</i><sub>CF</sub> = 243.3, 14.0 Hz), 146.8 (dd, <i>J</i><sub>CF</sub> = 237.6, 13.8 Hz), 134.6, 119.7 (d, <i>J</i><sub>CF</sub> = 11.2 Hz), 118.6, 115.5 (d, <i>J</i><sub>CF</sub> = 18.3 Hz), 108.5, 71.1, 45.3, 18.3, 13.9, 13.0; HRMS calcd for C<sub>13</sub>H<sub>16</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 240.1194, found: 240.1188; [α]<sub>D</sub><sup>20</sup> −46.8 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (+)-[2-[6-(Allyloxy)-2,3-difluorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22b</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.06 (q, <i>J</i> = 9.6 Hz, 1H), 6.75–6.71 (m, 1H), 6.16–6.08 (m, 1H), 5.46 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.32 (dd, <i>J</i> = 10.4, 1.6 Hz, 1H), 4.59 (d, <i>J</i> = 5.6 Hz, 2H), 3.07 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 3.00 (dd, <i>J</i> = 13.2, 7.6 Hz, 1H), 1.91–1.85 (m, 1H), 1.60–1.56 (m, 1H), 1.31–1.26 (m, 1H), 1.11–1.06 (m, 1H); HRMS calcd for C<sub>13</sub>H<sub>16</sub>F<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 240.1194, found: 240.1191; [α]<sub>D</sub><sup>20</sup> +41.6 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (−)-[2-[2-(Allyloxy)-5-chloro-4-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.8%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.07 (d, <i>J</i> = 8.4 Hz, 1H), 6.90 (d, <i>J</i> = 11.2 Hz, 1H), 6.18–6.08 (m, 1H), 5.47 (dd, <i>J</i> = 13.6, 1.6 Hz, 1H), 5.34 (dd, <i>J</i> = 10.4, 1.6 Hz, 1H), 4.62 (d, <i>J</i> = 5.2 Hz, 2H), 3.06 (dd, <i>J</i> = 12.8, 7.2 Hz, 1H), 2.98 (dd, <i>J</i> = 12.8, 8.0 Hz, 1H), 2.11–2.05 (m, 1H), 1.32–1.28 (m, 1H), 1.13–1.01 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.5, 158.4 (d, <i>J</i><sub>CF</sub> = 243.8 Hz), 134.3, 129.2, 128.3, 118.8, 112.3 (d, <i>J</i><sub>CF</sub> = 17.6 Hz), 102.4 (d, <i>J</i><sub>CF</sub> = 25.4 Hz), 70.9, 45.0, 19.2, 17.9, 13.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0875; [α]<sub>D</sub><sup>20</sup> −36.2 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (+)-[2-[2-(Allyloxy)-5-chloro-4-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22c</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.07 (d, <i>J</i> = 8.4 Hz, 1H), 6.91 (d, <i>J</i> = 11.2 Hz, 1H), 6.17–6.08 (m, 1H), 5.47 (dd, <i>J</i> = 13.6, 1.6 Hz, 1H), 5.34 (dd, <i>J</i> = 11.2, 1.2 Hz, 1H), 4.62 (d, <i>J</i> = 5.2 Hz, 2H), 3.06 (dd, <i>J</i> = 11.2, 7.2 Hz, 1H), 2.99 (dd, <i>J</i> = 12.8, 5.6 Hz, 1H), 2.11–2.05 (m, 1H), 1.32–1.28 (m, 1H), 1.13–1.01 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.5, 158.4 (d, <i>J</i><sub>CF</sub> = 243.7 Hz), 134.3, 129.2, 128.3, 118.8, 112.3 (d, <i>J</i><sub>CF</sub> = 17.6 Hz), 102.4 (d, <i>J</i><sub>CF</sub> = 25.4 Hz), 70.9, 45.0, 19.2, 17.9, 13.2; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0880; [α]<sub>D</sub><sup>20</sup> +34.6 (<i>c</i> 0.5, MeOH).</div></div><div id="sec3_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (−)-[2-[6-(Allyloxy)-3-chloro-2-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22d</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.5%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.26 (t, <i>J</i> = 8.4 Hz, 1H), 6.79 (d, <i>J</i> = 9.2 Hz, 1H), 6.17–6.07 (m, 1H), 5.46 (d, <i>J</i> = 17.2 Hz, 1H), 5.33 (d, <i>J</i> = 10.4 Hz, 1H), 4.61 (d, <i>J</i> = 5.2 Hz, 2H), 3.08–2.97 (m, 2H), 1.88–1.83 (m, 1H), 1.59–1.52 (m, 1H), 1.28–1.22 (m, 1H), 1.11–1.06 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.0 (d, <i>J</i><sub>CF</sub> = 6.4 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 243.9 Hz), 134.4, 129.4, 119.2 (d, <i>J</i><sub>CF</sub> = 14.6 Hz), 118.7, 113.9 (d, <i>J</i><sub>CF</sub> = 19.3 Hz), 109.7, 70.9, 45.3, 18.4, 13.9, 13.1; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0900; [α]<sub>D</sub><sup>20</sup> −54.0 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (+)-[2-[6-(Allyloxy)-3-chloro-2-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22d</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.6%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.26 (t, <i>J</i> = 8.6 Hz, 1H), 6.79 (dd, <i>J</i> = 9.2, 1.6 Hz, 1H), 6.17–6.07 (m, 1H), 5.46 (dd, <i>J</i> = 17.2, 1.4 Hz, 1H), 5.33 (dd, <i>J</i> = 10.4, 1.2 Hz, 1H), 4.61 (d, <i>J</i> = 5.6 Hz, 2H), 3.08–2.97 (m, 2H), 1.88–1.83 (m, 1H), 1.57–1.52 (m, 1H), 1.28–1.22 (m, 1H), 1.11–1.06 (m, 1H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 159.0 (d, <i>J</i><sub>CF</sub> = 6.6 Hz), 158.7 (d, <i>J</i><sub>CF</sub> = 243.8 Hz), 134.4, 129.4, 119.2 (d, <i>J</i><sub>CF</sub> = 14.5 Hz), 118.7, 113.9 (d, <i>J</i><sub>CF</sub> = 19.2 Hz), 109.7, 70.9, 45.3, 18.4, 13.9, 13.1; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0901; [α]<sub>D</sub><sup>20</sup> +55.0 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (−)-[2-[2-(Allyloxy)-4,5-dichlorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.1%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.12 (s, 1H), 7.10 (s, 1H), 6.17–6.07 (m, 1H), 5.47 (dd, <i>J</i> = 17.6, 1.6 Hz, 1H), 5.34 (dd, <i>J</i> = 10.4, 1.6 Hz, 1H), 4.63 (d, <i>J</i> = 5.2 Hz, 2H), 3.08–2.97 (m, 2H), 2.14–2.09 (m, 1H), 1.37–1.32 (m, 1H), 1.15–1.03 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 157.9, 134.3, 131.9, 131.4, 129.2, 124.7, 118.7, 115.0, 70.9, 44.9, 19.4, 17.9, 13.5; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 272.0603, found: 272.0596; [α]<sub>D</sub><sup>20</sup> −35.0 (<i>c</i> 0.4, MeOH).</div></div><div id="sec3_2_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (+)-[2-[2-(Allyloxy)-4,5-dichlorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22e</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.2%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.12 (s, 1H), 7.10 (s, 1H), 6.17–6.07 (m, 1H), 5.47 (dd, <i>J</i> = 17.2, 1.2 Hz, 1H), 5.34 (d, <i>J</i> = 10.4 Hz, 1H), 4.63 (d, <i>J</i> = 5.2 Hz, 2H), 3.08–2.96 (m, 2H), 2.14–2.09 (m, 1H), 1.39–1.32 (m, 1H), 1.15–1.03 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 157.9, 134.3, 131.9, 131.4, 129.2, 124.7, 118.7, 115.0, 70.9, 44.9, 19.4, 17.9, 13.5; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 272.0603, found: 272.0597; [α]<sub>D</sub><sup>20</sup> +37.6 (<i>c</i> 0.3, MeOH).</div></div><div id="sec3_2_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (−)-[2-[6-(Allyloxy)-2,3-dichlorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22f</b>)</h4><div class="NLM_p last">White solid. HPLC: 98.3%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.37 (d, <i>J</i> = 9.2 Hz, 1H), 6.94 (d, <i>J</i> = 9.2 Hz, 1H), 6.18–6.08 (m, 1H), 5.46 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.34 (dd, <i>J</i> = 10.8, 1.2 Hz, 1H), 4.62 (d, <i>J</i> = 5.2 Hz, 2H), 3.30 (dd, <i>J</i> = 13.2, 8.8 Hz, 1H), 2.86 (dd, <i>J</i> = 13.2, 8.8 Hz, 1H), 1.83–1.77 (m, 1H), 1.48–1.45 (m, 1H), 1.23–1.12 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.8, 135.9, 134.4, 130.0, 129.9, 125.8, 118.9, 113.3, 70.9, 45.3, 20.2, 18.5, 15.3; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 272.0603, found: 272.0611; [α]<sub>D</sub><sup>20</sup> −68.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (+)-[2-[6-(Allyloxy)-2,3-dichlorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22f</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.1%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.37 (d, <i>J</i> = 8.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 1H), 6.18–6.08 (m, 1H), 5.47 (dd, <i>J</i> = 17.2, 1.6 Hz, 1H), 5.34 (dd, <i>J</i> = 10.4, 1.2 Hz, 1H), 4.63 (d, <i>J</i> = 5.2 Hz, 2H), 3.30 (dd, <i>J</i> = 12.8, 8.8 Hz, 1H), 2.86 (dd, <i>J</i> = 12.8, 8.8 Hz, 1H), 1.83–1.79 (m, 1H), 1.48–1.46 (m, 1H), 1.23–1.15 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 158.8, 135.9, 134.5, 130.0, 129.9, 125.8, 118.8, 113.3, 71.0, 45.4, 20.2, 18.6, 15.3; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>Cl<sub>2</sub>NO<sup>+</sup> ([M + H]<sup>+</sup>): 272.0603, found: 272.0596; [α]<sub>D</sub><sup>20</sup> +64.0 (<i>c</i> 0.1, MeOH).</div></div><div id="sec3_2_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (−)-[2-[6-(Allyloxy)-2-chloro-3-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((−)-<b>22g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.09 (t, <i>J</i> = 8.8 Hz, 1H), 6.92 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 6.16–6.07 (m, 1H), 5.46 (dd, <i>J</i> = 17.6, 1.6 Hz, 1H), 5.33 (dd, <i>J</i> = 10.6, 1.4 Hz, 1H), 4.60 (d, <i>J</i> = 5.6 Hz, 2H), 3.29 (dd, <i>J</i> = 13.2, 6.4 Hz, 1H), 2.87 (dd, <i>J</i> = 12.8, 8.6 Hz, 1H), 1.84–1.77 (m, 1H), 1.53–1.47 (m, 1H), 1.22–1.17 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.1, 154.3 (d, <i>J</i><sub>CF</sub> = 238.3 Hz), 134.7, 129.5, 124.5 (d, <i>J</i><sub>CF</sub> = 18.2 Hz), 118.7, 115.4 (d, <i>J</i><sub>CF</sub> = 22.7 Hz), 112.8 (d, <i>J</i><sub>CF</sub> = 7.5 Hz), 71.1, 45.4, 19.7, 17.7, 14.8; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0895; [α]<sub>D</sub><sup>20</sup> −52.0 (<i>c</i> 0.2, MeOH).</div></div><div id="sec3_2_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (+)-[2-[6-(Allyloxy)-2-chloro-3-fluorophenyl]cyclopropyl]methanamine Hydrochloride ((+)-<b>22g</b>)</h4><div class="NLM_p last">White solid. HPLC: 99.7%; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.09 (t, <i>J</i> = 8.8 Hz, 1H), 6.92 (dd, <i>J</i> = 9.2, 4.4 Hz, 1H), 6.17–6.08 (m, 1H), 5.46 (dd, <i>J</i> = 17.6, 1.6 Hz, 1H), 5.33 (dd, <i>J</i> = 10.4, 1.2 Hz, 1H), 4.60 (d, <i>J</i> = 4.8 Hz, 2H), 3.29 (dd, <i>J</i> = 13.6, 6.0 Hz, 1H), 2.87 (dd, <i>J</i> = 12.8, 8.8 Hz, 1H), 1.84–1.78 (m, 1H), 1.53–1.47 (m, 1H), 1.21–1.17 (m, 2H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 156.1, 154.3 (d, <i>J</i><sub>CF</sub> = 238.0 Hz), 134.7, 129.5, 124.5 (d, <i>J</i><sub>CF</sub> = 18.1 Hz), 118.7, 115.4 (d, <i>J</i><sub>CF</sub> = 22.7 Hz), 112.8 (d, <i>J</i><sub>CF</sub> = 6.6 Hz), 71.1, 45.3, 19.7, 17.7, 14.8; HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>16</sub>ClFNO<sup>+</sup> ([M + H]<sup>+</sup>): 256.0899, found: 256.0906; [α]<sub>D</sub><sup>20</sup> +61.8 (<i>c</i> 0.4, MeOH).</div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Calcium Flux Assay</h3><div class="NLM_p last">Calcium flux assay was recorded on a FLIPR<sup>TETRA</sup> fluorescence imaging plate reader (Molecular Dynamics) on Flp-In-293 cells stably expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C-INI</sub> as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For each experiment, 16 concentrations of the compound (from 3.3 × 10<sup>–13</sup> to 1 × 10<sup>–5</sup> M based on a 3.3 × serial dilution) were tested to acquire a dose–response curve. Expression levels of the receptors were determined using saturation binding assays, 5-HT<sub>2A</sub>: 1200 fmol/mg (<sup>3</sup>H-ketanserin, <i>K</i><sub>d</sub> = 1.6 nM), 5-HT<sub>2B</sub>: 500 fmol/mg (<sup>3</sup>H-lysergic acid diethylamide (LSD), <i>K</i><sub>d</sub> = 2.2 nM), and 5-HT<sub>2C</sub>: 1800 fmol/mg (<sup>3</sup>H-mesulergine, <i>K</i><sub>d</sub> = 4.5 nM).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Off-Target Screening of Compound (+)-<b>22a</b> by the National Institute of Mental Health’s Psychoactive Drug Screening Program (NIMH PDSP)</h3><div class="NLM_p last">Primary binding experiments were performed at 10 μM for compound (+)-<b>22a</b>, and the percentage displacement of the radioligand was measured. Targets showing >50% inhibition of binding at 10 μM were selected for full concentration–response competitive binding experiments, and binding constants (<i>K</i><sub>i</sub>) were determined. For experimental details, refer to the PDSP Web site: <a href="http://pdspdb.unc.edu/pdspWeb/" class="extLink">http://pdspdb.unc.edu/pdspWeb/</a>.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> ADMET Tests</h3><div class="NLM_p last">The liver microsomal stability study, brain penetration test, cytochrome P450 inhibition test, and hERG inhibition study were conducted by Pharmaron, Inc. (Beijing, China).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Animal Behavioral Methods</h3><div id="sec3_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Animals</h4><div class="NLM_p last">Adult male and female C57BL/6J (Jackson Laboratories, Bar Harbor, ME) and NR1 mice were used for behavioral testing. All mice were between 14–18 weeks of age at the time of testing. Mice were maintained on a 14 h light/10 h dark light-dark cycle with the onset of the dark cycle at 2000 h. Testing was conducted during the light cycle between 1000–1600 h. All animals were housed by genotype and sex. Forty-eight hours before testing, mice were weighed and moved into the appropriate test room. Mice remained in the test room for the duration of testing and had ad libitum access to food and water. All studies were conducted with an approved protocol from the Duke University Institutional Animal Care and Use Committee.</div></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Drugs</h4><div class="NLM_p last">Haloperidol (Sigma-Aldrich, St. Louis MO) and compound (+)-<b>22a</b> were dissolved in 0.5% <i>N</i>,<i>N</i>-dimethylacetamide and 10% (2-hydroxypropyl)-β-cyclodextrin in sterile saline. <i>d</i>-Amphetamine (AMPH; Tocris Bioscience, Bristol, UK) was dissolved in sterile saline. All treatments were delivered in a 4 mL/kg volume (ip).</div></div><div id="sec3_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Open Field Activity</h4><div class="NLM_p last">Activity in the open field was assessed as distance traveled in a novel environment (20 × 20 × 20 cm) using a Versamax Analyzer system (Omnitech Electronics, Columbus, OH). Locomotor activity was monitored by infrared diodes interfaced to a computer running Fusion software (Omnitech Electronics). C57BL/6J mice (<i>n</i> = 7–10 mice/treatment) were injected with vehicle (Veh) or 2, 5, 10, 20, or 30 mg/kg compound (+)-<b>22a</b> and placed into the open field. After 15 min, each animal was removed and given Veh or 3 mg/kg AMPH and returned immediately to the open field for an additional 105 min. Controls consisted of separate groups of mice administered Veh-Veh or 20 mg/kg compound (+)-<b>22a</b> + Veh. The results are depicted as total distance traveled in 5 min intervals over testing or cumulative distance traveled over the 15 min of baseline and 75 min following injection of AMPH or the vehicle.</div></div><div id="sec3_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Prepulse Inhibition</h4><div class="NLM_p last">Prepulse inhibition (PPI) was assessed using the SR Startle Lab Response system for mice (San Diego Instruments, San Diego, CA). Adult C57BL/6J males (<i>n</i> = 8–11 mice/treatment group) were administered the Veh or 0.5, 1, 2, or 4 mg/kg compound (+)-<b>22a</b> followed 10 min later with Veh or 3 mg/kg AMPH. Mice were placed into a Plexiglas holder which was positioned into the test chamber that was interfaced to a computer running SR Lab Startle Reflex software.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> After a 10 min acclimatization period, mice were exposed to 42 test trials composed of 18 pulse-only trials, 18 prepulse–pulse trials, and 6 null trials. A 62 dB white noise background was present during testing. Pulse-only trials consisted of a single 40 ms 120 dB burst of white noise. Prepulse–pulse trials consisted of a 20 ms prepulse of white noise that was 4, 8, or 12 dB above the 62 dB background, followed 100 ms later with the 120 dB pulse. The white noise background was the only stimulus present during the null only trials. Testing began and ended with a block of five pulse-only trials; the remaining pulse-only trials were randomized with the null trials and the prepulse–pulse trials between these two blocks of pulse-only trials. The percent PPI for each prepulse intensity was calculated as the ratio of the average response during the prepulse–pulse trials to the average pulse-only responses, subtracted from 1, multiplied by 100, and expressed as a percentage. Null activity and pulse-only responses are reported in arbitrary units (AU) as measured by the SR Startle Lab Response system. The peak of the startle response (AU) was measured within a 65 ms window following onset of the pulse-only stimulus.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec3_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Novel Object Recognition Memory</h4><div class="NLM_p last">Wild type (WT) and NR1-KD mice (<i>n</i> = 9–10 mice/genotype/treatment) were randomly assigned to three treatment groups that received Veh or 0.5 or 1 mg/kg compound (+)-<b>22a</b>. Testing was conducted over 3 days with a single trial (5 min) on each day.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Mice were acclimated to the empty test chambers (38 × 22 × 20 cm) on day 1 and exposed to two identical objects on day 2. Twenty-four hours later, mice were presented with one of the same objects from day 2 which was paired with a novel object to evaluate long-term memory (LTM). Mice were administered Veh or compound (+)-<b>22a</b> 30 min prior to the trials on days 2 and 3. All trials were video-recorded using the Noldus Media Recorder (Noldus Technologies, Wageningen, Netherlands), and behavioral data were analyzed using Noldus Ethovision 10. Duration of time spent investigating the objects was scored. The results are presented as preference scores; object preference = (time spent with novel object–time spent with familiar object)/total time with both objects. Positive scores denote preference for the novel object, negative scores signify preference for the familiar object, and scores approaching zero indicate no preference for either object.</div></div><div id="sec3_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Catalepsy</h4><div class="NLM_p last">Male C57BL/6J mice (<i>n</i> = 8–10 mice/treatment/time-point) were assessed for cataleptic responses. Baseline cataleptic responses were assessed following removal from the home-cage by placing both front paws on a 60 cm horizontal bar (2.5 mm diameter) elevated above the bench with both rear paws in direct contact with the bench. Immediately following the baseline assessment, each animal was injected with vehicle, haloperidol, or compound (+)-<b>22a</b> and returned to its home cage. Catalepsy was evaluated in separate groups of mice at 60 min. The time spent in catalepsy was measured as the time following placement to removal of the front paws from the bar, with a maximum cutoff time of 60 s.</div></div><div id="sec3_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Statistics</h4><div class="NLM_p last">All data were analyzed using SPSS 22 (IBM SPSS, Chicago, IL) and are presented as means and standard errors of the mean (SEM). Distance traveled in the open field was assessed with RMANOVA with time as the within subjects effect and treatment condition as the between subjects effect. For PPI, null and startle activities were assessed using ANOVA with treatment as the between subjects variable. Differences in PPI were examined with RMANOVA with prepulse intensity as the within subjects variable and treatment condition as the between subjects variable. Responses in NORM were evaluated using ANOVA for preference scores in the LTM test with genotype and treatment as independent variables. Duration of contact with the objects during the training session and the LTM test were analyzed with RMANOVA using test-session as the within subjects variable and genotype and treatment as the between subjects variables. For time spent in catalepsy, a one-way ANOVA was performed examining the effects of treatment. Posthoc comparisons were performed with Bonferroni corrected pairwise comparisons for all analyses. In all cases, a <i>p</i> < 0.05 was considered significant.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01153">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14625" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14625" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01153" class="ext-link">10.1021/acs.jmedchem.5b01153</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic procedures for compounds <b>16a</b>–<b>g</b>, <b>18a</b>–<b>g</b>, and <b>19a</b>–<b>g</b>, and characterization data of all chemical intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds (−)-<b>20a</b>–<b>g</b>, (+)-<b>20a</b>–<b>g</b>, (−)-<b>21a</b>–<b>g</b>, (+)-<b>21a</b>–<b>g</b>, (−)-<b>22a</b>–<b>g</b>, and (+)-<b>22a</b>–<b>g</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_002.pdf">jm5b01153_si_002.pdf (455.19 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_003.csv">jm5b01153_si_003.csv (4.5 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01153" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan P. Kozikowski</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Department of Medicinal Chemistry and Pharmacognosy,
College of Pharmacy, University of Illinois
at Chicago, Chicago, Illinois 60612, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e68d899c8f8d899187a6938f85c8838293"><span class="__cf_email__" data-cfemail="bad1d5c0d3d1d5cddbfacfd3d994dfdecf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Cheng</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Program, Department of Medicinal Chemistry and Pharmacognosy,
College of Pharmacy, University of Illinois
at Chicago, Chicago, Illinois 60612, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick M. Giguere</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Mental Health Psychoactive Drug Screening Program, Department
of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire M. Schmerberg</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine
Analysis Core Facility, Duke University
Medical Center, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vladimir M. Pogorelov</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine
Analysis Core Facility, Duke University
Medical Center, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramona M. Rodriguiz</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine
Analysis Core Facility, Duke University
Medical Center, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xi-Ping Huang</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Mental Health Psychoactive Drug Screening Program, Department
of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hu Zhu</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Mental Health Psychoactive Drug Screening Program, Department
of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. McCorvy</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Mental Health Psychoactive Drug Screening Program, Department
of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William C. Wetsel</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry and Behavioral Sciences, Mouse Behavioral and Neuroendocrine
Analysis Core Facility, Duke University
Medical Center, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan L. Roth</span> - <span class="hlFld-Affiliation affiliation">National
Institute of Mental Health Psychoactive Drug Screening Program, Department
of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27599, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d330e5733-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support from the National Institute of Mental Health (NIMH) (no. R01MH99993) and Psychoactive Drug Screening Program (PDSP, Contract no. HHSN-271-2013-00017-C) is gratefully acknowledged. We thank Dr. Werner Tueckmantel for proofreading the manuscript and providing valuable suggestions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i77" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i77"> Abbreviations Used</h2><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">serotonin</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion and toxicity</p></td></tr><tr><td class="NLM_term">AMPH</td><td class="NLM_def"><p class="first last"><i>d</i>-amphetamine</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal symptoms</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">US Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">HEK-293</td><td class="NLM_def"><p class="first last">human embryonic kidney 293 cells</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">knockdown</p></td></tr><tr><td class="NLM_term">LTM</td><td class="NLM_def"><p class="first last">long-term memory</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NORM</td><td class="NLM_def"><p class="first last">novel object recognition memory</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">prepulse inhibition</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Tph2</td><td class="NLM_def"><p class="first last">tryptophan hydroxylase 2</p></td></tr><tr><td class="NLM_term">Veh</td><td class="NLM_def"><p class="first last">vehicle</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><a href="http://www.who.int/mental_health/management/schizophrenia/en/" class="extLink">http://www.who.int/mental_health/management/schizophrenia/en/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.who.int%2Fmental_health%2Fmanagement%2Fschizophrenia%2Fen%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span> </span><span class="NLM_article-title">Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci</span>.  <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schizophrenia+Working+Group+of+the+Psychiatric+Genomics+Consortium.+Biological+insights+from+108+schizophrenia-associated+genetic+loci.+Nature+2014%2C+511%2C+421%E2%80%93427."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DSchizophrenia%2520Working%2520Group%2520of%2520the%2520Psychiatric%2520Genomics%2520Consortium.%2520Biological%2520insights%2520from%2520108%2520schizophrenia-associated%2520genetic%2520loci%26jtitle%3DNature%26date%3D2014%26volume%3D511%26spage%3D421%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The pipeline and future of drug development in schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1038/sj.mp.4002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.mp.4002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17667958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=904-922&author=J.+A.+Grayauthor=B.+L.+Roth&title=The+pipeline+and+future+of+drug+development+in+schizophrenia&doi=10.1038%2Fsj.mp.4002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The pipeline and future of drug development in schizophrenia</span></div><div class="casAuthors">Gray, J. A.; Roth, B. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">904-922</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease.  In particular, improved treatment of the neg. symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed.  In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs.  Many of these compds. have great potential as augmenting agents in the treatment of neg. symptoms and cognition.  In addn., we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets.  Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia.  Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZ3qO-W1xFLVg90H21EOLACvtfcHk0lgfGJUFOikbwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L&md5=f0b2e1ece99057228282fa1ad71855b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002062%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520pipeline%2520and%2520future%2520of%2520drug%2520development%2520in%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D904%26epage%3D922%26doi%3D10.1038%2Fsj.mp.4002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Harvey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S. E.</span><span> </span><span class="NLM_article-title">Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1176/appi.ajp.158.2.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1176%2Fappi.ajp.158.2.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11156796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BD3M7ktFKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=176-184&author=P.+D.+Harveyauthor=R.+S.+E.+Keefe&title=Studies+of+cognitive+change+in+patients+with+schizophrenia+following+novel+antipsychotic+treatment&doi=10.1176%2Fappi.ajp.158.2.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment</span></div><div class="casAuthors">Harvey P D; Keefe R S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-84</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia.  However, these effects have been assessed in studies with considerable variation in methodology.  A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia.  The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice.  METHOD:  This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results.  RESULTS:  Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning.  However, the methodology for assessing the treatment of cognitive deficits is still being developed.  CONCLUSIONS:  Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPA9I2rBv4PKcY7HFp97qMfW6udTcc2ea7R6TwTOkKYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7ktFKjsw%253D%253D&md5=b574f391b3f1be001132cab248e80aa8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.2.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.2.176%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DP.%2BD.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%2BE.%26atitle%3DStudies%2520of%2520cognitive%2520change%2520in%2520patients%2520with%2520schizophrenia%2520following%2520novel%2520antipsychotic%2520treatment%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D176%26epage%3D184%26doi%3D10.1176%2Fappi.ajp.158.2.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerner, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schooler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. G.</span><span> </span><span class="NLM_article-title">Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia - Is it a practice effect?</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1122</span><span class="refDoi"> DOI: 10.1001/archpsyc.64.10.1115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1001%2Farchpsyc.64.10.1115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17909123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CnsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=1115-1122&author=T.+E.+Goldbergauthor=R.+S.+Goldmanauthor=K.+E.+Burdickauthor=A.+K.+Malhotraauthor=T.+Lenczauthor=R.+C.+Patelauthor=M.+G.+Woernerauthor=N.+R.+Schoolerauthor=J.+M.+Kaneauthor=D.+G.+Robinson&title=Cognitive+improvement+after+treatment+with+second-generation+antipsychotic+medications+in+first-episode+schizophrenia+-+Is+it+a+practice+effect%3F&doi=10.1001%2Farchpsyc.64.10.1115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?</span></div><div class="casAuthors">Goldberg, Terry E.; Goldman, Robert S.; Burdick, Katherine E.; Malhotra, Anil K.; Lencz, Todd; Patel, Raman C.; Woerner, Margaret G.; Schooler, Nina R.; Kane, John M.; Robinson, Delbert G.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1122</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Cognitive impairment in schizophrenia is frequent, involves multiple domains, and is enduring.  Numerous recent clin. trials have suggested that second-generation antipsychotic medications significantly enhance cognition in schizophrenia.  However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects.  Objective: To report the results on cognition of a randomized comparison of 2 widely prescribed second-generation antipsychotic medications, olanzapine and risperidone, in patients with first-episode schizophrenia and a healthy control group.  Design: Randomized clin. trial.  Setting: Hospital-based research units.  Patients: A total of 104 participants with first-episode schizophrenia and 84 healthy controls.  Main Outcome Measures: Cognitive assessment of all study participants occurred at baseline, 6 wk later, and 16 wk later.  Neurocognitive tests included measures of working memory and attention, speed, motor function, episodic memory, and executive function.  Results: No differential drug effects were obsd.  Of 16 cognitive measures, 9 demonstrated improvement over time and only 2 demonstrated greater rates of change than those obsd. in the healthy control group undergoing repeated assessment.  The composite effect size for cognitive change was 0.33 in the healthy control group (attributed to practice) and 0.36 in the patients with first-episode schizophrenia.  Improvements in cognition in the first-episode schizophrenia group could not be accounted for by medication dose, demog. variables, or intellectual level.  Conclusions: The cognitive improvements obsd. in the trial were consistent in magnitude with practice effects obsd. in healthy controls, suggesting that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (ie, exposure, familiarity, and/or procedural learning).  Our results also indicated that differential medication effects on cognition were small.  We believe that these findings have important implications for drug discovery and the design of registration trials that attempt to demonstrate cognitive enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgt1du_jdD7Vg90H21EOLACvtfcHk0lgfGJUFOikbwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CnsrfJ&md5=ab62ddb0cb5be4d7c6eb8622628a9e28</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.10.1115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.10.1115%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DGoldman%26aufirst%3DR.%2BS.%26aulast%3DBurdick%26aufirst%3DK.%2BE.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DLencz%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DR.%2BC.%26aulast%3DWoerner%26aufirst%3DM.%2BG.%26aulast%3DSchooler%26aufirst%3DN.%2BR.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26aulast%3DRobinson%26aufirst%3DD.%2BG.%26atitle%3DCognitive%2520improvement%2520after%2520treatment%2520with%2520second-generation%2520antipsychotic%2520medications%2520in%2520first-episode%2520schizophrenia%2520-%2520Is%2520it%2520a%2520practice%2520effect%253F%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D1115%26epage%3D1122%26doi%3D10.1001%2Farchpsyc.64.10.1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4991</span><span class="refDoi"> DOI: 10.1172/JCI70678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1172%2FJCI70678" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=4986-4991&author=H.+Y.+Meltzerauthor=B.+L.+Roth&title=Lorcaserin+and+pimavanserin%3A+Emerging+selectivity+of+serotonin+receptor+subtype-targeted+drugs&doi=10.1172%2FJCI70678"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI70678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70678%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DLorcaserin%2520and%2520pimavanserin%253A%2520Emerging%2520selectivity%2520of%2520serotonin%2520receptor%2520subtype-targeted%2520drugs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D4986%26epage%3D4991%26doi%3D10.1172%2FJCI70678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The expanded biology of serotonin</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1146/annurev.med.60.042307.110802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1146%2Fannurev.med.60.042307.110802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=19630576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=355-366&author=M.+Bergerauthor=J.+A.+Grayauthor=B.+L.+Roth&title=The+expanded+biology+of+serotonin&doi=10.1146%2Fannurev.med.60.042307.110802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded biology of serotonin</span></div><div class="casAuthors">Berger, Miles; Gray, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychol. processes, and drugs that target serotonin receptors are used widely in psychiatry and neurol.  However, most serotonin is found outside the central nervous system, and virtually all of the 15 serotonin receptors are expressed outside as well as within the brain.  Serotonin regulates numerous biol. processes including cardiovascular function, bowel motility, ejaculatory latency, and bladder control.  Addnl., new work suggests that serotonin may regulate some processes, including platelet aggregation, by receptor-independent, transglutaminase-dependent covalent linkage to cellular proteins.  We review this new expanded serotonin biol. and discuss how drugs targeting specific serotonin receptors are beginning to help treat a wide range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz0HW5hdNOrVg90H21EOLACvtfcHk0liPilwV51_doQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D&md5=0557e01e6b79dbfb50559aca03f8b31f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.60.042307.110802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.60.042307.110802%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520expanded%2520biology%2520of%2520serotonin%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2009%26volume%3D60%26spage%3D355%26epage%3D366%26doi%3D10.1146%2Fannurev.med.60.042307.110802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>ClinicalTrials.gov Identifier: NCT02044874.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+Identifier%3A+NCT02044874."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span>ClinicalTrials.gov Identifier: NCT00563706.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+Identifier%3A+NCT00563706."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Shen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detke, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span> </span><span class="NLM_article-title">A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.jpsychires.2014.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.jpsychires.2014.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=24613032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BC2crisVWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=14-22&author=J.+H.+Shenauthor=Y.+Zhaoauthor=S.+Rosenzweig-Lipsonauthor=D.+Poppauthor=J.+B.+Williamsauthor=E.+Gillerauthor=M.+J.+Detkeauthor=J.+M.+Kane&title=A+6-week+randomized%2C+double-blind%2C+placebo-controlled%2C+comparator+referenced+trial+of+vabicaserin+in+acute+schizophrenia&doi=10.1016%2Fj.jpsychires.2014.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia</span></div><div class="casAuthors">Shen Joan H Q; Zhao Yonggang; Rosenzweig-Lipson Sharon; Popp Danielle; Giller Earl; Williams Janet B W; Detke Michael J; Kane John M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Vabicaserin, a potent 5-HT2C receptor agonist, decreases nucleus accumbens extracellular dopamine levels in rats, without affecting striatal dopamine, indicating mesolimbic selectivity.  This is the first study of efficacy, safety and tolerability of vabicaserin in adults with acute schizophrenia.  Three hundred fourteen hospitalized subjects were randomized to: Vabicaserin 200 or 400 mg/day, olanzapine 15 mg/day or placebo.  Central raters assessed the PANSS and CGI-S.  Site raters performed the BPRS and CGI-I.  Central rated PANSS Positive (PANSS-PPS) was the primary endpoint.  Two hundred eighty-nine subjects were included in the mITT efficacy analysis.  Vabicaserin was well tolerated with no major safety concerns.  Olanzapine, but not vabicaserin, caused weight gain.  Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement at week 6 vs. placebo on PANSS-PSS.  A non-significant decrease vs. placebo was observed for 400 mg/day.  Both vabicaserin groups demonstrated significant improvement over baseline on PANSS Negative while placebo worsened.  Vabicaserin 200 mg/day and olanzapine demonstrated significantly greater improvement over placebo on PANSS Total whereas 400 mg/day showed a trend toward improvement.  There was no significant improvement vs. placebo for either vabicaserin group on site-rated BPRS.  Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement vs. placebo on CGI-I and CGI-S but not 400 mg/day vabicaserin.  Vabicaserin demonstrated efficacy on primary and secondary endpoints at 200 mg/day, but not at 400 mg/day which showed a trend for efficacy.  The 200 mg/day vabicaserin group achieved proof of concept using central ratings.  Both vabicaserin doses were well tolerated with no significant safety signals and no weight gain.  TRIAL REGISTRATION:  clinicaltrials.gov.  Identifier: NCT00265551.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU4Ml3861NqENHe_gFldTbfW6udTcc2ebosr1G74pUGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crisVWitQ%253D%253D&md5=1d4be17f9d6341641c68809a61495003</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2014.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2014.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%2BH.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DPopp%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BB.%26aulast%3DGiller%26aufirst%3DE.%26aulast%3DDetke%26aufirst%3DM.%2BJ.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26atitle%3DA%25206-week%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520comparator%2520referenced%2520trial%2520of%2520vabicaserin%2520in%2520acute%2520schizophrenia%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2014%26volume%3D53%26spage%3D14%26epage%3D22%26doi%3D10.1016%2Fj.jpsychires.2014.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Lee, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Decreased serotonin<sub>2C</sub> receptor responses in male patients with schizophrenia</span> <span class="citation_source-journal">Psychiatry Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1016/j.psychres.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.psychres.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=25650049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2015&pages=308-315&author=M.+A.+Leeauthor=K.+Jayathilakeauthor=M.+Y.+Simauthor=H.+Y.+Meltzer&title=Decreased+serotonin2C+receptor+responses+in+male+patients+with+schizophrenia&doi=10.1016%2Fj.psychres.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased serotonin2C receptor responses in male patients with schizophrenia</span></div><div class="casAuthors">Lee, Myung Ae; Jayathilake, Karuna; Sim, Min Young; Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">308-315</span>CODEN:
                <span class="NLM_cas:coden">PSRSDR</span>;
        ISSN:<span class="NLM_cas:issn">0165-1781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Serotonin (5-HT)2C receptors in brain affect psychosis, reward, substance abuse, anxiety, other behaviors, appetite, body temp., and other physiol. measures.  They also have been implicated in antipsychotic drug efficacy and side effects.  We previously reported that the hyperthermia following administration of MK-212, a predominantly 5-HT2C receptor agonist, was diminished in a small sample of patients with schizophrenia (SCH), suggesting decreased 5-HT2C receptor responsiveness.  We have now studied the responses to oral MK-212 and placebo in a larger sample of unmedicated male SCH (n=69) and normal controls (CON) (n=33), and assessed the influence of comorbid substance abuse (SA) on oral body temp., behavioral responses, etc.  The placebo-adjusted oral body temp. response to MK-212 was significantly lower in SCH compared to CON and not significantly different between the SCH with or without SA.  Some behavioral responses to MK-212, e.g. self-rated feelings of increased anxiety, depression and decreased calmness, or good overall feeling, were significantly lower in the SCH patients compared to CON.  These results add to the evidence for diminished 5-HT2C receptor responsiveness in SCH patients compared to CON and are consistent with reported assocn. of HTR2C polymorphisms, leading to decreased expression or function of the HTR2C in patients with SCH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZkp5ElR_5-rVg90H21EOLACvtfcHk0liPKhev8JdEVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisLw%253D&md5=fa37f05a6d69c77a2028051bf357d49d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.psychres.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psychres.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DSim%26aufirst%3DM.%2BY.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DDecreased%2520serotonin2C%2520receptor%2520responses%2520in%2520male%2520patients%2520with%2520schizophrenia%26jtitle%3DPsychiatry%2520Res.%26date%3D2015%26volume%3D226%26spage%3D308%26epage%3D315%26doi%3D10.1016%2Fj.psychres.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor stimulation are differentially involved in the cortical dopamine efflux-studied in 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> genetic mutant mice</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">652</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2010.10.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.ejphar.2010.10.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=21118683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Kisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=2011&pages=40-45&author=M.+Huangauthor=J.+Daiauthor=H.+Y.+Meltzer&title=5-HT2A+and+5-HT2C+receptor+stimulation+are+differentially+involved+in+the+cortical+dopamine+efflux-studied+in+5-HT2A+and+5-HT2C+genetic+mutant+mice&doi=10.1016%2Fj.ejphar.2010.10.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT2A and 5-HT2C genetic mutant mice</span></div><div class="casAuthors">Huang, Mei; Dai, Jin; Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both 5-HT2A and 5-HT2C receptors modulate cortical dopamine efflux, but in opposite directions.  We have now compared the ability of the three 5-HT2A/2C receptor agonists, DOI (R(-)-2,5-dimethoxy-4-iodoamphetamine), mCPP (meta-chlorophenylpiperazine) and MK-212 (6-Chloro-2-(piperazinyl) pyrazine), to modulate cortical dopamine efflux in 5-HT2A and 5-HT2C genetic mutant mice.  In the 5-HT2A mice, the preferential 5-HT2A receptor agonist DOI (2.5 mg/kg, s.c.) induced a slight but significant increase in cortical dopamine efflux only in the wild type (WT) mice; MK-212 (2.5 mg/kg) reduced dopamine efflux in both WT and receptor knockout (KO) mice; moreover, MCPP, 2.5 mg/kg, had no effect in either types.  In 5-HT2C mice, DOI increased dopamine efflux in both types; while MK-212 decreased dopamine efflux in the WT, but not the receptor KO mice.  These results provide new evidence that 5-HT2A receptor stimulation enhances and 5-HT2C receptor stimulation inhibits cortical dopamine efflux, and suggest the effects of DOI, MK-212 and mCPP on the cortical dopamine efflux are due to their different abilities on 5-HT2A and 5-HT2C receptors stimulation.  Of these three agents, only DOI, the more selective 5-HT2A receptor agonist, is hallucinogenic.  The absence of hallucinations with mCPP may be due to its relatively more potent 5-HT2C receptor agonist effect, inhibiting the ability of mCPP to enhance dopamine efflux in cortical and perhaps limbic regions as well.  The present data provide addnl. evidence that hallucinations are due, in part, to 5-HT2A rather than 5-HT2C receptor stimulation.  These findings suggest that 5-HT2C receptor agonists may be useful as antipsychotics, consistent with previous suggestions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc4WEX0WXT_bVg90H21EOLACvtfcHk0liPKhev8JdEVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Kisg%253D%253D&md5=77eef47319a8b2ad242e1d6d1798223b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.10.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.10.094%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3D5-HT2A%2520and%25205-HT2C%2520receptor%2520stimulation%2520are%2520differentially%2520involved%2520in%2520the%2520cortical%2520dopamine%2520efflux-studied%2520in%25205-HT2A%2520and%25205-HT2C%2520genetic%2520mutant%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D652%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.ejphar.2010.10.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine<sub>2C</sub> receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11561066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=83-89&author=L.+Rauserauthor=J.+E.+Savageauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=Inverse+agonist+actions+of+typical+and+atypical+antipsychotic+drugs+at+the+human+5-hydroxytryptamine2C+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor</span></div><div class="casAuthors">Rauser, Laura; Savage, Jason E.; Meltzer, Herbert Y.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-89</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs, which are distinguished from typical antipsychotic drugs by a lower incidence of extra-pyramidal side effects and less propensity to elevate serum prolactin levels (e.g., clozapine, olanzapine, risperidone, quetiapine, ziprasidone), have become the most widely used treatments for schizophrenia, although their precise mechanism of action remains controversial.  It has been suggested that this group of atypical antipsychotic drugs is characterized by preferentially high affinities for 5-hydroxytryptamine (5-HT)2A serotonin receptors and relatively low affinities for D2-dopamine receptors.  It has recently been proposed that these atypical antipsychotic drugs may also be distinguished from typical antipsychotic drugs (e.g., haloperidol, fluphenazine, chlorpromazine, and so on) by inverse agonist actions at the 5-HT2C-INI RNA edited isoform of the human 5-HT2C receptor transiently expressed in COS-7 cells.  We have examd. the relation among 5-HT2C inverse agonist potency, efficacy, and atypical antipsychotic drug status in HEK-293 cells of a large no. of typical and atypical antipsychotic drugs using human embryonic kidney (HEK)-293 cells stably transfected with the h5-HT2C-INI receptor.  Inverse agonist actions at h5-HT2C-INI receptors were measured for both typical and atypical antipsychotic drugs.  Thus, some typical antipsychotic drugs (chlorpromazine, mesoridazine, fluphenazine, and loxapine) were efficient inverse agonists, whereas several clin. effective atypical antipsychotic drugs (remoxipride, quetiapine, sulpiride, melperone, amperozide) were not.  Addnl., several drugs without significant antipsychotic actions (M100907, ketanserin, mianserin, ritanserin, and amitriptyline) were potent inverse agonists at the 5-HT2C-INI isoform expressed in HEK-293 cells.  Taken together, these results demonstrate that both typical and atypical antipsychotic drugs may exhibit inverse agonist effects at the 5-HT2C-INI isoform of the human 5-HT2C receptor and that no relation exists between inverse agonist actions and atypicality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQYyIwLMQ1z7Vg90H21EOLACvtfcHk0ljumndT6Jlf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltrY%253D&md5=1a4485604f512006fcb46a49ec2c2cf4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DInverse%2520agonist%2520actions%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520at%2520the%2520human%25205-hydroxytryptamine2C%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D83%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.npp.1300027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=12629531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslyjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+Renockauthor=S.+A.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs&doi=10.1038%2Fsj.npp.1300027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs</span></div><div class="casAuthors">Kroeze, Wesley K.; Hufeisen, Sandra J.; Popadak, Beth A.; Renock, Sean M.; Steinberg, SeAnna; Ernsberger, Paul; Jayathilake, Karu; Meltzer, Herbert Y.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia and related disorders, despite their side effects.  Wt. gain is a common and potentially serious complication of some antipsychotic drug therapy, and may be accompanied by hyperlipidemia, hypertension and hyperglycemia and, in some extreme cases, diabetic ketoacidosis.  The mol. mechanism(s) responsible for antipsychotic drug-induced wt. gain are unknown, but have been hypothesized to be because of interactions of antipsychotic drugs with several neurotransmitter receptors, including 5-HT2A and 5-HT2C serotonin receptors, H1-histamine receptors, α1- and α2-adrenergic receptors, and m3-muscarinic receptors.  To det. the receptor(s) likely to be responsible for antipsychotic-drug-induced wt. gain, we screened 17 typical and atypical antipsychotic drugs for binding to 12 neurotransmitter receptors.  H1-histamine receptor affinities for this group of typical and atypical antipsychotic drugs were significantly correlated with wt. gain (Spearman ρ=-0.72; p∼0.01), as were affinities for α1A adrenergic (ρ=-0.54; p∼0.05), 5-HT2C (ρ=-0.49; p∼0.05) and 5-HT6 receptors (ρ=-0.54; p∼0.05), whereas eight other receptors' affinities were not.  A principal components anal. showed that affinities at the H1, α2A, α2B, 5-HT2A, 5-HT2C, and 5-HT6 receptors were most highly correlated with the first principal component, and affinities for the D2, 5-HT1A, and 5-HT7 receptors were most highly correlated with the second principal component.  A discriminant functions anal. showed that affinities for the H1 and α1A receptors were most highly correlated with the discriminant function axis.  The discriminant function anal., as well as the affinity for the H1-histamine receptor alone, correctly classified 15 of the 17 drugs into two groups; those that induce wt. gain and those that do not.  Because centrally acting H1-histamine receptor antagonists are known to induce wt. gain with chronic use, and because H1-histamine receptor affinities are pos. correlated with wt. gain among typical and atypical antipsychotic drugs, it is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-8aw1zlLc1bVg90H21EOLACvtfcHk0ljumndT6Jlf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslyjt7Y%253D&md5=353d231f2afe414e58646baf8692ecf5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300027%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DS.%2BA.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526%26doi%3D10.1038%2Fsj.npp.1300027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Marquis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabb, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logue, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piesla, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comery, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span> </span><span class="NLM_article-title">WAY-163909 [(7b<i>R</i>, 10a<i>R</i>)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1124/jpet.106.106989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fjpet.106.106989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17038512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=486-496&author=K.+L.+Marquisauthor=A.+L.+Sabbauthor=S.+F.+Logueauthor=J.+A.+Brennanauthor=M.+J.+Pieslaauthor=T.+A.+Comeryauthor=S.+M.+Grauerauthor=C.+R.+Ashbyauthor=H.+Q.+Nguyenauthor=L.+A.+Dawsonauthor=J.+E.+Barrettauthor=G.+Stackauthor=H.+Y.+Meltzerauthor=B.+L.+Harrisonauthor=S.+Rosenzweig-Lipson&title=WAY-163909+%5B%287bR%2C+10aR%29-1%2C2%2C3%2C4%2C8%2C9%2C10%2C10a-octahydro-7bH-cyclopenta%5Bb%5D%5B1%2C4%5Ddiazepino%5B6%2C7%2C1hi%5Dindole%5D%3A+A+novel+5-hydroxytryptamine+2C+receptor-selective+agonist+with+preclinical+antipsychotic-like+activity&doi=10.1124%2Fjpet.106.106989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity</span></div><div class="casAuthors">Marquis, Karen L.; Sabb, Annmarie L.; Logue, Sheree F.; Brennan, Julie A.; Piesla, Michael J.; Comery, Tom A.; Grauer, Steven M.; Ashby, Charles R., Jr.; Nguyen, Huy Q.; Dawson, Lee A.; Barrett, James E.; Stack, Gary; Meltzer, Herbert Y.; Harrison, Boyd L.; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">486-496</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Serotonin-2C (5-HT2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists selectively decreasing mesolimbic DA.  As antipsychotic efficacy is proposed to be assocd. with decreased mesolimbic DA neurotransmission by virtue of DA D2 receptor antagonism, the 5-HT2C-selective receptor agonist, WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], was evaluated in animal models of schizophrenia and in vivo microdialysis and electrophysiol. to det. the effects on mesolimbic and nigrostriatal DA neurotransmission.  Similar to clozapine, WAY-163909 (1.7-30 mg/kg i.p.) decreased apomorphine-induced climbing with little effect on stereotypy and no significant induction of catalepsy.  WAY-163909 (0.3-3 mg/kg s.c.) more potently reduced phencyclidine-induced locomotor activity compared with d-amphetamine with no effect on spontaneous activity.  WAY-163909 (1.7-17 mg/kg i.p.) reversed MK-801 (5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)- and DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-disrupted prepulse inhibition of startle (PPI) and improved PPI in DBA/2N mice.  In conditioned avoidance responding, WAY-163909 (0.3-3 mg/kg i.p.; 1-17 mg/kg p.o.) reduced avoidance responding, an effect blocked by the 5-HT2B/2C receptor antagonist SB 206553 [5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole].  WAY-163909 (10 mg/kg s.c.) selectively decreased extracellular levels of DA in the nucleus accumbens without affecting the striatum.  Likewise, in vivo electrophysiol. recordings showed a decrease in the no. of spontaneously firing DA neurons in the ventral tegmental area but not in the substantia nigra with both acute and chronic (21-day) administration of WAY-163909 (1-10 mg/kg i.p.).  Thus, the profile of the 5-HT2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and addnl. may have rapid onset properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemOaXlISXJrVg90H21EOLACvtfcHk0ljumndT6Jlf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFCgtg%253D%253D&md5=f70bb5a91c306aa208b5a19cd2e21937</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.106989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.106989%26sid%3Dliteratum%253Aachs%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DLogue%26aufirst%3DS.%2BF.%26aulast%3DBrennan%26aufirst%3DJ.%2BA.%26aulast%3DPiesla%26aufirst%3DM.%2BJ.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DGrauer%26aufirst%3DS.%2BM.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DNguyen%26aufirst%3DH.%2BQ.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BE.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DWAY-163909%2520%255B%25287bR%252C%252010aR%2529-1%252C2%252C3%252C4%252C8%252C9%252C10%252C10a-octahydro-7bH-cyclopenta%255Bb%255D%255B1%252C4%255Ddiazepino%255B6%252C7%252C1hi%255Dindole%255D%253A%2520A%2520novel%25205-hydroxytryptamine%25202C%2520receptor-selective%2520agonist%2520with%2520preclinical%2520antipsychotic-like%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D486%26epage%3D496%26doi%3D10.1124%2Fjpet.106.106989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Musil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russ, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamerle, M.</span><span> </span><span class="NLM_article-title">Weight gain and antipsychotics: A drug safety review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1517/14740338.2015.974549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1517%2F14740338.2015.974549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=25400109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFahtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=73-96&author=R.+Musilauthor=M.+Obermeierauthor=P.+Russauthor=M.+Hamerle&title=Weight+gain+and+antipsychotics%3A+A+drug+safety+review&doi=10.1517%2F14740338.2015.974549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Weight gain and antipsychotics: a drug safety review</span></div><div class="casAuthors">Musil, Richard; Obermeier, Michael; Russ, Paul; Hamerle, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-96</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Second-generation antipsychotics (SGAs) are widely used in several psychiatric disease entities and exert to a different extent a risk for antipsychotic-induced wt. gain (AIWG).  As AIWG is assocd. with an increase in metabolic syndrome or cardiovascular events, knowledge of these risks is crucial for further monitoring and the initiation of counteractive measures.  Areas covered: We searched PubMed and Web of Sciences for randomized-controlled trials and naturalistic observational studies published between 2010 and 2014 with sample sizes exceeding 100, including all marketed SGAs apart from zotepine, and providing data on wt. increase.  We also summarized relevant systematic reviews and meta-analyses of head-to-head comparisons.  Expert opinion: Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews ranking clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone, quetiapine, risperidone and sertindole in the middle, and aripiprazole, lurasidone and ziprasidone with the lowest risk.  No. needed to harm varied considerably in our meta-anal.  Younger patients and patients with a lower baseline body mass index are most vulnerable.  The greatest amt. of wt. gain occurs within the first weeks of treatment.  AIWG occurs in all diagnostic groups and is also common in treatment with first-generation antipsychotics; therefore, awareness of this adverse event is essential for anyone prescribing antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9jb7K7ITVGrVg90H21EOLACvtfcHk0lj6Rj4TnkPqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFahtLvJ&md5=b0dd9abd97f58b1702b933bdb16fdcd8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.974549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.974549%26sid%3Dliteratum%253Aachs%26aulast%3DMusil%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DRuss%26aufirst%3DP.%26aulast%3DHamerle%26aufirst%3DM.%26atitle%3DWeight%2520gain%2520and%2520antipsychotics%253A%2520A%2520drug%2520safety%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D73%26epage%3D96%26doi%3D10.1517%2F14740338.2015.974549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Calcagno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baviera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, R. W.</span><span> </span><span class="NLM_article-title">Endogenous serotonin and serotonin<sub>2C</sub> receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05789.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1111%2Fj.1471-4159.2008.05789.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=19046357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=521-532&author=E.+Calcagnoauthor=M.+Carliauthor=M.+Bavieraauthor=R.+W.+Invernizzi&title=Endogenous+serotonin+and+serotonin2C+receptors+are+involved+in+the+ability+of+M100907+to+suppress+cortical+glutamate+release+induced+by+NMDA+receptor+blockade&doi=10.1111%2Fj.1471-4159.2008.05789.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade</span></div><div class="casAuthors">Calcagno, Eleonora; Carli, Mirjana; Baviera, Marta; Invernizzi, Roberto W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">521-532</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Blockade of NMDA receptors by intracortical infusion of 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP) increases glutamate (GLU) and serotonin (5-HT) release in the medial prefrontal cortex and impairs attentional performance in the 5-choice serial reaction time task.  These effects are prevented by the 5-HT2A receptor antagonist, (R)-(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol (M100907).  We explored the roles of endogenous 5-HT and 5-HT1A and 5-HT2C receptors in the mechanisms by which M100907 suppresses CPP-induced release of cortical GLU and 5-HT using in vivo microdialysis.  CPP raised extracellular GLU and 5-HT by about 250% and 170% resp.  The 5-HT synthesis inhibitor, p-chlorophenylalanine (300 mg/kg), prevented M100907 suppressing CPP-induced GLU release.  The effect of M100907 on these rises of GLU and 5-HT and attentional performance deficit was mimicked by the 5-HT2C receptor agonist, (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine fumarate, (Ro60-0175, 30 μg/kg) while intra-mPFC (SB242084, 6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline, 0.1 μM), a 5-HT2C receptor antagonist, prevented the effect of M100907 on extracellular GLU.  The 5-HT1A receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexane carboxenide trihydrochloride (100 μM) abolished the effect of M100907 on the CPP-induced 5-HT release.  The data show that blockade of 5-HT2A receptors is not sufficient to suppress the CPP-induced rise of extracellular GLU and 5-HT and suggest that M100907 suppresses GLU release induced by CPP by enhancing the action of endogenous 5-HT on 5-HT2C receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpax0KCgcrJA7Vg90H21EOLACvtfcHk0lj6Rj4TnkPqyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCqtA%253D%253D&md5=185b52f99bdcfa78c72f9d1370a42fbc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05789.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05789.x%26sid%3Dliteratum%253Aachs%26aulast%3DCalcagno%26aufirst%3DE.%26aulast%3DCarli%26aufirst%3DM.%26aulast%3DBaviera%26aufirst%3DM.%26aulast%3DInvernizzi%26aufirst%3DR.%2BW.%26atitle%3DEndogenous%2520serotonin%2520and%2520serotonin2C%2520receptors%2520are%2520involved%2520in%2520the%2520ability%2520of%2520M100907%2520to%2520suppress%2520cortical%2520glutamate%2520release%2520induced%2520by%2520NMDA%2520receptor%2520blockade%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D108%26spage%3D521%26epage%3D532%26doi%3D10.1111%2Fj.1471-4159.2008.05789.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Del’Guidice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemasson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levasseur-Moreau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etievant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escoffier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span> </span><span class="NLM_article-title">Stimulation of 5-HT<sub>2C</sub> receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1125</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1038/npp.2013.313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnpp.2013.313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=1125-1134&author=T.+Del%E2%80%99Guidiceauthor=F.+Lemayauthor=M.+Lemassonauthor=J.+Levasseur-Moreauauthor=S.+Mantaauthor=A.+Etievantauthor=G.+Escoffierauthor=F.+Y.+Doreauthor=F.+S.+Romanauthor=J.+M.+Beaulieu&title=Stimulation+of+5-HT2C+receptors+improves+cognitive+deficits+induced+by+human+tryptophan+hydroxylase+2+loss+of+function+mutation&doi=10.1038%2Fnpp.2013.313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.313%26sid%3Dliteratum%253Aachs%26aulast%3DDel%25E2%2580%2599Guidice%26aufirst%3DT.%26aulast%3DLemay%26aufirst%3DF.%26aulast%3DLemasson%26aufirst%3DM.%26aulast%3DLevasseur-Moreau%26aufirst%3DJ.%26aulast%3DManta%26aufirst%3DS.%26aulast%3DEtievant%26aufirst%3DA.%26aulast%3DEscoffier%26aufirst%3DG.%26aulast%3DDore%26aufirst%3DF.%2BY.%26aulast%3DRoman%26aufirst%3DF.%2BS.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26atitle%3DStimulation%2520of%25205-HT2C%2520receptors%2520improves%2520cognitive%2520deficits%2520induced%2520by%2520human%2520tryptophan%2520hydroxylase%25202%2520loss%2520of%2520function%2520mutation%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D1125%26epage%3D1134%26doi%3D10.1038%2Fnpp.2013.313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Hallucinogens</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0ljJkUEiQjV6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for possible involvement of 5-HT<sub>2B</sub> receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span><span class="refDoi"> DOI: 10.1161/01.CIR.102.23.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1161%2F01.CIR.102.23.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11104741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+possible+involvement+of+5-HT2B+receptors+in+the+cardiac+valvulopathy+associated+with+fenfluramine+and+other+serotonergic+medications&doi=10.1161%2F01.CIR.102.23.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Savage, Jason E.; Rauser, Laura; McBride, Ace; Hufeisen, Sandra J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2836-2841</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being investigated as treatments for drug dependence.  The occurrence of fenfluramine-assocd. valvular heart disease (VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD.  We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis.  Medications known or suspected to cause VHD (pos. controls) and medications not assocd. with VHD (neg. controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of ligand-binding methods and functional assays.  The pos. control drugs were (±)-fenfluramine; (+)-fenfluramine; (-)-fenfluramine; its metabolites (±)-norfenfluramine, (+)-norfenfluramine, and (-)-norfenfluramine; ergotamine; and methysergide and its metabolite methylergonovine.  The neg. control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine.  (±)-, (+)-, And (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor.  Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT2B receptors are unlikely to produce VHD.  We suggest that all clin. available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6spUXOCLtLrVg90H21EOLACvtfcHk0ljJkUEiQjV6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D&md5=6b8c6059885dd9b058859089914c61b3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.102.23.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.102.23.2836%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520possible%2520involvement%2520of%25205-HT2B%2520receptors%2520in%2520the%2520cardiac%2520valvulopathy%2520associated%2520with%2520fenfluramine%2520and%2520other%2520serotonergic%2520medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26spage%3D2836%26epage%3D2841%26doi%3D10.1161%2F01.CIR.102.23.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Saldana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espitia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuskin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D.</span><span> </span><span class="NLM_article-title">Lorcaserin, a novel selective human 5-hydroxytryptamine<sub>2C</sub> agonist: In vitro and in vivo pharmacological characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1124/jpet.107.133348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fjpet.107.133348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18252809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=577-587&author=W.+J.+Thomsenauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=H.+Reyes-Saldanaauthor=S.+Espitiaauthor=D.+Yuskinauthor=K.+Whelanauthor=M.+Martinauthor=M.+Morganauthor=W.+Chenauthor=H.+Al-Shammaauthor=B.+Smithauthor=D.+Chalmersauthor=D.+Behan&title=Lorcaserin%2C+a+novel+selective+human+5-hydroxytryptamine2C+agonist%3A+In+vitro+and+in+vivo+pharmacological+characterization&doi=10.1124%2Fjpet.107.133348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization</span></div><div class="casAuthors">Thomsen, William J.; Grottick, Andrew J.; Menzaghi, Frederique; Reyes-Saldana, Hazel; Espitia, Stephen; Yuskin, Diane; Whelan, Kevin; Martin, Michael; Morgan, Michael; Chen, Weichao; Al-Shamma, Hussein; Smith, Brian; Chalmers, Derek; Behan, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)2C receptor agonists hold promise for the treatment of obesity.  In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT2C full agonist.  Lorcaserin bound to human and rat 5-HT2C receptors with high affinity (Ki = 15±1 nM, 29±7 nM, resp.), and it was a full agonist for the human 5-HT2C receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT2A and 5-HT2B receptors, resp.  Lorcaserin was also highly selective for human 5-HT2C over other human 5-HT receptors (5-HT1A, 5-HT3, 5-HT4C, 5-HT55A, 5-HT6, and 5-HT7), in addn. to a panel of 67 other G protein-coupled receptors and ion channels.  Lorcaserin did not compete for binding of ligands to serotonin, dopamine, and norepinephrine transporters, and it did not alter their function in vitro.  Behavioral observations indicated that unlike the 5-HT2A agonist (±)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane, lorcaserin did not induce behavioral changes indicative of functional 5-HT2A agonist activity.  Acutely, lorcaserin reduced food intake in rats, an effect that was reversed by pretreatment with the 5-HT2C-selective antagonist 6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl-carbamoyl]indoline (SB242,084) but not the 5-HT2A antagonist (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL 100,907), demonstrating mediation by the 5-HT2C receptor.  Chronic daily treatment with lorcaserin to rats maintained on a high fat diet produced dose-dependent redns. in food intake and body wt. gain that were maintained during the 4-wk study.  Upon discontinuation, body wt. returned to control levels.  These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT2C receptor, with potential for the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDHE28aF3k7Vg90H21EOLACvtfcHk0ljJkUEiQjV6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D&md5=0626c3dabb7e89066e45ecd12cbc81f8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133348%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DReyes-Saldana%26aufirst%3DH.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DYuskin%26aufirst%3DD.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChalmers%26aufirst%3DD.%26aulast%3DBehan%26aufirst%3DD.%26atitle%3DLorcaserin%252C%2520a%2520novel%2520selective%2520human%25205-hydroxytryptamine2C%2520agonist%253A%2520In%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D577%26epage%3D587%26doi%3D10.1124%2Fjpet.107.133348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">DiNicolantonio, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, P.</span><span> </span><span class="NLM_article-title">Lorcaserin for the treatment of obesity? A closer look at its side effects</span> <span class="citation_source-journal">Open Heart</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e000173</span><span class="refDoi"> DOI: 10.1136/openhrt-2014-000173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1136%2Fopenhrt-2014-000173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=e000173&author=J.+J.+DiNicolantonioauthor=S.+Chatterjeeauthor=J.+H.+O%E2%80%99Keefeauthor=P.+Meier&title=Lorcaserin+for+the+treatment+of+obesity%3F+A+closer+look+at+its+side+effects&doi=10.1136%2Fopenhrt-2014-000173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1136%2Fopenhrt-2014-000173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fopenhrt-2014-000173%26sid%3Dliteratum%253Aachs%26aulast%3DDiNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DJ.%2BH.%26aulast%3DMeier%26aufirst%3DP.%26atitle%3DLorcaserin%2520for%2520the%2520treatment%2520of%2520obesity%253F%2520A%2520closer%2520look%2520at%2520its%2520side%2520effects%26jtitle%3DOpen%2520Heart%26date%3D2014%26volume%3D1%26spage%3De000173%26doi%3D10.1136%2Fopenhrt-2014-000173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaisin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunosewoyo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmerberg, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogorelov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span><span class="refDoi"> DOI: 10.1021/jm5019274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1992-2002&author=J.+Chengauthor=P.+M.+Giguereauthor=O.+K.+Onajoleauthor=W.+Lvauthor=A.+Gaisinauthor=H.+Gunosewoyoauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=G.+Vistoliauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Optimization+of+2-phenylcyclopropylmethylamines+as+selective+serotonin+2C+receptor+agonists+and+their+evaluation+as+potential+antipsychotic+agents&doi=10.1021%2Fjm5019274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Onajole, Oluseye K.; Lv, Wei; Gaisin, Arsen; Gunosewoyo, Hendra; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Vistoli, Giulio; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1992-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a new series of compds. that are potent, selective 5-HT2C receptor agonists is described herein as the authors continue the efforts to optimize the 2-phenylcyclopropylmethylamine scaffold.  Modifications focused on the alkoxyl substituent present on the arom. ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors.  ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compds. possessing drug-like profiles and having antipsychotic properties.  Compd. I, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date.  The likely binding mode of this series of compds. to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Ar63unExNbVg90H21EOLACvtfcHk0liz9ojZclICog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D&md5=f2884cbae8062702164da57a0de7381f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm5019274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019274%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DGaisin%26aufirst%3DA.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DOptimization%2520of%25202-phenylcyclopropylmethylamines%2520as%2520selective%2520serotonin%25202C%2520receptor%2520agonists%2520and%2520their%2520evaluation%2520as%2520potential%2520antipsychotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1992%26epage%3D2002%26doi%3D10.1021%2Fjm5019274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svennebring, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational drug design leading to the identification of a potent 5-HT<sub>2C</sub> agonist lacking 5-HT<sub>2B</sub> Activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span><span class="refDoi"> DOI: 10.1021/ml200206z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200206z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=929-932&author=G.+Chenauthor=S.+J.+Choauthor=X.+P.+Huangauthor=N.+H.+Jensenauthor=A.+Svennebringauthor=M.+F.+Sassanoauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Rational+drug+design+leading+to+the+identification+of+a+potent+5-HT2C+agonist+lacking+5-HT2B+Activity&doi=10.1021%2Fml200206z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fml200206z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200206z%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DSvennebring%26aufirst%3DA.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520drug%2520design%2520leading%2520to%2520the%2520identification%2520of%2520a%2520potent%25205-HT2C%2520agonist%2520lacking%25205-HT2B%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Fml200206z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svennebring, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">HTS and rational drug design to generate a class of 5-HT<sub>2C</sub>-selective ligands for possible use in schizophrenia</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span><span class="refDoi"> DOI: 10.1002/cmdc.201000186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1002%2Fcmdc.201000186" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1221-1225&author=A.+P.+Kozikowskiauthor=S.+J.+Choauthor=N.+H.+Jensenauthor=J.+A.+Allenauthor=A.+M.+Svennebringauthor=B.+L.+Roth&title=HTS+and+rational+drug+design+to+generate+a+class+of+5-HT2C-selective+ligands+for+possible+use+in+schizophrenia&doi=10.1002%2Fcmdc.201000186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000186%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DSvennebring%26aufirst%3DA.%2BM.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DHTS%2520and%2520rational%2520drug%2520design%2520to%2520generate%2520a%2520class%2520of%25205-HT2C-selective%2520ligands%2520for%2520possible%2520use%2520in%2520schizophrenia%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1221%26epage%3D1225%26doi%3D10.1002%2Fcmdc.201000186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurome, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manzano, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: Identification of drugs with antidepressant-like action</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1885</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span><span class="refDoi"> DOI: 10.1021/jm801354e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801354e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1885-1902&author=S.+J.+Choauthor=N.+H.+Jensenauthor=T.+Kuromeauthor=S.+Kadariauthor=M.+L.+Manzanoauthor=J.+E.+Malbergauthor=B.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Selective+5-hydroxytryptamine+2C+receptor+agonists+derived+from+the+lead+compound+tranylcypromine%3A+Identification+of+drugs+with+antidepressant-like+action&doi=10.1021%2Fjm801354e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span></div><div class="casAuthors">Cho, Sung Jin; Jensen, Niels H.; Kurome, Toru; Kadari, Sudhakar; Manzano, Michael L.; Malberg, Jessica E.; Caldarone, Barbara; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1885-1902</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here the design, synthesis, and pharmacol. properties of a series of compds. related to tranylcypromine (9), which itself was discovered as a lead compd. in a high-throughput screening campaign.  Starting from 9, which shows modest activity as a 5-HT2C agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT2C agonists through iterative structural modifications.  Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring.  Among the tested compds., several were potent and efficacious 5-HT2C receptor agonists with selectivity over both 5-HT2A and 5-HT2B receptors in functional assays.  The most promising compd. is 37, with 120- and 14-fold selectivity over 5-HT2A and 5-HT2B, resp. (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, resp.).  In animal studies, compd. 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh5xre4fJybVg90H21EOLACvtfcHk0liUYb2Oj3kKAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D&md5=d7711d01a8d462824a8fcf535e0a1be4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm801354e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801354e%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKurome%26aufirst%3DT.%26aulast%3DKadari%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DM.%2BL.%26aulast%3DMalberg%26aufirst%3DJ.%2BE.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%25205-hydroxytryptamine%25202C%2520receptor%2520agonists%2520derived%2520from%2520the%2520lead%2520compound%2520tranylcypromine%253A%2520Identification%2520of%2520drugs%2520with%2520antidepressant-like%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1885%26epage%3D1902%26doi%3D10.1021%2Fjm801354e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The many roles for fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4369</span><span class="refDoi"> DOI: 10.1021/jm800219f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+many+roles+for+fluorine+in+medicinal+chemistry&doi=10.1021%2Fjm800219f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0liHAEqVjhOuCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520many%2520roles%2520for%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369%26doi%3D10.1021%2Fjm800219f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalchick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">(2<i>R</i>)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8<i>H</i>)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-+yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+A+potent%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-%2520yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520A%2520potent%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure-based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure-based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1016/S0893-133X(98)00099-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0893-133X%2898%2900099-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10327430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=612-627&author=C.+P.+Lawlerauthor=C.+Prioleauauthor=M.+M.+Lewisauthor=C.+Makauthor=D.+Jiangauthor=J.+A.+Schetzauthor=A.+M.+Gonzalezauthor=D.+R.+Sibleyauthor=R.+B.+Mailman&title=Interactions+of+the+novel+antipsychotic+aripiprazole+%28OPC-14597%29+with+dopamine+and+serotonin+receptor+subtypes&doi=10.1016%2FS0893-133X%2898%2900099-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span></div><div class="casAuthors">Lawler, Cindy P.; Prioleau, Cassandra; Lewis, Mechelle M.; Mak, Chun; Jiang, Dong; Schetz, John A.; Gonzalez, Antonio M.; Sibley, David R.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">612-627</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">OPC-14597 {aripiprazole; 7- (4- (4-(2,3-dichlorophenyl) -1-piperazinyl) butyloxy) -3, 4-dihydro-2 (1H) -quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects.  These studies characterized the mol. pharmacol. of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone deriv. OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors.  All three compds. exhibited highest affinity for D2L and D2S receptors relative to the other cloned receptors examd.  Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D2L receptors, although the metabolite DM-1451 behaved as a pure antagonist.  These data suggest that clin. atypicality can occur with drugs that exhibit selectivity for D2L/D2S rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compd. interacting with a single dopamine receptor subtype (D2) in distinct cellular locales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhC9HkOART7Vg90H21EOLACvtfcHk0liwruS0CSLlcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D&md5=6075301b17f119d4040742751425bb92</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900099-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900099-2%26sid%3Dliteratum%253Aachs%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DSchetz%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DInteractions%2520of%2520the%2520novel%2520antipsychotic%2520aripiprazole%2520%2528OPC-14597%2529%2520with%2520dopamine%2520and%2520serotonin%2520receptor%2520subtypes%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D20%26spage%3D612%26epage%3D627%26doi%3D10.1016%2FS0893-133X%2898%2900099-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lgolaE24CR0jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Voth, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. S.</span><span> </span><span class="NLM_article-title">Halogen bonds as orthogonal molecular interactions to hydrogen bonds</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1038/nchem.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnchem.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=21378804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlSlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=74-79&author=A.+R.+Vothauthor=P.+Khuuauthor=K.+Oishiauthor=P.+S.+Ho&title=Halogen+bonds+as+orthogonal+molecular+interactions+to+hydrogen+bonds&doi=10.1038%2Fnchem.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen bonds as orthogonal molecular interactions to hydrogen bonds</span></div><div class="casAuthors">Voth, Andrea Regier; Khuu, Patricia; Oishi, Keita; Ho, P. Shing</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-79</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Halogen bonds (X-bonds) are shown to be geometrically perpendicular to and energetically independent of hydrogen bonds (H-bonds) that share a common carbonyl oxygen acceptor.  This orthogonal relationship is accommodated by the in-plane and out-of-plane electroneg. potentials of the oxygen, which are differentially populated by H- and X-bonds.  Furthermore, the local conformation of a peptide helps to define the geometry of the H-bond and thus the oxygen surface that is accessible for X-bonding.  These electrostatic and steric forces conspire to impose a strong preference for the orthogonal geometry of X- and H-bonds.  Thus, the optimum geometry of an X-bond can be predicted from the pattern of H-bonds in a folded protein, enabling X-bonds to be introduced to improve ligand affinities without disrupting these structurally important interactions.  This concept of orthogonal mol. interactions can be exploited for the rational design of halogenated ligands as inhibitors and drugs, and in biomol. engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBR3qQ1-IvprVg90H21EOLACvtfcHk0lgolaE24CR0jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlSlsb4%253D&md5=fd9ef235df86c00261b9bd0a782f88c2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchem.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.112%26sid%3Dliteratum%253Aachs%26aulast%3DVoth%26aufirst%3DA.%2BR.%26aulast%3DKhuu%26aufirst%3DP.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DP.%2BS.%26atitle%3DHalogen%2520bonds%2520as%2520orthogonal%2520molecular%2520interactions%2520to%2520hydrogen%2520bonds%26jtitle%3DNat.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D74%26epage%3D79%26doi%3D10.1038%2Fnchem.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Toy, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanabalasingam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">A substituted hypersensitive radical probe for enzyme-catalyzed hydroxylations: Synthesis of racemic and enantiomerically enriched forms and application in a cytochrome P450-catalyzed oxidation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">9114</span><span class="NLM_x">–</span> <span class="NLM_lpage">9122</span><span class="refDoi"> DOI: 10.1021/jo9712097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9712097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=9114-9122&author=P.+H.+Toyauthor=B.+Dhanabalasingamauthor=M.+Newcombauthor=I.+H.+Hannaauthor=P.+F.+Hollenberg&title=A+substituted+hypersensitive+radical+probe+for+enzyme-catalyzed+hydroxylations%3A+Synthesis+of+racemic+and+enantiomerically+enriched+forms+and+application+in+a+cytochrome+P450-catalyzed+oxidation&doi=10.1021%2Fjo9712097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo9712097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9712097%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DP.%2BH.%26aulast%3DDhanabalasingam%26aufirst%3DB.%26aulast%3DNewcomb%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DI.%2BH.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DA%2520substituted%2520hypersensitive%2520radical%2520probe%2520for%2520enzyme-catalyzed%2520hydroxylations%253A%2520Synthesis%2520of%2520racemic%2520and%2520enantiomerically%2520enriched%2520forms%2520and%2520application%2520in%2520a%2520cytochrome%2520P450-catalyzed%2520oxidation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D9114%26epage%3D9122%26doi%3D10.1021%2Fjo9712097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Gooden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabadi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, D. G.</span><span> </span><span class="NLM_article-title">Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3047</span><span class="NLM_x">–</span> <span class="NLM_lpage">3051</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.bmcl.2008.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18242989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVagurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3047-3051&author=D.+M.+Goodenauthor=D.+M.+Z.+Schmidtauthor=J.+A.+Pollockauthor=A.+M.+Kabadiauthor=D.+G.+McCafferty&title=Facile+synthesis+of+substituted+trans-2-arylcyclopropylamine+inhibitors+of+the+human+histone+demethylase+LSD1+and+monoamine+oxidases+A+and+B&doi=10.1016%2Fj.bmcl.2008.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B</span></div><div class="casAuthors">Gooden, David M.; Schmidt, Dawn M. Z.; Pollock, Julie A.; Kabadi, Ami M.; McCafferty, Dewey G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3047-3051</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A facile synthetic route to substituted trans-2-arylcyclopropylamines was developed to provide access to mechanism-based inhibitors of the human flavoenzyme oxidase lysine-specific histone demethylase LSD1 and related enzyme family members such as monoamine oxidases A and B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojt7YjHKC3yrVg90H21EOLACvtfcHk0ligZ0fIke32OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVagurs%253D&md5=2459dcb4cde160186fc17c09258c5906</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGooden%26aufirst%3DD.%2BM.%26aulast%3DSchmidt%26aufirst%3DD.%2BM.%2BZ.%26aulast%3DPollock%26aufirst%3DJ.%2BA.%26aulast%3DKabadi%26aufirst%3DA.%2BM.%26aulast%3DMcCafferty%26aufirst%3DD.%2BG.%26atitle%3DFacile%2520synthesis%2520of%2520substituted%2520trans-2-arylcyclopropylamine%2520inhibitors%2520of%2520the%2520human%2520histone%2520demethylase%2520LSD1%2520and%2520monoamine%2520oxidases%2520A%2520and%2520B%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3047%26epage%3D3051%26doi%3D10.1016%2Fj.bmcl.2008.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0ligZ0fIke32OA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Benhamu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Fontecha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez-Villa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Rodriguez, M. L.</span><span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7160</span><span class="NLM_x">–</span> <span class="NLM_lpage">7181</span><span class="refDoi"> DOI: 10.1021/jm5003952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7160-7181&author=B.+Benhamuauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=L.+Pardoauthor=M.+L.+Lopez-Rodriguez&title=Serotonin+5-HT6+receptor+antagonists+for+the+treatment+of+cognitive+deficiency+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm5003952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease</span></div><div class="casAuthors">Benhamu, Bellinda; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Pardo, Leonardo; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7160-7181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clin. and socioeconomic impact.  In the search for novel therapeutic strategies, serotonin 5-HT6 receptor (5-HT6R) has been proposed as a promising drug target for cognition enhancement in AD.  This manuscript reviews the compelling evidence for the implication of this receptor in learning and memory processes.  We have summarized the current status of the medicinal chem. of 5-HT6R antagonists and the encouraging preclin. findings that demonstrate their significant procognitive behavioral effects in a no. of learning paradigms, probably acting through modulation of multiple neurotransmitter systems and signaling pathways.  The results of the ongoing clin. trials are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic cognitive impairment in AD, either as stand-alone therapy or in combination with established agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTO6_2THvaLVg90H21EOLACvtfcHk0lgQXD2EQfWjwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D&md5=bf8d2cba73f72e04a5caf8b295647064</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm5003952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003952%26sid%3Dliteratum%253Aachs%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520deficiency%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7160%26epage%3D7181%26doi%3D10.1021%2Fjm5003952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Karila, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freret, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulouard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallemagne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochais, C.</span><span> </span><span class="NLM_article-title">Therapeutic potential of 5-HT<sub>6</sub> receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7901</span><span class="NLM_x">–</span> <span class="NLM_lpage">7912</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKitr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7901-7912&author=D.+Karilaauthor=T.+Freretauthor=V.+Bouetauthor=M.+Boulouardauthor=P.+Dallemagneauthor=C.+Rochais&title=Therapeutic+potential+of+5-HT6+receptor+agonists&doi=10.1021%2Facs.jmedchem.5b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of 5-HT6 Receptor Agonists</span></div><div class="casAuthors">Karila, Delphine; Freret, Thomas; Bouet, Valentine; Boulouard, Michel; Dallemagne, Patrick; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7901-7912</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given its predominant expression in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (5-HT6R) has been considered as a valuable target for the development of CNS drugs with limited side effects.  After 2 decades of intense research, numerous selective ligands have been developed to target this receptor; this holds potential interest for the treatment of neuropathol. disorders.  In fact, some agents (mainly antagonists) are currently undergoing clin. trial.  More recently, a series of potent and selective agonists have been developed, and preclin. studies have been conducted that suggest the therapeutic interest of 5-HT6R agonists.  This review details the medicinal chem. of these agonists, highlights their activities, and discusses their potential for treating cognitive issues assocd. with Alzheimer's disease (AD), depression, or obesity.  Surprisingly, some studies have shown that both 5-HT6R agonists and antagonists exert similar procognitive activities.  This article summarizes the hypotheses that could explain this paradox.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJqIFtQjIYrVg90H21EOLACvtfcHk0lgQXD2EQfWjwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKitr3E&md5=4fba085fbefee0b614ea122821c7787f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00179%26sid%3Dliteratum%253Aachs%26aulast%3DKarila%26aufirst%3DD.%26aulast%3DFreret%26aufirst%3DT.%26aulast%3DBouet%26aufirst%3DV.%26aulast%3DBoulouard%26aufirst%3DM.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520potential%2520of%25205-HT6%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7901%26epage%3D7912%26doi%3D10.1021%2Facs.jmedchem.5b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span> </span><span class="NLM_article-title">Predictive in silico modeling for hERG channel blockers</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03278-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS1359-6446%2804%2903278-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=15718164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFarsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=149-155&author=A.+M.+Aronov&title=Predictive+in+silico+modeling+for+hERG+channel+blockers&doi=10.1016%2FS1359-6446%2804%2903278-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive in silico modeling for hERG channel blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-155</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  HERG-mediated sudden death as a side effect of non-antiarrhythmic drugs has been receiving increased regulatory attention.  Perhaps owing to the unique shape of the ligand-binding site and its hydrophobic character, the hERG channel has been shown to interact with pharmaceuticals of widely varying structure.  Several in silico approaches have attempted to predict hERG channel blockade.  Some of these approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, others involve understanding structure-activity relationships governing hERG-drug interactions.  This review summarizes the most recent efforts in this emerging field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgIcgWdJQJrVg90H21EOLACvtfcHk0ljSR9Yv0qOOnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFarsbY%253D&md5=112b79a48e3d6f5ab3e313f00cf2a4fa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903278-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903278-7%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DPredictive%2520in%2520silico%2520modeling%2520for%2520hERG%2520channel%2520blockers%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D149%26epage%3D155%26doi%3D10.1016%2FS1359-6446%2804%2903278-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of beta-arrestin-biased dopamine D<sub>2</sub> ligands for probing signal transduction pathways essential for antipsychotic efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+beta-arrestin-biased+dopamine+D2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0ljSR9Yv0qOOnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520beta-arrestin-biased%2520dopamine%2520D2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Chitty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyyalol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Iverson, M. T.</span><span> </span><span class="NLM_article-title">Dexamphetamine effects on prepulse inhibition (PPI) and startle in healthy volunteers</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">2327</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span><span class="refDoi"> DOI: 10.1007/s00213-013-3395-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1007%2Fs00213-013-3395-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2327-2337&author=K.+Chittyauthor=M.+A.+Albrechtauthor=K.+Grahamauthor=C.+Kerrauthor=J.+W.+Y.+Leeauthor=R.+Iyyalolauthor=M.+T.+Martin-Iverson&title=Dexamphetamine+effects+on+prepulse+inhibition+%28PPI%29+and+startle+in+healthy+volunteers&doi=10.1007%2Fs00213-013-3395-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3395-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3395-z%26sid%3Dliteratum%253Aachs%26aulast%3DChitty%26aufirst%3DK.%26aulast%3DAlbrecht%26aufirst%3DM.%2BA.%26aulast%3DGraham%26aufirst%3DK.%26aulast%3DKerr%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BW.%2BY.%26aulast%3DIyyalol%26aufirst%3DR.%26aulast%3DMartin-Iverson%26aufirst%3DM.%2BT.%26atitle%3DDexamphetamine%2520effects%2520on%2520prepulse%2520inhibition%2520%2528PPI%2529%2520and%2520startle%2520in%2520healthy%2520volunteers%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2327%26epage%3D2337%26doi%3D10.1007%2Fs00213-013-3395-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Ramsey, A. J.</span><span> </span><span class="NLM_article-title">NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia</span> <span class="citation_source-journal">Prog. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/S0079-6123(09)17906-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0079-6123%2809%2917906-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=20302817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFekt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2009&pages=51-58&author=A.+J.+Ramsey&title=NR1+knockdown+mice+as+a+representative+model+of+the+glutamate+hypothesis+of+schizophrenia&doi=10.1016%2FS0079-6123%2809%2917906-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia</span></div><div class="casAuthors">Ramsey, Amy J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">Genetic Models of Schizophrenia</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  N-Me d-aspartate (NMDA) receptor subunit NR1 knockdown (NR1-KD) mice have a global redn. of NMDA receptors, enabling their use as a genetic model to study the role of NMDA receptors in the pathophysiol. of schizophrenia.  This targeted mutation results in a spectrum of altered behaviors that are similar to those induced by NMDA receptor antagonists, which have long been used to model schizophrenia in animals.  NR1-KD mice serve as a complementary tool to pharmacol. models, providing insight into the consequences of sustained NMDA receptor dysfunction in early brain development and throughout the life of the animal.  Though in many respects the phenotype of NR1-KD mice mimics that of acute NMDA receptor antagonism, there are also notable differences.  In this chapter we highlight some of the mol., behavioral, and neurophysiol. phenotypes of NR1-KD mice and compare these to pharmacol. models of NMDA receptor dysfunction.  Through the study of these models, our improved understanding of how the brain adapts to persistent NMDA receptor hypofunction may eventually suggest new therapeutic strategies for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGC4oH7Y4IUbVg90H21EOLACvtfcHk0ljSR9Yv0qOOnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFekt78%253D&md5=86ed6b4271427b0a9186acb6a897e2e4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2809%2917906-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252809%252917906-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DA.%2BJ.%26atitle%3DNR1%2520knockdown%2520mice%2520as%2520a%2520representative%2520model%2520of%2520the%2520glutamate%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2009%26volume%3D179%26spage%3D51%26epage%3D58%26doi%3D10.1016%2FS0079-6123%2809%2917906-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Danion, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidailhet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berna, F.</span><span> </span><span class="NLM_article-title">Functional mechanisms of episodic memory impairment in schizophrenia</span> <span class="citation_source-journal">Can. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18399036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ktVShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=693-701&author=J.+M.+Danionauthor=C.+Huronauthor=P.+Vidailhetauthor=F.+Berna&title=Functional+mechanisms+of+episodic+memory+impairment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Functional mechanisms of episodic memory impairment in schizophrenia</span></div><div class="casAuthors">Danion Jean-Marie; Huron Caroline; Vidailhet Pierre; Berna Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of psychiatry. Revue canadienne de psychiatrie</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">693-701</span>
        ISSN:<span class="NLM_cas:issn">0706-7437</span>.
    </div><div class="casAbstract">OBJECTIVE:  To achieve a better understanding of the functional mechanisms underlying episodic memory dysfunction in schizophrenia, which is a prerequisite for unravelling schizophrenia's neural correlates in neuroimaging studies and, more generally, for developing an integrated approach to the pathophysiology of schizophrenia.  It is also crucial for developing cognitive remediation.  METHOD:  This paper reviews empirical evidence of episodic memory dysfunction in schizophrenia obtained with reference to various theoretical models of episodic memory.  RESULTS:  All the studies converge to show a significant impairment of the critical feature of episodic memory: conscious recollection.  Schizophrenia is also associated with a defect of autobiographical memory.  The episodic memory dysfunction results from a predominant failure of strategic processing at encoding, although an impairment of strategic processing at retrieval cannot be ruled out.  The possibility that it is not the execution of the encoding strategies that is defective but, rather, their self-initiation by the patients is plausible.  CONCLUSIONS:  These findings may explain some behavioural abnormalities associated with schizophrenia, notably, inadequate functional outcomes in everyday life.  They may also have implications for cognitive remediation and better social and work functioning of patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFFXwl23dMcekdrW1FkXG-fW6udTcc2eZC8pWcYWIvR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ktVShug%253D%253D&md5=c0be1020e3374f820431a86ba2643b51</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanion%26aufirst%3DJ.%2BM.%26aulast%3DHuron%26aufirst%3DC.%26aulast%3DVidailhet%26aufirst%3DP.%26aulast%3DBerna%26aufirst%3DF.%26atitle%3DFunctional%2520mechanisms%2520of%2520episodic%2520memory%2520impairment%2520in%2520schizophrenia%26jtitle%3DCan.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D52%26spage%3D693%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Horiguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">The role of 5-HT<sub>1A</sub> receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">221</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1007/s00213-011-2561-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1007%2Fs00213-011-2561-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=22227609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BC38zpvFylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2012&pages=205-215&author=M.+Horiguchiauthor=H.+Y.+Meltzer&title=The+role+of+5-HT1A+receptors+in+phencyclidine+%28PCP%29-induced+novel+object+recognition+%28NOR%29+deficit+in+rats&doi=10.1007%2Fs00213-011-2561-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats</span></div><div class="casAuthors">Horiguchi M; Meltzer H Y</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Atypical antipsychotic drugs (APDs), many of which are direct or indirect serotonin (5-HT)(1A) agonists, and tandospirone, a 5-HT(1A) partial agonist, have been reported to improve cognition in schizophrenia.  OBJECTIVES AND METHODS:  We tested the effect of 5-HT(1A) agonism, alone, and in combination with other psychotropic agents, including the atypical APD, lurasidone, in reversing the deficit in novel object recognition (NOR) induced by subchronic treatment with the non-competitive NMDA receptor antagonist, phencyclidine (PCP) (2 mg/kg, b.i.d., for 7 days).  RESULTS:  Subchronic treatment with PCP induced a persistent NOR deficit.  Lurasidone (0.1 mg/kg), a potent 5-HT(1A) partial agonist, 5-HT(2A) antagonist, and weaker D(2) antagonist, tandospirone (0.6 mg/kg), and the selective post-synaptic 5-HT(1A) agonist, F15599 (0.16 mg/kg), ameliorated the subchronic PCP-induced-NOR deficit.  The 5-HT(1A) antagonist, WAY100635 (0.6 mg/kg), blocked the ameliorating effects of tandospirone and lurasidone.  The combination of sub-effective doses of tandospirone (0.2 mg/kg) and lurasidone (0.03 mg/kg) also reversed the PCP-induced NOR-deficit.  Buspirone, a less potent partial 5-HT(1A) agonist than tandospirone, was less effective.  Co-administration of tandospirone (0.2 mg/kg) and pimavanserin (3 mg/kg), a relatively selective 5-HT(2A) receptor inverse agonist, did not reverse the effect of sub-chronic PCP on NOR.  The D(2) antagonist, haloperidol, blocked the ameliorating effect of tandospirone on the PCP-induced deficit in NOR.  CONCLUSIONS:  These results indicate that 5-HT(1A) agonism is adequate to ameliorate the PCP-induced impairment in NOR and suggest further study of utilizing the combination of a 5-HT(1A) agonist and an atypical APD to ameliorate some types of cognitive impairment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_kRq9BE6ZfrHHuJhbyicZfW6udTcc2eZC8pWcYWIvR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zpvFylsg%253D%253D&md5=3e92009a015042f003e926f20280090f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs00213-011-2561-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-011-2561-4%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DThe%2520role%2520of%25205-HT1A%2520receptors%2520in%2520phencyclidine%2520%2528PCP%2529-induced%2520novel%2520object%2520recognition%2520%2528NOR%2529%2520deficit%2520in%2520rats%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2012%26volume%3D221%26spage%3D205%26epage%3D215%26doi%3D10.1007%2Fs00213-011-2561-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span> </span><span class="NLM_article-title">Position 5.46 of the serotonin 5-HT<sub>2A</sub> receptor contributes to a species-dependent variation for the 5-HT<sub>2C</sub> agonist (<i>R</i>)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1211</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1124/mol.109.059204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fmol.109.059204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=1211-1219&author=K.+J.+Millerauthor=G.+Y.+Wuauthor=J.+G.+Varnesauthor=P.+Levesqueauthor=J.+L.+Liauthor=D.+S.+Liauthor=J.+A.+Roblauthor=K.+A.+Rossiauthor=D.+A.+Wacker&title=Position+5.46+of+the+serotonin+5-HT2A+receptor+contributes+to+a+species-dependent+variation+for+the+5-HT2C+agonist+%28R%29-9-ethyl-1%2C3%2C4%2C10b-tetrahydro-7-trifluoromethylpyrazino%5B2%2C1-a%5Disoindol-6%282H%29-one%3A+impact+on+selectivity+and+toxicological+evaluation&doi=10.1124%2Fmol.109.059204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.059204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.059204%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DLevesque%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26atitle%3DPosition%25205.46%2520of%2520the%2520serotonin%25205-HT2A%2520receptor%2520contributes%2520to%2520a%2520species-dependent%2520variation%2520for%2520the%25205-HT2C%2520agonist%2520%2528R%2529-9-ethyl-1%252C3%252C4%252C10b-tetrahydro-7-trifluoromethylpyrazino%255B2%252C1-a%255Disoindol-6%25282H%2529-one%253A%2520impact%2520on%2520selectivity%2520and%2520toxicological%2520evaluation%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D1211%26epage%3D1219%26doi%3D10.1124%2Fmol.109.059204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sipes, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">DOI disrupts prepulse inhibition of startle in rats via 5-HT<sub>2A</sub> receptors in the ventral pallidum</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">761</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1016/S0006-8993(97)00316-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0006-8993%2897%2900316-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=9247071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADyaK2sXjslKmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=1997&pages=97-104&author=T.+E.+Sipesauthor=M.+A.+Geyer&title=DOI+disrupts+prepulse+inhibition+of+startle+in+rats+via+5-HT2A+receptors+in+the+ventral+pallidum&doi=10.1016%2FS0006-8993%2897%2900316-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum</span></div><div class="casAuthors">Sipes, Thomas E.; Geyer, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Serotonin (5-HT)2A receptors are known to be involved in prepulse inhibition of the startle response (PPI), a measure of sensorimotor inhibition that is deficient in schizophrenia, Huntington's disease, and obsessive compulsive disorder.  In the present studies, the localization of the 5-HT2A receptors responsible for modulating PPI was investigated using central injections of the hallucinogenic 5-HT2 agonist DOI and the novel 5-HT2A antagonist MDL 100,907. 5-HT2A receptors are densely localized in the nucleus accumbens (NAC) and the ventral pallidum (VP), areas known to be important components of neural circuitry that mediates the ventral forebrain modulation of PPI.  In the present studies, it was found that the infusion of DOI (0.0-5.0 μg/0.5 μl) into the VP disrupted PPI without having effects on startle reactivity.  In contrast, similar infusions into the NAC had no effect on PPI or startle reactivity.  The infusion of MDL 100,907 into the VP was found to increase PPI by itself and to attenuate the PPI-disruptive effects of systemically administered DOI.  It is concluded that 5-HT2A receptors within the VP are important for the modulation of PPI, presumably through interactions at intrinsic GABAergic or cholinergic interneurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqujK_adxkw-7Vg90H21EOLACvtfcHk0lhL7FPLVuI3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjslKmtr4%253D&md5=570d99fc158d624abadda32ea6ab99c9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2897%2900316-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252897%252900316-8%26sid%3Dliteratum%253Aachs%26aulast%3DSipes%26aufirst%3DT.%2BE.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DDOI%2520disrupts%2520prepulse%2520inhibition%2520of%2520startle%2520in%2520rats%2520via%25205-HT2A%2520receptors%2520in%2520the%2520ventral%2520pallidum%26jtitle%3DBrain%2520Res.%26date%3D1997%26volume%3D761%26spage%3D97%26epage%3D104%26doi%3D10.1016%2FS0006-8993%2897%2900316-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT<sub>1A</sub> agonist, as a putative mediator of quetiapine’s antidepressant activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2303</span><span class="NLM_x">–</span> <span class="NLM_lpage">2312</span><span class="refDoi"> DOI: 10.1038/sj.npp.1301646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.npp.1301646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18059438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=2303-2312&author=N.+H.+Jensenauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=W.+C.+Wetselauthor=R.+B.+Rothmanauthor=B.+L.+Roth&title=N-Desalkylquetiapine%2C+a+potent+norepinephrine+reuptake+inhibitor+and+partial+5-HT1A+agonist%2C+as+a+putative+mediator+of+quetiapine%E2%80%99s+antidepressant+activity&doi=10.1038%2Fsj.npp.1301646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity</span></div><div class="casAuthors">Jensen, Niels H.; Rodriguiz, Ramona M.; Caron, Marc G.; Wetsel, William C.; Rothman, Richard B.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2303-2312</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quetiapine is an atypical antipsychotic drug that is also US FDA approved for treating bipolar depression, albeit by an unknown mechanism.  To discover the potential mechanism for this apparently unique action, we screened quetiapine, its metabolite N-Desalkylquetiapine, and dibenzo[b,f][1,4]thiazepine-11(10-H)-one (DBTO) against a large panel of G-protein-coupled receptors, ion channels, and neurotransmitter transporters.  DBTO was inactive at all tested mol. targets.  N-Desalkylquetiapine had a high affinity (3.4 nM) for the histamine H1 receptor and moderate affinities (10-100 nM) for the norepinephrine reuptake transporter (NET), the serotonin 5-HT1A, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT7 receptors, the α1B-adrenergic receptor, and the M1, M3, and M5 muscarinic receptors.  The compd. had low affinities (100-1000 nM) for the 5-HT1D, 5-HT2C, 5-HT3, 5-HT5, 5-HT6, α1A, α2A, α2B, α2C, H2, M2, M4, and dopamine D1, D2, D3, and D4 receptors.  N-Desalkylquetiapine potently inhibited human NE transporter with a Ki of 12 nM, about 100-fold more potent than quetiapine itself.  N-Desalkylquetiapine was also 10-fold more potent and more efficacious than quetiapine at the 5-HT1A receptor.  N-Desalkylquetiapine was an antagonist at 5-HT2A, 5-HT2B, 5-HT2C, α1A, α1D, α2A, α2C, H1, M1, M3, and M5 receptors.  In the mouse tail suspension test, N-Desalkylquetiapine displayed potent antidepressant-like activity in VMAT2 heterozygous mice at doses as low as 0.1 mg/kg.  These data strongly suggest that the antidepressant activity of quetiapine is mediated, at least in part, by its metabolite N-Desalkylquetiapine through NET inhibition and partial 5-HT1A agonism.  Possible contributions of this metabolite to the side effects of quetiapine are discussed.  Neuropsychopharmacol. (2008) 33, 2303-2312; doi:10.1038/sj.npp.1301646; published online 5 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZgCGV-N8xrVg90H21EOLACvtfcHk0liWBV9vSkIwVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSisbs%253D&md5=1ed7827ed03ba02899e51cc8e2f1c554</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301646%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DN-Desalkylquetiapine%252C%2520a%2520potent%2520norepinephrine%2520reuptake%2520inhibitor%2520and%2520partial%25205-HT1A%2520agonist%252C%2520as%2520a%2520putative%2520mediator%2520of%2520quetiapine%25E2%2580%2599s%2520antidepressant%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D2303%26epage%3D2312%26doi%3D10.1038%2Fsj.npp.1301646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Park, S. M.; Chen, M.; Schmerberg, C. M.; Dulman, R. S.; Rodriguiz, R. M.; Caron, M. G.; Jin, J.; Wetsel, W. C.</span><span> </span><span class="NLM_article-title">Effects of β-arrestin biased dopamine D<sub>2</sub> receptor ligands on schizophrenia-like behavior in hypoglutmatergic mice</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span>in press, <span class="refDoi"> DOI: 10.1038/npp.2015.196</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+M.+Park&author=M.+Chen&author=C.+M.+Schmerberg&author=R.+S.+Dulman&author=R.+M.+Rodriguiz&author=M.+G.+Caron&author=J.+Jin&author=W.+C.+Wetsel&title=Effects+of+%CE%B2-arrestin+biased+dopamine+D2+receptor+ligands+on+schizophrenia-like+behavior+in+hypoglutmatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520%25CE%25B2-arrestin%2520biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520schizophrenia-like%2520behavior%2520in%2520hypoglutmatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Geyer, M. A.; Swerdlow, N. R.</span><span> </span><span class="NLM_article-title">Measurement of startle response, prepulse inhibition, and habituation.</span> <span class="citation_source-book">Current Protocols in Neuroscience</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>Chapter 8, 8.7.1–8.7.15.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1002%2F0471142301.ns0807s03" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+A.+Geyer&author=N.+R.+Swerdlow&title=Current+Protocols+in+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2F0471142301.ns0807s03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471142301.ns0807s03%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DMeasurement%2520of%2520startle%2520response%252C%2520prepulse%2520inhibition%252C%2520and%2520habituation.%26btitle%3DCurrent%2520Protocols%2520in%2520Neuroscience%26pub%3DWiley%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Qingtong Zhou, Wenzhong Yan, Jian Sun, Alan P. Kozikowski, Suwen Zhao, Xi-Ping Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4579-4602. <a href="https://doi.org/10.1021/acs.jmedchem.9b01835" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01835%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBitopic%252B2-Phenylcyclopropylmethylamine%252B%252528PCPMA%252529%252BDerivatives%252Bas%252BSelective%252BDopamine%252BD3%252BReceptor%252BLigands%26aulast%3DTan%26aufirst%3DLiang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18112019%26date%3D23042020%26date%3D13042020%26volume%3D63%26issue%3D9%26spage%3D4579%26epage%3D4602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bingjie Zhang, Simeng Zhao, Dehua Yang, Yiran Wu, Ye Xin, Haijie Cao, Xi-Ping Huang, Xiaoqing Cai, Wen Sun, Na Ye, Yueming Xu, Yao Peng, Suwen Zhao, Zhi-Jie Liu, Guisheng Zhong, Ming-Wei Wang, <span class="NLM_string-name hlFld-ContribAuthor">Wenqing Shui</span>. </span><span class="cited-content_cbyCitation_article-title">A Novel G Protein-Biased and Subtype-Selective Agonist for a G Protein-Coupled Receptor Discovered from Screening Herbal Extracts. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2020,</strong> <em>6 </em>
                                    (2)
                                     , 213-225. <a href="https://doi.org/10.1021/acscentsci.9b01125" title="DOI URL">https://doi.org/10.1021/acscentsci.9b01125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.9b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.9b01125%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DA%252BNovel%252BG%252BProtein-Biased%252Band%252BSubtype-Selective%252BAgonist%252Bfor%252Ba%252BG%252BProtein-Coupled%252BReceptor%252BDiscovered%252Bfrom%252BScreening%252BHerbal%252BExtracts%26aulast%3DZhang%26aufirst%3DBingjie%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03112019%26date%3D23012020%26volume%3D6%26issue%3D2%26spage%3D213%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guiping  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">John D.  McCorvy</span>, <span class="hlFld-ContribAuthor ">Paul J.  Lorello</span>, <span class="hlFld-ContribAuthor ">Barbara J.  Caldarone</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, and <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (14)
                                     , 6273-6288. <a href="https://doi.org/10.1021/acs.jmedchem.7b00584" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00584%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-Substituted%252B%2525282-Phenylcyclopropyl%252529methylamines%252Bas%252BFunctionally%252BSelective%252BSerotonin%252B2C%252BReceptor%252BAgonists%252Bfor%252BPotential%252BUse%252Bas%252BAntipsychotic%252BMedications%26aulast%3DZhang%26aufirst%3DGuiping%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D17042017%26date%3D18072017%26date%3D27072017%26date%3D28062017%26volume%3D60%26issue%3D14%26spage%3D6273%26epage%3D6288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juhyeon  Kim</span>, <span class="hlFld-ContribAuthor ">Byung Seok  Moon</span>, <span class="hlFld-ContribAuthor ">Byung Chul  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Young  Lee</span>, <span class="hlFld-ContribAuthor ">Hak-Joong  Kim</span>, <span class="hlFld-ContribAuthor ">Hyunah  Choo</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Yong Seo  Cho</span>, and <span class="hlFld-ContribAuthor ">Sun-Joon  Min</span>  . </span><span class="cited-content_cbyCitation_article-title">A Potential PET Radiotracer for the 5-HT2C Receptor: Synthesis and in Vivo Evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2017,</strong> <em>8 </em>
                                    (5)
                                     , 996-1003. <a href="https://doi.org/10.1021/acschemneuro.6b00445" title="DOI URL">https://doi.org/10.1021/acschemneuro.6b00445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.6b00445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.6b00445%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DA%252BPotential%252BPET%252BRadiotracer%252Bfor%252Bthe%252B5-HT2C%252BReceptor%25253A%252BSynthesis%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252B4-%2525283-%25255B18F%25255Dfluorophenethoxy%252529pyrimidine%26aulast%3DKim%26aufirst%3DJuhyeon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D20122016%26date%3D14022017%26date%3D27022017%26date%3D17052017%26date%3D14022017%26volume%3D8%26issue%3D5%26spage%3D996%26epage%3D1003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">John D.  McCorvy</span>, <span class="hlFld-ContribAuthor ">Patrick M.  Giguere</span>, <span class="hlFld-ContribAuthor ">Hu  Zhu</span>, <span class="hlFld-ContribAuthor ">Terry  Kenakin</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, and <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9866-9880. <a href="https://doi.org/10.1021/acs.jmedchem.6b01194" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01194%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BDiscovery%252Bof%252BFunctionally%252BSelective%252BSerotonin%252B2C%252B%2525285-HT2C%252529%252BReceptor%252BAgonists%26aulast%3DCheng%26aufirst%3DJianjun%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D10082016%26date%3D25102016%26date%3D10112016%26date%3D11102016%26volume%3D59%26issue%3D21%26spage%3D9866%26epage%3D9880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas M.  Barnes</span>, <span class="hlFld-ContribAuthor ">Gerard P.  Ahern</span>, <span class="hlFld-ContribAuthor ">Carine  Becamel</span>, <span class="hlFld-ContribAuthor ">Joël  Bockaert</span>, <span class="hlFld-ContribAuthor ">Michael  Camilleri</span>, <span class="hlFld-ContribAuthor ">Severine  Chaumont-Dubel</span>, <span class="hlFld-ContribAuthor ">Sylvie  Claeysen</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Cunningham</span>, <span class="hlFld-ContribAuthor ">Kevin C.  Fone</span>, <span class="hlFld-ContribAuthor ">Michael  Gershon</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Di Giovanni</span>, <span class="hlFld-ContribAuthor ">Nathalie M.  Goodfellow</span>, <span class="hlFld-ContribAuthor ">Adam L.  Halberstadt</span>, <span class="hlFld-ContribAuthor ">Rachel M.  Hartley</span>, <span class="hlFld-ContribAuthor ">Ghérici  Hassaine</span>, <span class="hlFld-ContribAuthor ">Katharine  Herrick-Davis</span>, <span class="hlFld-ContribAuthor ">Ruud  Hovius</span>, <span class="hlFld-ContribAuthor ">Enza  Lacivita</span>, <span class="hlFld-ContribAuthor ">Evelyn K.  Lambe</span>, <span class="hlFld-ContribAuthor ">Marcello  Leopoldo</span>, <span class="hlFld-ContribAuthor ">Finn Olav  Levy</span>, <span class="hlFld-ContribAuthor ">Sarah C. R.  Lummis</span>, <span class="hlFld-ContribAuthor ">Philippe  Marin</span>, <span class="hlFld-ContribAuthor ">Luc  Maroteaux</span>, <span class="hlFld-ContribAuthor ">Andrew C.  McCreary</span>, <span class="hlFld-ContribAuthor ">David L.  Nelson</span>, <span class="hlFld-ContribAuthor ">John F.  Neumaier</span>, <span class="hlFld-ContribAuthor ">Adrian  Newman-Tancredi</span>, <span class="hlFld-ContribAuthor ">Hugues  Nury</span>, <span class="hlFld-ContribAuthor ">Alexander  Roberts</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, <span class="hlFld-ContribAuthor ">Anne  Roumier</span>, <span class="hlFld-ContribAuthor ">Gareth J.  Sanger</span>, <span class="hlFld-ContribAuthor ">Milt  Teitler</span>, <span class="hlFld-ContribAuthor ">Trevor  Sharp</span>, <span class="hlFld-ContribAuthor ">Carlos M.  Villalón</span>, <span class="hlFld-ContribAuthor ">Horst  Vogel</span>, <span class="hlFld-ContribAuthor ">Stephanie W.  Watts</span>, <span class="hlFld-ContribAuthor ">Daniel  Hoyer</span>, . </span><span class="cited-content_cbyCitation_article-title">International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Reviews</span><span> <strong>2021,</strong> <em>73 </em>
                                    (1)
                                     , 310-520. <a href="https://doi.org/10.1124/pr.118.015552" title="DOI URL">https://doi.org/10.1124/pr.118.015552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/pr.118.015552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fpr.118.015552%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Reviews%26atitle%3DInternational%252BUnion%252Bof%252BBasic%252Band%252BClinical%252BPharmacology.%252BCX.%252BClassification%252Bof%252BReceptors%252Bfor%252B5-hydroxytryptamine%25253B%252BPharmacology%252Band%252BFunction%26aulast%3DBarnes%26aufirst%3DNicholas%2BM.%26date%3D2021%26date%3D2020%26volume%3D73%26issue%3D1%26spage%3D310%26epage%3D520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sayyad  Ali</span>, <span class="hlFld-ContribAuthor ">Muhammad Hassham Hassan Bin  Asad</span>, <span class="hlFld-ContribAuthor ">Fahad  Khan</span>, <span class="hlFld-ContribAuthor ">Ghulam  Murtaza</span>, <span class="hlFld-ContribAuthor ">Albert A.  Rizvanov</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>, <span class="hlFld-ContribAuthor ">Borhan  Babak</span>, <span class="hlFld-ContribAuthor ">Izhar  Hussain</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Evaluation of Newly Synthesized Biaryl Guanidine Derivatives to Arrest
              β
              -Secretase Enzymatic Activity Involved in Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">BioMed Research International</span><span> <strong>2020,</strong> <em>2020 </em>, 1-11. <a href="https://doi.org/10.1155/2020/8934289" title="DOI URL">https://doi.org/10.1155/2020/8934289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2020/8934289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2020%2F8934289%26sid%3Dliteratum%253Aachs%26jtitle%3DBioMed%2520Research%2520International%26atitle%3DBiological%252BEvaluation%252Bof%252BNewly%252BSynthesized%252BBiaryl%252BGuanidine%252BDerivatives%252Bto%252BArrest%252B%2525CE%2525B2%252B-Secretase%252BEnzymatic%252BActivity%252BInvolved%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DAli%26aufirst%3DSayyad%26date%3D2020%26volume%3D2020%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K.  Kiilerich</span>, <span class="hlFld-ContribAuthor ">N.  Speth</span>, <span class="hlFld-ContribAuthor ">J.  Lorenz</span>, <span class="hlFld-ContribAuthor ">A.  Casado-Sainz</span>, <span class="hlFld-ContribAuthor ">V.  Shalgunov</span>, <span class="hlFld-ContribAuthor ">D.  Lange</span>, <span class="hlFld-ContribAuthor ">M.  Xiong</span>, <span class="hlFld-ContribAuthor ">M.M.  Herth</span>, <span class="hlFld-ContribAuthor ">A.  Overgaard</span>, <span class="hlFld-ContribAuthor ">H.D.  Hansen</span>, <span class="hlFld-ContribAuthor ">M.  Palner</span>. </span><span class="cited-content_cbyCitation_article-title">P.228 The polypharmacological profile of psilocybin and potential behavioural effects of very low doses. </span><span class="cited-content_cbyCitation_journal-name">European Neuropsychopharmacology</span><span> <strong>2019,</strong> <em>29 </em>, S175-S176. <a href="https://doi.org/10.1016/j.euroneuro.2019.09.271" title="DOI URL">https://doi.org/10.1016/j.euroneuro.2019.09.271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.euroneuro.2019.09.271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.euroneuro.2019.09.271%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Neuropsychopharmacology%26atitle%3DP.228%252BThe%252Bpolypharmacological%252Bprofile%252Bof%252Bpsilocybin%252Band%252Bpotential%252Bbehavioural%252Beffects%252Bof%252Bvery%252Blow%252Bdoses%26aulast%3DKiilerich%26aufirst%3DK.%26date%3D2019%26volume%3D29%26spage%3DS175%26epage%3DS176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guiping  Zhang</span>, <span class="hlFld-ContribAuthor ">John D.  McCorvy</span>, <span class="hlFld-ContribAuthor ">Sida  Shen</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kozikowski</span>. </span><span class="cited-content_cbyCitation_article-title">Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111626. <a href="https://doi.org/10.1016/j.ejmech.2019.111626" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111626%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bfluorinated%252Bcyclopropane%252Bderivatives%252Bof%252B2-phenylcyclopropylmethylamine%252Bleading%252Bto%252Bidentification%252Bof%252Ba%252Bselective%252Bserotonin%252B2C%252B%2525285-HT2C%252529%252Breceptor%252Bagonist%252Bwithout%252B5-HT2B%252Bagonism%26aulast%3DZhang%26aufirst%3DGuiping%26date%3D2019%26volume%3D182%26spage%3D111626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric A.  Wold</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Wild</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Cunningham</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (16)
                                     , 1381-1398. <a href="https://doi.org/10.2174/1568026619666190709101449" title="DOI URL">https://doi.org/10.2174/1568026619666190709101449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190709101449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190709101449%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252B5-HT2C%252BReceptor%252Bin%252BBiological%252BContext%252Band%252Bthe%252BCurrent%252BState%252Bof%252B5-HT2C%252BReceptor%252BLigand%252BDevelopment%26aulast%3DWold%26aufirst%3DEric%2BA.%26date%3D2019%26volume%3D19%26issue%3D16%26spage%3D1381%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kartikey  Singh</span>, <span class="hlFld-ContribAuthor ">Chandan  Sona</span>, <span class="hlFld-ContribAuthor ">Vikash  Ojha</span>, <span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Ankita  Mishra</span>, <span class="hlFld-ContribAuthor ">Ajeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>, <span class="hlFld-ContribAuthor ">Rama P.  Tripathi</span>, <span class="hlFld-ContribAuthor ">Prem N.  Yadav</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT2C and negative allosteric modulator of 5-HT2B receptors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 499-516. <a href="https://doi.org/10.1016/j.ejmech.2018.12.070" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.070%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bdual%252Brole%252Bof%252Bpiperazine-linked%252Bphenyl%252Bcyclopropyl%252Bmethanone%252Bas%252Bpositive%252Ballosteric%252Bmodulator%252Bof%252B5-HT2C%252Band%252Bnegative%252Ballosteric%252Bmodulator%252Bof%252B5-HT2B%252Breceptors%26aulast%3DSingh%26aufirst%3DKartikey%26date%3D2019%26volume%3D164%26spage%3D499%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Markus  Wöhr</span>, <span class="hlFld-ContribAuthor ">Marcel M.  van Gaalen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Studies on the Role of Serotonin in Regulating Socioemotional Ultrasonic Vocalizations in Rats. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 295-307. <a href="https://doi.org/10.1016/B978-0-12-809600-0.00028-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-809600-0.00028-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809600-0.00028-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809600-0.00028-7%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacological%252BStudies%252Bon%252Bthe%252BRole%252Bof%252BSerotonin%252Bin%252BRegulating%252BSocioemotional%252BUltrasonic%252BVocalizations%252Bin%252BRats%26aulast%3DW%25C3%25B6hr%26aufirst%3DMarkus%26date%3D2018%26spage%3D295%26epage%3D307%26pub%3DElsevier%26atitle%3DHandbook%252Bof%252BUltrasonic%252BVocalization%252B-%252BA%252BWindow%252Binto%252Bthe%252BEmotional%252BBrain%26date%3D2018%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vladimir M  Pogorelov</span>, <span class="hlFld-ContribAuthor ">Ramona M  Rodriguiz</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Mei  Huang</span>, <span class="hlFld-ContribAuthor ">Claire M  Schmerberg</span>, <span class="hlFld-ContribAuthor ">Herbert Y  Meltzer</span>, <span class="hlFld-ContribAuthor ">Bryan L  Roth</span>, <span class="hlFld-ContribAuthor ">Alan P  Kozikowski</span>, <span class="hlFld-ContribAuthor ">William C  Wetsel</span>. </span><span class="cited-content_cbyCitation_article-title">5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. </span><span class="cited-content_cbyCitation_journal-name">Neuropsychopharmacology</span><span> <strong>2017,</strong> <em>42 </em>
                                    (11)
                                     , 2163-2177. <a href="https://doi.org/10.1038/npp.2017.52" title="DOI URL">https://doi.org/10.1038/npp.2017.52</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/npp.2017.52&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnpp.2017.52%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropsychopharmacology%26atitle%3D5-HT2C%252BAgonists%252BModulate%252BSchizophrenia-Like%252BBehaviors%252Bin%252BMice%26aulast%3DPogorelov%26aufirst%3DVladimir%2BM%26date%3D2017%26date%3D2017%26volume%3D42%26issue%3D11%26spage%3D2163%26epage%3D2177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juhyeon  Kim</span>, <span class="hlFld-ContribAuthor ">Hanbyeol  Jo</span>, <span class="hlFld-ContribAuthor ">Hyunseung  Lee</span>, <span class="hlFld-ContribAuthor ">Hyunah  Choo</span>, <span class="hlFld-ContribAuthor ">Hak  Kim</span>, <span class="hlFld-ContribAuthor ">Ae  Pae</span>, <span class="hlFld-ContribAuthor ">Yong  Cho</span>, <span class="hlFld-ContribAuthor ">Sun-Joon  Min</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Optically Active Pyrimidine Derivatives as Selective 5-HT2C Modulators. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (9)
                                     , 1416. <a href="https://doi.org/10.3390/molecules22091416" title="DOI URL">https://doi.org/10.3390/molecules22091416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22091416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22091416%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DIdentification%252Bof%252BOptically%252BActive%252BPyrimidine%252BDerivatives%252Bas%252BSelective%252B5-HT2C%252BModulators%26aulast%3DKim%26aufirst%3DJuhyeon%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D9%26spage%3D1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raghda T.  Abdel-Latif</span>, <span class="hlFld-ContribAuthor ">Sawsan A.  Zaitone</span>, <span class="hlFld-ContribAuthor ">Yousra  Abdel-mottaleb</span>, <span class="hlFld-ContribAuthor ">Nabila N.  El-Maraghy</span>. </span><span class="cited-content_cbyCitation_article-title">The anorectic agent, lorcaserin, disturbs estrous cyclicity and produces endometrial hyperplasia without affecting ovarian population in female rats. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2017,</strong> <em>183 </em>, 69-77. <a href="https://doi.org/10.1016/j.lfs.2017.06.006" title="DOI URL">https://doi.org/10.1016/j.lfs.2017.06.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2017.06.006%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DThe%252Banorectic%252Bagent%25252C%252Blorcaserin%25252C%252Bdisturbs%252Bestrous%252Bcyclicity%252Band%252Bproduces%252Bendometrial%252Bhyperplasia%252Bwithout%252Baffecting%252Bovarian%252Bpopulation%252Bin%252Bfemale%252Brats%26aulast%3DAbdel-Latif%26aufirst%3DRaghda%2BT.%26date%3D2017%26volume%3D183%26spage%3D69%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samir  Yahiaoui</span>, <span class="hlFld-ContribAuthor ">Katia  Hamidouche</span>, <span class="hlFld-ContribAuthor ">Céline  Ballandonne</span>, <span class="hlFld-ContribAuthor ">Audrey  Davis</span>, <span class="hlFld-ContribAuthor ">Jana Sopkova  de Oliveira Santos</span>, <span class="hlFld-ContribAuthor ">Thomas  Freret</span>, <span class="hlFld-ContribAuthor ">Michel  Boulouard</span>, <span class="hlFld-ContribAuthor ">Christophe  Rochais</span>, <span class="hlFld-ContribAuthor ">Patrick  Dallemagne</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>121 </em>, 283-293. <a href="https://doi.org/10.1016/j.ejmech.2016.05.048" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.05.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.05.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.05.048%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bmultitarget-directed%252Bligands%252Bwith%252Bboth%252Bserotonergic%252Bsubtype%252B4%252Breceptor%252B%2525285-HT4R%252529%252Bpartial%252Bagonist%252Band%252B5-HT6R%252Bantagonist%252Bactivities%25252C%252Bas%252Bpotential%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DYahiaoui%26aufirst%3DSamir%26date%3D2016%26volume%3D121%26spage%3D283%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of lorcaserin (<b>1</b>), vabicaserin (<b>2</b>), and compounds <b>3</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative drugs having a multihalogen substitution pattern and the general structure of new 2-phenylcyclopropylmethylamines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Target Compounds <b>20a</b>–<b>g</b>, <b>21a</b>–<b>g</b>, and <b>22a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Ph<sub>3</sub>P═CHC(O)N(OMe)Me, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (b) Me<sub>3</sub>S<sup>+</sup>(O)I<sup>–</sup>, NaH, DMSO, rt, overnight; (c) DIBAL-H, THF, –78 °C, 2 h; then NaBH<sub>4</sub>, MeOH, 0 °C to rt, 0.5 h; (d) phthalimide, PPh<sub>3</sub>, DEAD, THF, rt, overnight; (e) N<sub>2</sub>H<sub>4</sub>–H<sub>2</sub>O, EtOH, reflux, 3 h; then Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5 h; (f) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, – 78 °C to rt, 3 h; then Boc<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5 h; (g) 2-fluoroethanol, Ph<sub>3</sub>P, DEAD, THF, 0 to 60 °C (microwave), 1 h; (h) allyl bromide, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C (microwave), 0.5–1 h; (i) (1) chiral preparative-HPLC; (2) 2 M HCl in Et<sub>2</sub>O, rt, 24–48 h. <b>11</b>–<b>22a</b>: 4,5-diF; <b>11</b>–<b>22b</b>: 5,6-diF; <b>11–22c</b>: 4-F, 5-Cl; <b>11</b>–<b>22d</b>: 5-Cl, 6-F; <b>11</b>–<b>22e</b>: 4,5-diCl; <b>11</b>–<b>22f</b>: 5,6-diCl; <b>11</b>–<b>22g</b>: 5-F, 6-Cl.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compound (+)-<b>22a</b> on <i>d</i>-amphetamine (AMPH)-stimulated hyperlocomotion in the open field. (A) Locomotor activity in the open field in 5 min blocks reflecting baseline responses (0–15 min) and AMPH-stimulated activity with its reduction by (+)-<b>22a</b> (15–120 min). (B) Cumulative baseline locomotor activities (0–15 min). (C) Cumulative AMPH-stimulated activities and reductions in activity with (+)-<b>22a</b> (15–90 min). <i>N</i> = 7–10 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh group; #, <i>p</i> < 0.05, compared to the Veh + AMPH group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound (+)-<b>22a</b> restores <i>d</i>-amphetamine (AMPH)-disrupted PPI in C57BL/6J mice. (A) Mice treated with vehicle–vehicle (Veh + Veh) showed prepulse dependency in PPI. Four mg/kg (+)-<b>22a</b> alone did not affect PPI relative to the Veh + Veh controls. Mice administered Veh + AMPH had a marked reduction in PPI. Treatment with 0.5, 1, or 2 mg/kg (+)-<b>22a</b> restored overall AMPH-disrupted PPI to the levels of the Veh + Veh group, with 1 mg/kg fully rescuing the prepulse dependency of the response. Mice given the 4 mg/kg dose + AMPH showed a reduction in PPI similar to that found in Veh + AMPH animals. <i>N</i> = 8–11 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh control; #, <i>p</i> < 0.05, compared to the Veh + AMPH group; ‡,<i>p</i> < 0.05, within treatment for 8 or 12 dB compared to the 4 dB response; §, <i>p</i> < 0.05, within treatment for 12 dB compared to the 8 dB response. (B) Pulse-only responses during PPI testing were not affected by treatment in the (+)-<b>22a</b> + Veh or the Veh + AMPH groups, but when (+)-<b>22a</b> was given before AMPH, the startle-only response was attenuated in the 0.5 and 2 mg/kg (+)-<b>22a</b> groups. <i>N</i> = 8–11 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh + Veh control; #, <i>p</i> < 0.05, compared to the Veh + AMPH group; + , <i>p</i> < 0.05 compared to 4 mg/kg (+)-<b>22a</b> + Veh treatment; †, <i>p</i> < 0.05, compared to the 4 mg/kg (+)-<b>22a</b> + AMPH treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound (+)-<b>22a</b> rescues novel object recognition memory in NR1-KD mice. Mice were given vehicle (Veh) or 0.5 or 1 mg/kg (+)-<b>22a</b> 30 min before training or at testing for long-term memory (LTM). (A) At testing for LTM, Veh-treated wild-type (WT) controls displayed a preference for the novel object, whereas NR1-KD mice showed no preference for either object. In contrast, 1 mg/kg (+)-<b>22a</b> rescued this deficit in the mutants while producing some deficiency in the WT animals. (B, C) As a control, the duration of object exploration was examined during (B) training and (C) LTM testing. At training and at testing, Veh-treated NR1-KD mice spent more time exploring the objects than WT mice, while (+)-<b>22a</b> reduced this exploration time to levels that were not significantly different from the WT controls. <i>N</i> = 9–10 mice/genotype/treatment; *, <i>p</i> < 0.05, (+)-<b>22a</b> compared to the Veh within genotype; <sup>x</sup>, <i>p</i> < 0.05, NR1-KD compared to the WT vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/medium/jm-2015-01153w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of catalepsy induced by haloperidol and (+)-<b>22a</b> in C57BL/6J mice with the horizontal bar test. Separate groups of mice were injected with vehicle (Veh), or 0.01, 0.1, 1, or 10 mg/kg haloperidol (Hal), or 0.01, 0.1, 1, 10, or 30 mg/kg compound (+)-<b>22a</b> and evaluated for catalepsy 60 min later. <i>N</i> = 8–10 mice/treatment; *, <i>p</i> < 0.05, compared to the Veh control; <sup>V</sup>, <i>p</i> < 0.05, compared to all other groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01153/20160122/images/large/jm-2015-01153w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01153&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><a href="http://www.who.int/mental_health/management/schizophrenia/en/" class="extLink">http://www.who.int/mental_health/management/schizophrenia/en/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.who.int%2Fmental_health%2Fmanagement%2Fschizophrenia%2Fen%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span> </span><span class="NLM_article-title">Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci</span>.  <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schizophrenia+Working+Group+of+the+Psychiatric+Genomics+Consortium.+Biological+insights+from+108+schizophrenia-associated+genetic+loci.+Nature+2014%2C+511%2C+421%E2%80%93427."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26atitle%3DSchizophrenia%2520Working%2520Group%2520of%2520the%2520Psychiatric%2520Genomics%2520Consortium.%2520Biological%2520insights%2520from%2520108%2520schizophrenia-associated%2520genetic%2520loci%26jtitle%3DNature%26date%3D2014%26volume%3D511%26spage%3D421%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The pipeline and future of drug development in schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1038/sj.mp.4002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.mp.4002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17667958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=904-922&author=J.+A.+Grayauthor=B.+L.+Roth&title=The+pipeline+and+future+of+drug+development+in+schizophrenia&doi=10.1038%2Fsj.mp.4002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The pipeline and future of drug development in schizophrenia</span></div><div class="casAuthors">Gray, J. A.; Roth, B. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">904-922</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease.  In particular, improved treatment of the neg. symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed.  In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs.  Many of these compds. have great potential as augmenting agents in the treatment of neg. symptoms and cognition.  In addn., we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets.  Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia.  Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZ3qO-W1xFLVg90H21EOLACvtfcHk0ligvMHG3_uXDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L&md5=f0b2e1ece99057228282fa1ad71855b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002062%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520pipeline%2520and%2520future%2520of%2520drug%2520development%2520in%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D904%26epage%3D922%26doi%3D10.1038%2Fsj.mp.4002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Harvey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keefe, R. S. E.</span><span> </span><span class="NLM_article-title">Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">158</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span><span class="refDoi"> DOI: 10.1176/appi.ajp.158.2.176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1176%2Fappi.ajp.158.2.176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11156796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BD3M7ktFKjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=176-184&author=P.+D.+Harveyauthor=R.+S.+E.+Keefe&title=Studies+of+cognitive+change+in+patients+with+schizophrenia+following+novel+antipsychotic+treatment&doi=10.1176%2Fappi.ajp.158.2.176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment</span></div><div class="casAuthors">Harvey P D; Keefe R S</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-84</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia.  However, these effects have been assessed in studies with considerable variation in methodology.  A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients with schizophrenia.  The ability to discriminate between high- and low-quality studies will be required to understand the true implications of these studies and their relevance to clinical practice.  METHOD:  This article addresses several aspects of research on cognitive enhancement in schizophrenia, emphasizing how the assessment of cognitive function in clinical trials requires certain standards of study design to lead to interpretable results.  RESULTS:  Novel antipsychotic medications appear to have preliminary promise for the enhancement of cognitive functioning.  However, the methodology for assessing the treatment of cognitive deficits is still being developed.  CONCLUSIONS:  Researchers and clinicians alike need to approach publications in this area with a watchful eye toward methodological weaknesses that limit the interpretability of findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPA9I2rBv4PKcY7HFp97qMfW6udTcc2eYzuB26ivQSO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7ktFKjsw%253D%253D&md5=b574f391b3f1be001132cab248e80aa8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.2.176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.2.176%26sid%3Dliteratum%253Aachs%26aulast%3DHarvey%26aufirst%3DP.%2BD.%26aulast%3DKeefe%26aufirst%3DR.%2BS.%2BE.%26atitle%3DStudies%2520of%2520cognitive%2520change%2520in%2520patients%2520with%2520schizophrenia%2520following%2520novel%2520antipsychotic%2520treatment%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D176%26epage%3D184%26doi%3D10.1176%2Fappi.ajp.158.2.176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Goldberg, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burdick, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malhotra, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lencz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woerner, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schooler, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, D. G.</span><span> </span><span class="NLM_article-title">Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia - Is it a practice effect?</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">–</span> <span class="NLM_lpage">1122</span><span class="refDoi"> DOI: 10.1001/archpsyc.64.10.1115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1001%2Farchpsyc.64.10.1115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17909123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CnsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2007&pages=1115-1122&author=T.+E.+Goldbergauthor=R.+S.+Goldmanauthor=K.+E.+Burdickauthor=A.+K.+Malhotraauthor=T.+Lenczauthor=R.+C.+Patelauthor=M.+G.+Woernerauthor=N.+R.+Schoolerauthor=J.+M.+Kaneauthor=D.+G.+Robinson&title=Cognitive+improvement+after+treatment+with+second-generation+antipsychotic+medications+in+first-episode+schizophrenia+-+Is+it+a+practice+effect%3F&doi=10.1001%2Farchpsyc.64.10.1115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?</span></div><div class="casAuthors">Goldberg, Terry E.; Goldman, Robert S.; Burdick, Katherine E.; Malhotra, Anil K.; Lencz, Todd; Patel, Raman C.; Woerner, Margaret G.; Schooler, Nina R.; Kane, John M.; Robinson, Delbert G.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1115-1122</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Cognitive impairment in schizophrenia is frequent, involves multiple domains, and is enduring.  Numerous recent clin. trials have suggested that second-generation antipsychotic medications significantly enhance cognition in schizophrenia.  However, none of these studies included healthy controls undergoing repeated testing to assess the possibility that improvements might reflect simple practice effects.  Objective: To report the results on cognition of a randomized comparison of 2 widely prescribed second-generation antipsychotic medications, olanzapine and risperidone, in patients with first-episode schizophrenia and a healthy control group.  Design: Randomized clin. trial.  Setting: Hospital-based research units.  Patients: A total of 104 participants with first-episode schizophrenia and 84 healthy controls.  Main Outcome Measures: Cognitive assessment of all study participants occurred at baseline, 6 wk later, and 16 wk later.  Neurocognitive tests included measures of working memory and attention, speed, motor function, episodic memory, and executive function.  Results: No differential drug effects were obsd.  Of 16 cognitive measures, 9 demonstrated improvement over time and only 2 demonstrated greater rates of change than those obsd. in the healthy control group undergoing repeated assessment.  The composite effect size for cognitive change was 0.33 in the healthy control group (attributed to practice) and 0.36 in the patients with first-episode schizophrenia.  Improvements in cognition in the first-episode schizophrenia group could not be accounted for by medication dose, demog. variables, or intellectual level.  Conclusions: The cognitive improvements obsd. in the trial were consistent in magnitude with practice effects obsd. in healthy controls, suggesting that some of the improvements in cognition in the first-episode schizophrenia group may have been due to practice effects (ie, exposure, familiarity, and/or procedural learning).  Our results also indicated that differential medication effects on cognition were small.  We believe that these findings have important implications for drug discovery and the design of registration trials that attempt to demonstrate cognitive enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgt1du_jdD7Vg90H21EOLACvtfcHk0lj5xTX-O4Sqpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CnsrfJ&md5=ab62ddb0cb5be4d7c6eb8622628a9e28</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.64.10.1115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.64.10.1115%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DT.%2BE.%26aulast%3DGoldman%26aufirst%3DR.%2BS.%26aulast%3DBurdick%26aufirst%3DK.%2BE.%26aulast%3DMalhotra%26aufirst%3DA.%2BK.%26aulast%3DLencz%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DR.%2BC.%26aulast%3DWoerner%26aufirst%3DM.%2BG.%26aulast%3DSchooler%26aufirst%3DN.%2BR.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26aulast%3DRobinson%26aufirst%3DD.%2BG.%26atitle%3DCognitive%2520improvement%2520after%2520treatment%2520with%2520second-generation%2520antipsychotic%2520medications%2520in%2520first-episode%2520schizophrenia%2520-%2520Is%2520it%2520a%2520practice%2520effect%253F%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2007%26volume%3D64%26spage%3D1115%26epage%3D1122%26doi%3D10.1001%2Farchpsyc.64.10.1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Lorcaserin and pimavanserin: Emerging selectivity of serotonin receptor subtype-targeted drugs</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4991</span><span class="refDoi"> DOI: 10.1172/JCI70678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1172%2FJCI70678" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=4986-4991&author=H.+Y.+Meltzerauthor=B.+L.+Roth&title=Lorcaserin+and+pimavanserin%3A+Emerging+selectivity+of+serotonin+receptor+subtype-targeted+drugs&doi=10.1172%2FJCI70678"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI70678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70678%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DLorcaserin%2520and%2520pimavanserin%253A%2520Emerging%2520selectivity%2520of%2520serotonin%2520receptor%2520subtype-targeted%2520drugs%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D4986%26epage%3D4991%26doi%3D10.1172%2FJCI70678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The expanded biology of serotonin</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1146/annurev.med.60.042307.110802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1146%2Fannurev.med.60.042307.110802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=19630576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=355-366&author=M.+Bergerauthor=J.+A.+Grayauthor=B.+L.+Roth&title=The+expanded+biology+of+serotonin&doi=10.1146%2Fannurev.med.60.042307.110802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded biology of serotonin</span></div><div class="casAuthors">Berger, Miles; Gray, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychol. processes, and drugs that target serotonin receptors are used widely in psychiatry and neurol.  However, most serotonin is found outside the central nervous system, and virtually all of the 15 serotonin receptors are expressed outside as well as within the brain.  Serotonin regulates numerous biol. processes including cardiovascular function, bowel motility, ejaculatory latency, and bladder control.  Addnl., new work suggests that serotonin may regulate some processes, including platelet aggregation, by receptor-independent, transglutaminase-dependent covalent linkage to cellular proteins.  We review this new expanded serotonin biol. and discuss how drugs targeting specific serotonin receptors are beginning to help treat a wide range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz0HW5hdNOrVg90H21EOLACvtfcHk0liT_Q4fvHQhVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D&md5=0557e01e6b79dbfb50559aca03f8b31f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.60.042307.110802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.60.042307.110802%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520expanded%2520biology%2520of%2520serotonin%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2009%26volume%3D60%26spage%3D355%26epage%3D366%26doi%3D10.1146%2Fannurev.med.60.042307.110802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>ClinicalTrials.gov Identifier: NCT02044874.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+Identifier%3A+NCT02044874."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span>ClinicalTrials.gov Identifier: NCT00563706.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+Identifier%3A+NCT00563706."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Shen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Detke, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, J. M.</span><span> </span><span class="NLM_article-title">A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia</span> <span class="citation_source-journal">J. Psychiatr. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1016/j.jpsychires.2014.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.jpsychires.2014.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=24613032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BC2crisVWitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=14-22&author=J.+H.+Shenauthor=Y.+Zhaoauthor=S.+Rosenzweig-Lipsonauthor=D.+Poppauthor=J.+B.+Williamsauthor=E.+Gillerauthor=M.+J.+Detkeauthor=J.+M.+Kane&title=A+6-week+randomized%2C+double-blind%2C+placebo-controlled%2C+comparator+referenced+trial+of+vabicaserin+in+acute+schizophrenia&doi=10.1016%2Fj.jpsychires.2014.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia</span></div><div class="casAuthors">Shen Joan H Q; Zhao Yonggang; Rosenzweig-Lipson Sharon; Popp Danielle; Giller Earl; Williams Janet B W; Detke Michael J; Kane John M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">UNLABELLED:  Vabicaserin, a potent 5-HT2C receptor agonist, decreases nucleus accumbens extracellular dopamine levels in rats, without affecting striatal dopamine, indicating mesolimbic selectivity.  This is the first study of efficacy, safety and tolerability of vabicaserin in adults with acute schizophrenia.  Three hundred fourteen hospitalized subjects were randomized to: Vabicaserin 200 or 400 mg/day, olanzapine 15 mg/day or placebo.  Central raters assessed the PANSS and CGI-S.  Site raters performed the BPRS and CGI-I.  Central rated PANSS Positive (PANSS-PPS) was the primary endpoint.  Two hundred eighty-nine subjects were included in the mITT efficacy analysis.  Vabicaserin was well tolerated with no major safety concerns.  Olanzapine, but not vabicaserin, caused weight gain.  Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement at week 6 vs. placebo on PANSS-PSS.  A non-significant decrease vs. placebo was observed for 400 mg/day.  Both vabicaserin groups demonstrated significant improvement over baseline on PANSS Negative while placebo worsened.  Vabicaserin 200 mg/day and olanzapine demonstrated significantly greater improvement over placebo on PANSS Total whereas 400 mg/day showed a trend toward improvement.  There was no significant improvement vs. placebo for either vabicaserin group on site-rated BPRS.  Vabicaserin 200 mg/day and olanzapine demonstrated significant improvement vs. placebo on CGI-I and CGI-S but not 400 mg/day vabicaserin.  Vabicaserin demonstrated efficacy on primary and secondary endpoints at 200 mg/day, but not at 400 mg/day which showed a trend for efficacy.  The 200 mg/day vabicaserin group achieved proof of concept using central ratings.  Both vabicaserin doses were well tolerated with no significant safety signals and no weight gain.  TRIAL REGISTRATION:  clinicaltrials.gov.  Identifier: NCT00265551.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSU4Ml3861NqENHe_gFldTbfW6udTcc2eZKxqCylZ-3YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crisVWitQ%253D%253D&md5=1d4be17f9d6341641c68809a61495003</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2014.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2014.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%2BH.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DPopp%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DJ.%2BB.%26aulast%3DGiller%26aufirst%3DE.%26aulast%3DDetke%26aufirst%3DM.%2BJ.%26aulast%3DKane%26aufirst%3DJ.%2BM.%26atitle%3DA%25206-week%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520comparator%2520referenced%2520trial%2520of%2520vabicaserin%2520in%2520acute%2520schizophrenia%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2014%26volume%3D53%26spage%3D14%26epage%3D22%26doi%3D10.1016%2Fj.jpsychires.2014.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Lee, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">Decreased serotonin<sub>2C</sub> receptor responses in male patients with schizophrenia</span> <span class="citation_source-journal">Psychiatry Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">226</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span><span class="refDoi"> DOI: 10.1016/j.psychres.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.psychres.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=25650049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVeisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2015&pages=308-315&author=M.+A.+Leeauthor=K.+Jayathilakeauthor=M.+Y.+Simauthor=H.+Y.+Meltzer&title=Decreased+serotonin2C+receptor+responses+in+male+patients+with+schizophrenia&doi=10.1016%2Fj.psychres.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased serotonin2C receptor responses in male patients with schizophrenia</span></div><div class="casAuthors">Lee, Myung Ae; Jayathilake, Karuna; Sim, Min Young; Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">308-315</span>CODEN:
                <span class="NLM_cas:coden">PSRSDR</span>;
        ISSN:<span class="NLM_cas:issn">0165-1781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Serotonin (5-HT)2C receptors in brain affect psychosis, reward, substance abuse, anxiety, other behaviors, appetite, body temp., and other physiol. measures.  They also have been implicated in antipsychotic drug efficacy and side effects.  We previously reported that the hyperthermia following administration of MK-212, a predominantly 5-HT2C receptor agonist, was diminished in a small sample of patients with schizophrenia (SCH), suggesting decreased 5-HT2C receptor responsiveness.  We have now studied the responses to oral MK-212 and placebo in a larger sample of unmedicated male SCH (n=69) and normal controls (CON) (n=33), and assessed the influence of comorbid substance abuse (SA) on oral body temp., behavioral responses, etc.  The placebo-adjusted oral body temp. response to MK-212 was significantly lower in SCH compared to CON and not significantly different between the SCH with or without SA.  Some behavioral responses to MK-212, e.g. self-rated feelings of increased anxiety, depression and decreased calmness, or good overall feeling, were significantly lower in the SCH patients compared to CON.  These results add to the evidence for diminished 5-HT2C receptor responsiveness in SCH patients compared to CON and are consistent with reported assocn. of HTR2C polymorphisms, leading to decreased expression or function of the HTR2C in patients with SCH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZkp5ElR_5-rVg90H21EOLACvtfcHk0liT_Q4fvHQhVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVeisLw%253D&md5=fa37f05a6d69c77a2028051bf357d49d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.psychres.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.psychres.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BA.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DSim%26aufirst%3DM.%2BY.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DDecreased%2520serotonin2C%2520receptor%2520responses%2520in%2520male%2520patients%2520with%2520schizophrenia%26jtitle%3DPsychiatry%2520Res.%26date%3D2015%26volume%3D226%26spage%3D308%26epage%3D315%26doi%3D10.1016%2Fj.psychres.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor stimulation are differentially involved in the cortical dopamine efflux-studied in 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> genetic mutant mice</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">652</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2010.10.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.ejphar.2010.10.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=21118683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Kisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=2011&pages=40-45&author=M.+Huangauthor=J.+Daiauthor=H.+Y.+Meltzer&title=5-HT2A+and+5-HT2C+receptor+stimulation+are+differentially+involved+in+the+cortical+dopamine+efflux-studied+in+5-HT2A+and+5-HT2C+genetic+mutant+mice&doi=10.1016%2Fj.ejphar.2010.10.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine efflux-Studied in 5-HT2A and 5-HT2C genetic mutant mice</span></div><div class="casAuthors">Huang, Mei; Dai, Jin; Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Both 5-HT2A and 5-HT2C receptors modulate cortical dopamine efflux, but in opposite directions.  We have now compared the ability of the three 5-HT2A/2C receptor agonists, DOI (R(-)-2,5-dimethoxy-4-iodoamphetamine), mCPP (meta-chlorophenylpiperazine) and MK-212 (6-Chloro-2-(piperazinyl) pyrazine), to modulate cortical dopamine efflux in 5-HT2A and 5-HT2C genetic mutant mice.  In the 5-HT2A mice, the preferential 5-HT2A receptor agonist DOI (2.5 mg/kg, s.c.) induced a slight but significant increase in cortical dopamine efflux only in the wild type (WT) mice; MK-212 (2.5 mg/kg) reduced dopamine efflux in both WT and receptor knockout (KO) mice; moreover, MCPP, 2.5 mg/kg, had no effect in either types.  In 5-HT2C mice, DOI increased dopamine efflux in both types; while MK-212 decreased dopamine efflux in the WT, but not the receptor KO mice.  These results provide new evidence that 5-HT2A receptor stimulation enhances and 5-HT2C receptor stimulation inhibits cortical dopamine efflux, and suggest the effects of DOI, MK-212 and mCPP on the cortical dopamine efflux are due to their different abilities on 5-HT2A and 5-HT2C receptors stimulation.  Of these three agents, only DOI, the more selective 5-HT2A receptor agonist, is hallucinogenic.  The absence of hallucinations with mCPP may be due to its relatively more potent 5-HT2C receptor agonist effect, inhibiting the ability of mCPP to enhance dopamine efflux in cortical and perhaps limbic regions as well.  The present data provide addnl. evidence that hallucinations are due, in part, to 5-HT2A rather than 5-HT2C receptor stimulation.  These findings suggest that 5-HT2C receptor agonists may be useful as antipsychotics, consistent with previous suggestions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc4WEX0WXT_bVg90H21EOLACvtfcHk0liVpt8Babn5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Kisg%253D%253D&md5=77eef47319a8b2ad242e1d6d1798223b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.10.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.10.094%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3D5-HT2A%2520and%25205-HT2C%2520receptor%2520stimulation%2520are%2520differentially%2520involved%2520in%2520the%2520cortical%2520dopamine%2520efflux-studied%2520in%25205-HT2A%2520and%25205-HT2C%2520genetic%2520mutant%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D652%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.ejphar.2010.10.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine<sub>2C</sub> receptor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">89</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11561066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntFWltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2001&pages=83-89&author=L.+Rauserauthor=J.+E.+Savageauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=Inverse+agonist+actions+of+typical+and+atypical+antipsychotic+drugs+at+the+human+5-hydroxytryptamine2C+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine2C receptor</span></div><div class="casAuthors">Rauser, Laura; Savage, Jason E.; Meltzer, Herbert Y.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-89</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs, which are distinguished from typical antipsychotic drugs by a lower incidence of extra-pyramidal side effects and less propensity to elevate serum prolactin levels (e.g., clozapine, olanzapine, risperidone, quetiapine, ziprasidone), have become the most widely used treatments for schizophrenia, although their precise mechanism of action remains controversial.  It has been suggested that this group of atypical antipsychotic drugs is characterized by preferentially high affinities for 5-hydroxytryptamine (5-HT)2A serotonin receptors and relatively low affinities for D2-dopamine receptors.  It has recently been proposed that these atypical antipsychotic drugs may also be distinguished from typical antipsychotic drugs (e.g., haloperidol, fluphenazine, chlorpromazine, and so on) by inverse agonist actions at the 5-HT2C-INI RNA edited isoform of the human 5-HT2C receptor transiently expressed in COS-7 cells.  We have examd. the relation among 5-HT2C inverse agonist potency, efficacy, and atypical antipsychotic drug status in HEK-293 cells of a large no. of typical and atypical antipsychotic drugs using human embryonic kidney (HEK)-293 cells stably transfected with the h5-HT2C-INI receptor.  Inverse agonist actions at h5-HT2C-INI receptors were measured for both typical and atypical antipsychotic drugs.  Thus, some typical antipsychotic drugs (chlorpromazine, mesoridazine, fluphenazine, and loxapine) were efficient inverse agonists, whereas several clin. effective atypical antipsychotic drugs (remoxipride, quetiapine, sulpiride, melperone, amperozide) were not.  Addnl., several drugs without significant antipsychotic actions (M100907, ketanserin, mianserin, ritanserin, and amitriptyline) were potent inverse agonists at the 5-HT2C-INI isoform expressed in HEK-293 cells.  Taken together, these results demonstrate that both typical and atypical antipsychotic drugs may exhibit inverse agonist effects at the 5-HT2C-INI isoform of the human 5-HT2C receptor and that no relation exists between inverse agonist actions and atypicality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQYyIwLMQ1z7Vg90H21EOLACvtfcHk0liVpt8Babn5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntFWltrY%253D&md5=1a4485604f512006fcb46a49ec2c2cf4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DInverse%2520agonist%2520actions%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520at%2520the%2520human%25205-hydroxytryptamine2C%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D299%26spage%3D83%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popadak, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ernsberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayathilake, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">H<sub>1</sub>-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.npp.1300027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=12629531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslyjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=519-526&author=W.+K.+Kroezeauthor=S.+J.+Hufeisenauthor=B.+A.+Popadakauthor=S.+Renockauthor=S.+A.+Steinbergauthor=P.+Ernsbergerauthor=K.+Jayathilakeauthor=H.+Y.+Meltzerauthor=B.+L.+Roth&title=H1-histamine+receptor+affinity+predicts+short-term+weight+gain+for+typical+and+atypical+antipsychotic+drugs&doi=10.1038%2Fsj.npp.1300027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs</span></div><div class="casAuthors">Kroeze, Wesley K.; Hufeisen, Sandra J.; Popadak, Beth A.; Renock, Sean M.; Steinberg, SeAnna; Ernsberger, Paul; Jayathilake, Karu; Meltzer, Herbert Y.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-526</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As a result of superior efficacy and overall tolerability, atypical antipsychotic drugs have become the treatment of choice for schizophrenia and related disorders, despite their side effects.  Wt. gain is a common and potentially serious complication of some antipsychotic drug therapy, and may be accompanied by hyperlipidemia, hypertension and hyperglycemia and, in some extreme cases, diabetic ketoacidosis.  The mol. mechanism(s) responsible for antipsychotic drug-induced wt. gain are unknown, but have been hypothesized to be because of interactions of antipsychotic drugs with several neurotransmitter receptors, including 5-HT2A and 5-HT2C serotonin receptors, H1-histamine receptors, α1- and α2-adrenergic receptors, and m3-muscarinic receptors.  To det. the receptor(s) likely to be responsible for antipsychotic-drug-induced wt. gain, we screened 17 typical and atypical antipsychotic drugs for binding to 12 neurotransmitter receptors.  H1-histamine receptor affinities for this group of typical and atypical antipsychotic drugs were significantly correlated with wt. gain (Spearman ρ=-0.72; p∼0.01), as were affinities for α1A adrenergic (ρ=-0.54; p∼0.05), 5-HT2C (ρ=-0.49; p∼0.05) and 5-HT6 receptors (ρ=-0.54; p∼0.05), whereas eight other receptors' affinities were not.  A principal components anal. showed that affinities at the H1, α2A, α2B, 5-HT2A, 5-HT2C, and 5-HT6 receptors were most highly correlated with the first principal component, and affinities for the D2, 5-HT1A, and 5-HT7 receptors were most highly correlated with the second principal component.  A discriminant functions anal. showed that affinities for the H1 and α1A receptors were most highly correlated with the discriminant function axis.  The discriminant function anal., as well as the affinity for the H1-histamine receptor alone, correctly classified 15 of the 17 drugs into two groups; those that induce wt. gain and those that do not.  Because centrally acting H1-histamine receptor antagonists are known to induce wt. gain with chronic use, and because H1-histamine receptor affinities are pos. correlated with wt. gain among typical and atypical antipsychotic drugs, it is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-8aw1zlLc1bVg90H21EOLACvtfcHk0liv5gJ5cc3AiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslyjt7Y%253D&md5=353d231f2afe414e58646baf8692ecf5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300027%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DPopadak%26aufirst%3DB.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DSteinberg%26aufirst%3DS.%2BA.%26aulast%3DErnsberger%26aufirst%3DP.%26aulast%3DJayathilake%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DH1-histamine%2520receptor%2520affinity%2520predicts%2520short-term%2520weight%2520gain%2520for%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D519%26epage%3D526%26doi%3D10.1038%2Fsj.npp.1300027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Marquis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabb, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logue, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piesla, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comery, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashby, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span> </span><span class="NLM_article-title">WAY-163909 [(7b<i>R</i>, 10a<i>R</i>)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span><span class="refDoi"> DOI: 10.1124/jpet.106.106989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fjpet.106.106989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=17038512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=486-496&author=K.+L.+Marquisauthor=A.+L.+Sabbauthor=S.+F.+Logueauthor=J.+A.+Brennanauthor=M.+J.+Pieslaauthor=T.+A.+Comeryauthor=S.+M.+Grauerauthor=C.+R.+Ashbyauthor=H.+Q.+Nguyenauthor=L.+A.+Dawsonauthor=J.+E.+Barrettauthor=G.+Stackauthor=H.+Y.+Meltzerauthor=B.+L.+Harrisonauthor=S.+Rosenzweig-Lipson&title=WAY-163909+%5B%287bR%2C+10aR%29-1%2C2%2C3%2C4%2C8%2C9%2C10%2C10a-octahydro-7bH-cyclopenta%5Bb%5D%5B1%2C4%5Ddiazepino%5B6%2C7%2C1hi%5Dindole%5D%3A+A+novel+5-hydroxytryptamine+2C+receptor-selective+agonist+with+preclinical+antipsychotic-like+activity&doi=10.1124%2Fjpet.106.106989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity</span></div><div class="casAuthors">Marquis, Karen L.; Sabb, Annmarie L.; Logue, Sheree F.; Brennan, Julie A.; Piesla, Michael J.; Comery, Tom A.; Grauer, Steven M.; Ashby, Charles R., Jr.; Nguyen, Huy Q.; Dawson, Lee A.; Barrett, James E.; Stack, Gary; Meltzer, Herbert Y.; Harrison, Boyd L.; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">486-496</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Serotonin-2C (5-HT2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists selectively decreasing mesolimbic DA.  As antipsychotic efficacy is proposed to be assocd. with decreased mesolimbic DA neurotransmission by virtue of DA D2 receptor antagonism, the 5-HT2C-selective receptor agonist, WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], was evaluated in animal models of schizophrenia and in vivo microdialysis and electrophysiol. to det. the effects on mesolimbic and nigrostriatal DA neurotransmission.  Similar to clozapine, WAY-163909 (1.7-30 mg/kg i.p.) decreased apomorphine-induced climbing with little effect on stereotypy and no significant induction of catalepsy.  WAY-163909 (0.3-3 mg/kg s.c.) more potently reduced phencyclidine-induced locomotor activity compared with d-amphetamine with no effect on spontaneous activity.  WAY-163909 (1.7-17 mg/kg i.p.) reversed MK-801 (5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate)- and DOI [1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]-disrupted prepulse inhibition of startle (PPI) and improved PPI in DBA/2N mice.  In conditioned avoidance responding, WAY-163909 (0.3-3 mg/kg i.p.; 1-17 mg/kg p.o.) reduced avoidance responding, an effect blocked by the 5-HT2B/2C receptor antagonist SB 206553 [5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole].  WAY-163909 (10 mg/kg s.c.) selectively decreased extracellular levels of DA in the nucleus accumbens without affecting the striatum.  Likewise, in vivo electrophysiol. recordings showed a decrease in the no. of spontaneously firing DA neurons in the ventral tegmental area but not in the substantia nigra with both acute and chronic (21-day) administration of WAY-163909 (1-10 mg/kg i.p.).  Thus, the profile of the 5-HT2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and addnl. may have rapid onset properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemOaXlISXJrVg90H21EOLACvtfcHk0liv5gJ5cc3AiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFCgtg%253D%253D&md5=f70bb5a91c306aa208b5a19cd2e21937</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.106989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.106989%26sid%3Dliteratum%253Aachs%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26aulast%3DSabb%26aufirst%3DA.%2BL.%26aulast%3DLogue%26aufirst%3DS.%2BF.%26aulast%3DBrennan%26aufirst%3DJ.%2BA.%26aulast%3DPiesla%26aufirst%3DM.%2BJ.%26aulast%3DComery%26aufirst%3DT.%2BA.%26aulast%3DGrauer%26aufirst%3DS.%2BM.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DNguyen%26aufirst%3DH.%2BQ.%26aulast%3DDawson%26aufirst%3DL.%2BA.%26aulast%3DBarrett%26aufirst%3DJ.%2BE.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DWAY-163909%2520%255B%25287bR%252C%252010aR%2529-1%252C2%252C3%252C4%252C8%252C9%252C10%252C10a-octahydro-7bH-cyclopenta%255Bb%255D%255B1%252C4%255Ddiazepino%255B6%252C7%252C1hi%255Dindole%255D%253A%2520A%2520novel%25205-hydroxytryptamine%25202C%2520receptor-selective%2520agonist%2520with%2520preclinical%2520antipsychotic-like%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D486%26epage%3D496%26doi%3D10.1124%2Fjpet.106.106989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Musil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obermeier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russ, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamerle, M.</span><span> </span><span class="NLM_article-title">Weight gain and antipsychotics: A drug safety review</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1517/14740338.2015.974549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1517%2F14740338.2015.974549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=25400109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFahtLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=73-96&author=R.+Musilauthor=M.+Obermeierauthor=P.+Russauthor=M.+Hamerle&title=Weight+gain+and+antipsychotics%3A+A+drug+safety+review&doi=10.1517%2F14740338.2015.974549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Weight gain and antipsychotics: a drug safety review</span></div><div class="casAuthors">Musil, Richard; Obermeier, Michael; Russ, Paul; Hamerle, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-96</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Second-generation antipsychotics (SGAs) are widely used in several psychiatric disease entities and exert to a different extent a risk for antipsychotic-induced wt. gain (AIWG).  As AIWG is assocd. with an increase in metabolic syndrome or cardiovascular events, knowledge of these risks is crucial for further monitoring and the initiation of counteractive measures.  Areas covered: We searched PubMed and Web of Sciences for randomized-controlled trials and naturalistic observational studies published between 2010 and 2014 with sample sizes exceeding 100, including all marketed SGAs apart from zotepine, and providing data on wt. increase.  We also summarized relevant systematic reviews and meta-analyses of head-to-head comparisons.  Expert opinion: Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews ranking clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone, quetiapine, risperidone and sertindole in the middle, and aripiprazole, lurasidone and ziprasidone with the lowest risk.  No. needed to harm varied considerably in our meta-anal.  Younger patients and patients with a lower baseline body mass index are most vulnerable.  The greatest amt. of wt. gain occurs within the first weeks of treatment.  AIWG occurs in all diagnostic groups and is also common in treatment with first-generation antipsychotics; therefore, awareness of this adverse event is essential for anyone prescribing antipsychotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9jb7K7ITVGrVg90H21EOLACvtfcHk0ljGQ1CnbWDmiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFahtLvJ&md5=b0dd9abd97f58b1702b933bdb16fdcd8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14740338.2015.974549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2015.974549%26sid%3Dliteratum%253Aachs%26aulast%3DMusil%26aufirst%3DR.%26aulast%3DObermeier%26aufirst%3DM.%26aulast%3DRuss%26aufirst%3DP.%26aulast%3DHamerle%26aufirst%3DM.%26atitle%3DWeight%2520gain%2520and%2520antipsychotics%253A%2520A%2520drug%2520safety%2520review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2015%26volume%3D14%26spage%3D73%26epage%3D96%26doi%3D10.1517%2F14740338.2015.974549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Calcagno, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baviera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Invernizzi, R. W.</span><span> </span><span class="NLM_article-title">Endogenous serotonin and serotonin<sub>2C</sub> receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">–</span> <span class="NLM_lpage">532</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05789.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1111%2Fj.1471-4159.2008.05789.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=19046357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=521-532&author=E.+Calcagnoauthor=M.+Carliauthor=M.+Bavieraauthor=R.+W.+Invernizzi&title=Endogenous+serotonin+and+serotonin2C+receptors+are+involved+in+the+ability+of+M100907+to+suppress+cortical+glutamate+release+induced+by+NMDA+receptor+blockade&doi=10.1111%2Fj.1471-4159.2008.05789.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade</span></div><div class="casAuthors">Calcagno, Eleonora; Carli, Mirjana; Baviera, Marta; Invernizzi, Roberto W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">521-532</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Blockade of NMDA receptors by intracortical infusion of 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP) increases glutamate (GLU) and serotonin (5-HT) release in the medial prefrontal cortex and impairs attentional performance in the 5-choice serial reaction time task.  These effects are prevented by the 5-HT2A receptor antagonist, (R)-(+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol (M100907).  We explored the roles of endogenous 5-HT and 5-HT1A and 5-HT2C receptors in the mechanisms by which M100907 suppresses CPP-induced release of cortical GLU and 5-HT using in vivo microdialysis.  CPP raised extracellular GLU and 5-HT by about 250% and 170% resp.  The 5-HT synthesis inhibitor, p-chlorophenylalanine (300 mg/kg), prevented M100907 suppressing CPP-induced GLU release.  The effect of M100907 on these rises of GLU and 5-HT and attentional performance deficit was mimicked by the 5-HT2C receptor agonist, (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine fumarate, (Ro60-0175, 30 μg/kg) while intra-mPFC (SB242084, 6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]- indoline, 0.1 μM), a 5-HT2C receptor antagonist, prevented the effect of M100907 on extracellular GLU.  The 5-HT1A receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexane carboxenide trihydrochloride (100 μM) abolished the effect of M100907 on the CPP-induced 5-HT release.  The data show that blockade of 5-HT2A receptors is not sufficient to suppress the CPP-induced rise of extracellular GLU and 5-HT and suggest that M100907 suppresses GLU release induced by CPP by enhancing the action of endogenous 5-HT on 5-HT2C receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpax0KCgcrJA7Vg90H21EOLACvtfcHk0likLzvOHt3loQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCqtA%253D%253D&md5=185b52f99bdcfa78c72f9d1370a42fbc</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05789.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05789.x%26sid%3Dliteratum%253Aachs%26aulast%3DCalcagno%26aufirst%3DE.%26aulast%3DCarli%26aufirst%3DM.%26aulast%3DBaviera%26aufirst%3DM.%26aulast%3DInvernizzi%26aufirst%3DR.%2BW.%26atitle%3DEndogenous%2520serotonin%2520and%2520serotonin2C%2520receptors%2520are%2520involved%2520in%2520the%2520ability%2520of%2520M100907%2520to%2520suppress%2520cortical%2520glutamate%2520release%2520induced%2520by%2520NMDA%2520receptor%2520blockade%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D108%26spage%3D521%26epage%3D532%26doi%3D10.1111%2Fj.1471-4159.2008.05789.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Del’Guidice, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemasson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levasseur-Moreau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etievant, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escoffier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roman, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span> </span><span class="NLM_article-title">Stimulation of 5-HT<sub>2C</sub> receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1125</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1038/npp.2013.313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnpp.2013.313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2014&pages=1125-1134&author=T.+Del%E2%80%99Guidiceauthor=F.+Lemayauthor=M.+Lemassonauthor=J.+Levasseur-Moreauauthor=S.+Mantaauthor=A.+Etievantauthor=G.+Escoffierauthor=F.+Y.+Doreauthor=F.+S.+Romanauthor=J.+M.+Beaulieu&title=Stimulation+of+5-HT2C+receptors+improves+cognitive+deficits+induced+by+human+tryptophan+hydroxylase+2+loss+of+function+mutation&doi=10.1038%2Fnpp.2013.313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.313%26sid%3Dliteratum%253Aachs%26aulast%3DDel%25E2%2580%2599Guidice%26aufirst%3DT.%26aulast%3DLemay%26aufirst%3DF.%26aulast%3DLemasson%26aufirst%3DM.%26aulast%3DLevasseur-Moreau%26aufirst%3DJ.%26aulast%3DManta%26aufirst%3DS.%26aulast%3DEtievant%26aufirst%3DA.%26aulast%3DEscoffier%26aufirst%3DG.%26aulast%3DDore%26aufirst%3DF.%2BY.%26aulast%3DRoman%26aufirst%3DF.%2BS.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26atitle%3DStimulation%2520of%25205-HT2C%2520receptors%2520improves%2520cognitive%2520deficits%2520induced%2520by%2520human%2520tryptophan%2520hydroxylase%25202%2520loss%2520of%2520function%2520mutation%26jtitle%3DNeuropsychopharmacology%26date%3D2014%26volume%3D39%26spage%3D1125%26epage%3D1134%26doi%3D10.1038%2Fnpp.2013.313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Hallucinogens</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0lgkEzpoU0g4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for possible involvement of 5-HT<sub>2B</sub> receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span><span class="refDoi"> DOI: 10.1161/01.CIR.102.23.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1161%2F01.CIR.102.23.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=11104741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+possible+involvement+of+5-HT2B+receptors+in+the+cardiac+valvulopathy+associated+with+fenfluramine+and+other+serotonergic+medications&doi=10.1161%2F01.CIR.102.23.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Savage, Jason E.; Rauser, Laura; McBride, Ace; Hufeisen, Sandra J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2836-2841</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being investigated as treatments for drug dependence.  The occurrence of fenfluramine-assocd. valvular heart disease (VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD.  We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis.  Medications known or suspected to cause VHD (pos. controls) and medications not assocd. with VHD (neg. controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of ligand-binding methods and functional assays.  The pos. control drugs were (±)-fenfluramine; (+)-fenfluramine; (-)-fenfluramine; its metabolites (±)-norfenfluramine, (+)-norfenfluramine, and (-)-norfenfluramine; ergotamine; and methysergide and its metabolite methylergonovine.  The neg. control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine.  (±)-, (+)-, And (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor.  Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT2B receptors are unlikely to produce VHD.  We suggest that all clin. available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6spUXOCLtLrVg90H21EOLACvtfcHk0lgkEzpoU0g4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D&md5=6b8c6059885dd9b058859089914c61b3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.102.23.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.102.23.2836%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520possible%2520involvement%2520of%25205-HT2B%2520receptors%2520in%2520the%2520cardiac%2520valvulopathy%2520associated%2520with%2520fenfluramine%2520and%2520other%2520serotonergic%2520medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26spage%3D2836%26epage%3D2841%26doi%3D10.1161%2F01.CIR.102.23.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Saldana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espitia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuskin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D.</span><span> </span><span class="NLM_article-title">Lorcaserin, a novel selective human 5-hydroxytryptamine<sub>2C</sub> agonist: In vitro and in vivo pharmacological characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1124/jpet.107.133348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fjpet.107.133348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18252809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=577-587&author=W.+J.+Thomsenauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=H.+Reyes-Saldanaauthor=S.+Espitiaauthor=D.+Yuskinauthor=K.+Whelanauthor=M.+Martinauthor=M.+Morganauthor=W.+Chenauthor=H.+Al-Shammaauthor=B.+Smithauthor=D.+Chalmersauthor=D.+Behan&title=Lorcaserin%2C+a+novel+selective+human+5-hydroxytryptamine2C+agonist%3A+In+vitro+and+in+vivo+pharmacological+characterization&doi=10.1124%2Fjpet.107.133348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization</span></div><div class="casAuthors">Thomsen, William J.; Grottick, Andrew J.; Menzaghi, Frederique; Reyes-Saldana, Hazel; Espitia, Stephen; Yuskin, Diane; Whelan, Kevin; Martin, Michael; Morgan, Michael; Chen, Weichao; Al-Shamma, Hussein; Smith, Brian; Chalmers, Derek; Behan, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)2C receptor agonists hold promise for the treatment of obesity.  In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT2C full agonist.  Lorcaserin bound to human and rat 5-HT2C receptors with high affinity (Ki = 15±1 nM, 29±7 nM, resp.), and it was a full agonist for the human 5-HT2C receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT2A and 5-HT2B receptors, resp.  Lorcaserin was also highly selective for human 5-HT2C over other human 5-HT receptors (5-HT1A, 5-HT3, 5-HT4C, 5-HT55A, 5-HT6, and 5-HT7), in addn. to a panel of 67 other G protein-coupled receptors and ion channels.  Lorcaserin did not compete for binding of ligands to serotonin, dopamine, and norepinephrine transporters, and it did not alter their function in vitro.  Behavioral observations indicated that unlike the 5-HT2A agonist (±)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane, lorcaserin did not induce behavioral changes indicative of functional 5-HT2A agonist activity.  Acutely, lorcaserin reduced food intake in rats, an effect that was reversed by pretreatment with the 5-HT2C-selective antagonist 6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl-carbamoyl]indoline (SB242,084) but not the 5-HT2A antagonist (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL 100,907), demonstrating mediation by the 5-HT2C receptor.  Chronic daily treatment with lorcaserin to rats maintained on a high fat diet produced dose-dependent redns. in food intake and body wt. gain that were maintained during the 4-wk study.  Upon discontinuation, body wt. returned to control levels.  These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT2C receptor, with potential for the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDHE28aF3k7Vg90H21EOLACvtfcHk0lgxpj_DVjcdzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D&md5=0626c3dabb7e89066e45ecd12cbc81f8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133348%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DReyes-Saldana%26aufirst%3DH.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DYuskin%26aufirst%3DD.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChalmers%26aufirst%3DD.%26aulast%3DBehan%26aufirst%3DD.%26atitle%3DLorcaserin%252C%2520a%2520novel%2520selective%2520human%25205-hydroxytryptamine2C%2520agonist%253A%2520In%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D577%26epage%3D587%26doi%3D10.1124%2Fjpet.107.133348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">DiNicolantonio, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Keefe, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, P.</span><span> </span><span class="NLM_article-title">Lorcaserin for the treatment of obesity? A closer look at its side effects</span> <span class="citation_source-journal">Open Heart</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e000173</span><span class="refDoi"> DOI: 10.1136/openhrt-2014-000173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1136%2Fopenhrt-2014-000173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=e000173&author=J.+J.+DiNicolantonioauthor=S.+Chatterjeeauthor=J.+H.+O%E2%80%99Keefeauthor=P.+Meier&title=Lorcaserin+for+the+treatment+of+obesity%3F+A+closer+look+at+its+side+effects&doi=10.1136%2Fopenhrt-2014-000173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1136%2Fopenhrt-2014-000173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fopenhrt-2014-000173%26sid%3Dliteratum%253Aachs%26aulast%3DDiNicolantonio%26aufirst%3DJ.%2BJ.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DJ.%2BH.%26aulast%3DMeier%26aufirst%3DP.%26atitle%3DLorcaserin%2520for%2520the%2520treatment%2520of%2520obesity%253F%2520A%2520closer%2520look%2520at%2520its%2520side%2520effects%26jtitle%3DOpen%2520Heart%26date%3D2014%26volume%3D1%26spage%3De000173%26doi%3D10.1136%2Fopenhrt-2014-000173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onajole, O. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lv, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaisin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunosewoyo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmerberg, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pogorelov, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span><span class="refDoi"> DOI: 10.1021/jm5019274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5019274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1992-2002&author=J.+Chengauthor=P.+M.+Giguereauthor=O.+K.+Onajoleauthor=W.+Lvauthor=A.+Gaisinauthor=H.+Gunosewoyoauthor=C.+M.+Schmerbergauthor=V.+M.+Pogorelovauthor=R.+M.+Rodriguizauthor=G.+Vistoliauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Optimization+of+2-phenylcyclopropylmethylamines+as+selective+serotonin+2C+receptor+agonists+and+their+evaluation+as+potential+antipsychotic+agents&doi=10.1021%2Fjm5019274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents</span></div><div class="casAuthors">Cheng, Jianjun; Giguere, Patrick M.; Onajole, Oluseye K.; Lv, Wei; Gaisin, Arsen; Gunosewoyo, Hendra; Schmerberg, Claire M.; Pogorelov, Vladimir M.; Rodriguiz, Ramona M.; Vistoli, Giulio; Wetsel, William C.; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1992-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a new series of compds. that are potent, selective 5-HT2C receptor agonists is described herein as the authors continue the efforts to optimize the 2-phenylcyclopropylmethylamine scaffold.  Modifications focused on the alkoxyl substituent present on the arom. ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors.  ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compds. possessing drug-like profiles and having antipsychotic properties.  Compd. I, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date.  The likely binding mode of this series of compds. to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Ar63unExNbVg90H21EOLACvtfcHk0lgZgP0kUbV8xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lt74%253D&md5=f2884cbae8062702164da57a0de7381f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm5019274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5019274%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DOnajole%26aufirst%3DO.%2BK.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DGaisin%26aufirst%3DA.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DPogorelov%26aufirst%3DV.%2BM.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DOptimization%2520of%25202-phenylcyclopropylmethylamines%2520as%2520selective%2520serotonin%25202C%2520receptor%2520agonists%2520and%2520their%2520evaluation%2520as%2520potential%2520antipsychotic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1992%26epage%3D2002%26doi%3D10.1021%2Fjm5019274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svennebring, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational drug design leading to the identification of a potent 5-HT<sub>2C</sub> agonist lacking 5-HT<sub>2B</sub> Activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span><span class="refDoi"> DOI: 10.1021/ml200206z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200206z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=929-932&author=G.+Chenauthor=S.+J.+Choauthor=X.+P.+Huangauthor=N.+H.+Jensenauthor=A.+Svennebringauthor=M.+F.+Sassanoauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Rational+drug+design+leading+to+the+identification+of+a+potent+5-HT2C+agonist+lacking+5-HT2B+Activity&doi=10.1021%2Fml200206z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fml200206z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200206z%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DSvennebring%26aufirst%3DA.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520drug%2520design%2520leading%2520to%2520the%2520identification%2520of%2520a%2520potent%25205-HT2C%2520agonist%2520lacking%25205-HT2B%2520Activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Fml200206z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svennebring, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">HTS and rational drug design to generate a class of 5-HT<sub>2C</sub>-selective ligands for possible use in schizophrenia</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1221</span><span class="NLM_x">–</span> <span class="NLM_lpage">1225</span><span class="refDoi"> DOI: 10.1002/cmdc.201000186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1002%2Fcmdc.201000186" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1221-1225&author=A.+P.+Kozikowskiauthor=S.+J.+Choauthor=N.+H.+Jensenauthor=J.+A.+Allenauthor=A.+M.+Svennebringauthor=B.+L.+Roth&title=HTS+and+rational+drug+design+to+generate+a+class+of+5-HT2C-selective+ligands+for+possible+use+in+schizophrenia&doi=10.1002%2Fcmdc.201000186"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000186%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DSvennebring%26aufirst%3DA.%2BM.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DHTS%2520and%2520rational%2520drug%2520design%2520to%2520generate%2520a%2520class%2520of%25205-HT2C-selective%2520ligands%2520for%2520possible%2520use%2520in%2520schizophrenia%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1221%26epage%3D1225%26doi%3D10.1002%2Fcmdc.201000186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Cho, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurome, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manzano, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malberg, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldarone, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: Identification of drugs with antidepressant-like action</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1885</span><span class="NLM_x">–</span> <span class="NLM_lpage">1902</span><span class="refDoi"> DOI: 10.1021/jm801354e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801354e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1885-1902&author=S.+J.+Choauthor=N.+H.+Jensenauthor=T.+Kuromeauthor=S.+Kadariauthor=M.+L.+Manzanoauthor=J.+E.+Malbergauthor=B.+Caldaroneauthor=B.+L.+Rothauthor=A.+P.+Kozikowski&title=Selective+5-hydroxytryptamine+2C+receptor+agonists+derived+from+the+lead+compound+tranylcypromine%3A+Identification+of+drugs+with+antidepressant-like+action&doi=10.1021%2Fjm801354e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Selective 5-Hydroxytryptamine 2C Receptor Agonists Derived from the Lead Compound Tranylcypromine: Identification of Drugs with Antidepressant-Like Action</span></div><div class="casAuthors">Cho, Sung Jin; Jensen, Niels H.; Kurome, Toru; Kadari, Sudhakar; Manzano, Michael L.; Malberg, Jessica E.; Caldarone, Barbara; Roth, Bryan L.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1885-1902</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report here the design, synthesis, and pharmacol. properties of a series of compds. related to tranylcypromine (9), which itself was discovered as a lead compd. in a high-throughput screening campaign.  Starting from 9, which shows modest activity as a 5-HT2C agonist, a series of 1-aminomethyl-2-phenylcyclopropanes was investigated as 5-HT2C agonists through iterative structural modifications.  Key pharmacophore feature of this new class of ligands is a 2-aminomethyl-trans-cyclopropyl side chain attached to a substituted benzene ring.  Among the tested compds., several were potent and efficacious 5-HT2C receptor agonists with selectivity over both 5-HT2A and 5-HT2B receptors in functional assays.  The most promising compd. is 37, with 120- and 14-fold selectivity over 5-HT2A and 5-HT2B, resp. (EC50 = 585, 65, and 4.8 nM at the 2A, 2B, and 2C subtypes, resp.).  In animal studies, compd. 37 (10-60 mg/kg) decreased immobility time in the mouse forced swim test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyh5xre4fJybVg90H21EOLACvtfcHk0ljZZFHoRB33Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFKntr0%253D&md5=d7711d01a8d462824a8fcf535e0a1be4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm801354e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801354e%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKurome%26aufirst%3DT.%26aulast%3DKadari%26aufirst%3DS.%26aulast%3DManzano%26aufirst%3DM.%2BL.%26aulast%3DMalberg%26aufirst%3DJ.%2BE.%26aulast%3DCaldarone%26aufirst%3DB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%25205-hydroxytryptamine%25202C%2520receptor%2520agonists%2520derived%2520from%2520the%2520lead%2520compound%2520tranylcypromine%253A%2520Identification%2520of%2520drugs%2520with%2520antidepressant-like%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1885%26epage%3D1902%26doi%3D10.1021%2Fjm801354e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hagmann, W. K.</span><span> </span><span class="NLM_article-title">The many roles for fluorine in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4359</span><span class="NLM_x">–</span> <span class="NLM_lpage">4369</span><span class="refDoi"> DOI: 10.1021/jm800219f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800219f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4359-4369&author=W.+K.+Hagmann&title=The+many+roles+for+fluorine+in+medicinal+chemistry&doi=10.1021%2Fjm800219f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The Many Roles for Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Hagmann, William K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4359-4369</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkZV7sio8RhbVg90H21EOLACvtfcHk0liE5LR3y-hGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1WjtLo%253D&md5=821f8076bb0f632f687b1c90b05dd382</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm800219f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800219f%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%2BK.%26atitle%3DThe%2520many%2520roles%2520for%2520fluorine%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4359%26epage%3D4369%26doi%3D10.1021%2Fjm800219f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalchick, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiting, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCann, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scapin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roy, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">(2<i>R</i>)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8<i>H</i>)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1021/jm0493156</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493156" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=141-151&author=D.+Kimauthor=L.+Wangauthor=M.+Beconiauthor=G.+J.+Eiermannauthor=M.+H.+Fisherauthor=H.+Heauthor=G.+J.+Hickeyauthor=J.+E.+Kowalchickauthor=B.+Leitingauthor=K.+Lyonsauthor=F.+Marsilioauthor=M.+E.+McCannauthor=R.+A.+Patelauthor=A.+Petrovauthor=G.+Scapinauthor=S.+B.+Patelauthor=R.+S.+Royauthor=J.+K.+Wuauthor=M.+J.+Wyvrattauthor=B.+B.+Zhangauthor=L.+Zhuauthor=N.+A.+Thornberryauthor=A.+E.+Weber&title=%282R%29-4-Oxo-4-%5B3-%28trifluoromethyl%29-5%2C6-dihydro%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dpyrazin-7%288H%29-+yl%5D-1-%282%2C4%2C5-trifluorophenyl%29butan-2-amine%3A+A+potent%2C+orally+active+dipeptidyl+peptidase+IV+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm0493156"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0493156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493156%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBeconi%26aufirst%3DM.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHickey%26aufirst%3DG.%2BJ.%26aulast%3DKowalchick%26aufirst%3DJ.%2BE.%26aulast%3DLeiting%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DK.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DMcCann%26aufirst%3DM.%2BE.%26aulast%3DPatel%26aufirst%3DR.%2BA.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DScapin%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DRoy%26aufirst%3DR.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BK.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DB.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DThornberry%26aufirst%3DN.%2BA.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25282R%2529-4-Oxo-4-%255B3-%2528trifluoromethyl%2529-5%252C6-dihydro%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dpyrazin-7%25288H%2529-%2520yl%255D-1-%25282%252C4%252C5-trifluorophenyl%2529butan-2-amine%253A%2520A%2520potent%252C%2520orally%2520active%2520dipeptidyl%2520peptidase%2520IV%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D141%26epage%3D151%26doi%3D10.1021%2Fjm0493156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure-based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure-based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prioleau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schetz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1016/S0893-133X(98)00099-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0893-133X%2898%2900099-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10327430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=612-627&author=C.+P.+Lawlerauthor=C.+Prioleauauthor=M.+M.+Lewisauthor=C.+Makauthor=D.+Jiangauthor=J.+A.+Schetzauthor=A.+M.+Gonzalezauthor=D.+R.+Sibleyauthor=R.+B.+Mailman&title=Interactions+of+the+novel+antipsychotic+aripiprazole+%28OPC-14597%29+with+dopamine+and+serotonin+receptor+subtypes&doi=10.1016%2FS0893-133X%2898%2900099-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</span></div><div class="casAuthors">Lawler, Cindy P.; Prioleau, Cassandra; Lewis, Mechelle M.; Mak, Chun; Jiang, Dong; Schetz, John A.; Gonzalez, Antonio M.; Sibley, David R.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">612-627</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">OPC-14597 {aripiprazole; 7- (4- (4-(2,3-dichlorophenyl) -1-piperazinyl) butyloxy) -3, 4-dihydro-2 (1H) -quinolinone} is a novel candidate antipsychotic that has high affinity for striatal dopamine D2-like receptors, but causes few extrapyramidal effects.  These studies characterized the mol. pharmacol. of OPC-14597, DM-1451 (its major rodent metabolite), and the related quinolinone deriv. OPC-4392 at each of the cloned dopamine receptors, and at serotonin 5HT6 and 5HT7 receptors.  All three compds. exhibited highest affinity for D2L and D2S receptors relative to the other cloned receptors examd.  Both OPC-4392 and OPC-14597 demonstrated dual agonist/antagonist actions at D2L receptors, although the metabolite DM-1451 behaved as a pure antagonist.  These data suggest that clin. atypicality can occur with drugs that exhibit selectivity for D2L/D2S rather than D3 or D4 receptors, and raise the possibility that the unusual profile of OPC-14597 in vivo (presynaptic agonist and postsynaptic antagonist) may reflect different functional consequences of this compd. interacting with a single dopamine receptor subtype (D2) in distinct cellular locales.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhC9HkOART7Vg90H21EOLACvtfcHk0lhrLOKsONdyiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsVamu7c%253D&md5=6075301b17f119d4040742751425bb92</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900099-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900099-2%26sid%3Dliteratum%253Aachs%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DPrioleau%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DMak%26aufirst%3DC.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DSchetz%26aufirst%3DJ.%2BA.%26aulast%3DGonzalez%26aufirst%3DA.%2BM.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DInteractions%2520of%2520the%2520novel%2520antipsychotic%2520aripiprazole%2520%2528OPC-14597%2529%2520with%2520dopamine%2520and%2520serotonin%2520receptor%2520subtypes%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D20%26spage%3D612%26epage%3D627%26doi%3D10.1016%2FS0893-133X%2898%2900099-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Wilcken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joerger, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1363</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lhrLOKsONdyiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Voth, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P. S.</span><span> </span><span class="NLM_article-title">Halogen bonds as orthogonal molecular interactions to hydrogen bonds</span> <span class="citation_source-journal">Nat. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1038/nchem.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnchem.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=21378804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktlSlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=74-79&author=A.+R.+Vothauthor=P.+Khuuauthor=K.+Oishiauthor=P.+S.+Ho&title=Halogen+bonds+as+orthogonal+molecular+interactions+to+hydrogen+bonds&doi=10.1038%2Fnchem.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Halogen bonds as orthogonal molecular interactions to hydrogen bonds</span></div><div class="casAuthors">Voth, Andrea Regier; Khuu, Patricia; Oishi, Keita; Ho, P. Shing</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-79</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Halogen bonds (X-bonds) are shown to be geometrically perpendicular to and energetically independent of hydrogen bonds (H-bonds) that share a common carbonyl oxygen acceptor.  This orthogonal relationship is accommodated by the in-plane and out-of-plane electroneg. potentials of the oxygen, which are differentially populated by H- and X-bonds.  Furthermore, the local conformation of a peptide helps to define the geometry of the H-bond and thus the oxygen surface that is accessible for X-bonding.  These electrostatic and steric forces conspire to impose a strong preference for the orthogonal geometry of X- and H-bonds.  Thus, the optimum geometry of an X-bond can be predicted from the pattern of H-bonds in a folded protein, enabling X-bonds to be introduced to improve ligand affinities without disrupting these structurally important interactions.  This concept of orthogonal mol. interactions can be exploited for the rational design of halogenated ligands as inhibitors and drugs, and in biomol. engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBR3qQ1-IvprVg90H21EOLACvtfcHk0lh-lUgmsjrP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktlSlsb4%253D&md5=fd9ef235df86c00261b9bd0a782f88c2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchem.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.112%26sid%3Dliteratum%253Aachs%26aulast%3DVoth%26aufirst%3DA.%2BR.%26aulast%3DKhuu%26aufirst%3DP.%26aulast%3DOishi%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DP.%2BS.%26atitle%3DHalogen%2520bonds%2520as%2520orthogonal%2520molecular%2520interactions%2520to%2520hydrogen%2520bonds%26jtitle%3DNat.%2520Chem.%26date%3D2009%26volume%3D1%26spage%3D74%26epage%3D79%26doi%3D10.1038%2Fnchem.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Toy, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanabalasingam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenberg, P. F.</span><span> </span><span class="NLM_article-title">A substituted hypersensitive radical probe for enzyme-catalyzed hydroxylations: Synthesis of racemic and enantiomerically enriched forms and application in a cytochrome P450-catalyzed oxidation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">9114</span><span class="NLM_x">–</span> <span class="NLM_lpage">9122</span><span class="refDoi"> DOI: 10.1021/jo9712097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9712097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=9114-9122&author=P.+H.+Toyauthor=B.+Dhanabalasingamauthor=M.+Newcombauthor=I.+H.+Hannaauthor=P.+F.+Hollenberg&title=A+substituted+hypersensitive+radical+probe+for+enzyme-catalyzed+hydroxylations%3A+Synthesis+of+racemic+and+enantiomerically+enriched+forms+and+application+in+a+cytochrome+P450-catalyzed+oxidation&doi=10.1021%2Fjo9712097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo9712097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9712097%26sid%3Dliteratum%253Aachs%26aulast%3DToy%26aufirst%3DP.%2BH.%26aulast%3DDhanabalasingam%26aufirst%3DB.%26aulast%3DNewcomb%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DI.%2BH.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DA%2520substituted%2520hypersensitive%2520radical%2520probe%2520for%2520enzyme-catalyzed%2520hydroxylations%253A%2520Synthesis%2520of%2520racemic%2520and%2520enantiomerically%2520enriched%2520forms%2520and%2520application%2520in%2520a%2520cytochrome%2520P450-catalyzed%2520oxidation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D9114%26epage%3D9122%26doi%3D10.1021%2Fjo9712097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Gooden, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, D. M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabadi, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, D. G.</span><span> </span><span class="NLM_article-title">Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3047</span><span class="NLM_x">–</span> <span class="NLM_lpage">3051</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2Fj.bmcl.2008.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18242989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVagurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3047-3051&author=D.+M.+Goodenauthor=D.+M.+Z.+Schmidtauthor=J.+A.+Pollockauthor=A.+M.+Kabadiauthor=D.+G.+McCafferty&title=Facile+synthesis+of+substituted+trans-2-arylcyclopropylamine+inhibitors+of+the+human+histone+demethylase+LSD1+and+monoamine+oxidases+A+and+B&doi=10.1016%2Fj.bmcl.2008.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B</span></div><div class="casAuthors">Gooden, David M.; Schmidt, Dawn M. Z.; Pollock, Julie A.; Kabadi, Ami M.; McCafferty, Dewey G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3047-3051</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A facile synthetic route to substituted trans-2-arylcyclopropylamines was developed to provide access to mechanism-based inhibitors of the human flavoenzyme oxidase lysine-specific histone demethylase LSD1 and related enzyme family members such as monoamine oxidases A and B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojt7YjHKC3yrVg90H21EOLACvtfcHk0lh-lUgmsjrP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVagurs%253D&md5=2459dcb4cde160186fc17c09258c5906</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DGooden%26aufirst%3DD.%2BM.%26aulast%3DSchmidt%26aufirst%3DD.%2BM.%2BZ.%26aulast%3DPollock%26aufirst%3DJ.%2BA.%26aulast%3DKabadi%26aufirst%3DA.%2BM.%26aulast%3DMcCafferty%26aufirst%3DD.%2BG.%26atitle%3DFacile%2520synthesis%2520of%2520substituted%2520trans-2-arylcyclopropylamine%2520inhibitors%2520of%2520the%2520human%2520histone%2520demethylase%2520LSD1%2520and%2520monoamine%2520oxidases%2520A%2520and%2520B%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3047%26epage%3D3051%26doi%3D10.1016%2Fj.bmcl.2008.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Besnard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruda, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norval, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeons, F. R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stojanovski, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidah, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constam, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerton, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, I. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span> </span><span class="NLM_article-title">Automated design of ligands to polypharmacological profiles</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">492</span><span class="NLM_x">, </span> <span class="NLM_fpage">215</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span><span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.+P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+design+of+ligands+to+polypharmacological+profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0ljDhhAH1Qu0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520design%2520of%2520ligands%2520to%2520polypharmacological%2520profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Benhamu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Fontecha, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vazquez-Villa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Rodriguez, M. L.</span><span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>6</sub> receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7160</span><span class="NLM_x">–</span> <span class="NLM_lpage">7181</span><span class="refDoi"> DOI: 10.1021/jm5003952</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003952" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7160-7181&author=B.+Benhamuauthor=M.+Martin-Fontechaauthor=H.+Vazquez-Villaauthor=L.+Pardoauthor=M.+L.+Lopez-Rodriguez&title=Serotonin+5-HT6+receptor+antagonists+for+the+treatment+of+cognitive+deficiency+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm5003952"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease</span></div><div class="casAuthors">Benhamu, Bellinda; Martin-Fontecha, Mar; Vazquez-Villa, Henar; Pardo, Leonardo; Lopez-Rodriguez, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7160-7181</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is one of the most frequent causes of death and disability worldwide and has a significant clin. and socioeconomic impact.  In the search for novel therapeutic strategies, serotonin 5-HT6 receptor (5-HT6R) has been proposed as a promising drug target for cognition enhancement in AD.  This manuscript reviews the compelling evidence for the implication of this receptor in learning and memory processes.  We have summarized the current status of the medicinal chem. of 5-HT6R antagonists and the encouraging preclin. findings that demonstrate their significant procognitive behavioral effects in a no. of learning paradigms, probably acting through modulation of multiple neurotransmitter systems and signaling pathways.  The results of the ongoing clin. trials are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic cognitive impairment in AD, either as stand-alone therapy or in combination with established agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeTO6_2THvaLVg90H21EOLACvtfcHk0ljDhhAH1Qu0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWjs7c%253D&md5=bf8d2cba73f72e04a5caf8b295647064</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm5003952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003952%26sid%3Dliteratum%253Aachs%26aulast%3DBenhamu%26aufirst%3DB.%26aulast%3DMartin-Fontecha%26aufirst%3DM.%26aulast%3DVazquez-Villa%26aufirst%3DH.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DLopez-Rodriguez%26aufirst%3DM.%2BL.%26atitle%3DSerotonin%25205-HT6%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520deficiency%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7160%26epage%3D7181%26doi%3D10.1021%2Fjm5003952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Karila, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freret, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulouard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallemagne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rochais, C.</span><span> </span><span class="NLM_article-title">Therapeutic potential of 5-HT<sub>6</sub> receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7901</span><span class="NLM_x">–</span> <span class="NLM_lpage">7912</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00179</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00179" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKitr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7901-7912&author=D.+Karilaauthor=T.+Freretauthor=V.+Bouetauthor=M.+Boulouardauthor=P.+Dallemagneauthor=C.+Rochais&title=Therapeutic+potential+of+5-HT6+receptor+agonists&doi=10.1021%2Facs.jmedchem.5b00179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Potential of 5-HT6 Receptor Agonists</span></div><div class="casAuthors">Karila, Delphine; Freret, Thomas; Bouet, Valentine; Boulouard, Michel; Dallemagne, Patrick; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7901-7912</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given its predominant expression in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (5-HT6R) has been considered as a valuable target for the development of CNS drugs with limited side effects.  After 2 decades of intense research, numerous selective ligands have been developed to target this receptor; this holds potential interest for the treatment of neuropathol. disorders.  In fact, some agents (mainly antagonists) are currently undergoing clin. trial.  More recently, a series of potent and selective agonists have been developed, and preclin. studies have been conducted that suggest the therapeutic interest of 5-HT6R agonists.  This review details the medicinal chem. of these agonists, highlights their activities, and discusses their potential for treating cognitive issues assocd. with Alzheimer's disease (AD), depression, or obesity.  Surprisingly, some studies have shown that both 5-HT6R agonists and antagonists exert similar procognitive activities.  This article summarizes the hypotheses that could explain this paradox.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCJqIFtQjIYrVg90H21EOLACvtfcHk0ljDhhAH1Qu0BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKitr3E&md5=4fba085fbefee0b614ea122821c7787f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00179%26sid%3Dliteratum%253Aachs%26aulast%3DKarila%26aufirst%3DD.%26aulast%3DFreret%26aufirst%3DT.%26aulast%3DBouet%26aufirst%3DV.%26aulast%3DBoulouard%26aufirst%3DM.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520potential%2520of%25205-HT6%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7901%26epage%3D7912%26doi%3D10.1021%2Facs.jmedchem.5b00179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span> </span><span class="NLM_article-title">Predictive in silico modeling for hERG channel blockers</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">149</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03278-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS1359-6446%2804%2903278-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=15718164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFarsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=149-155&author=A.+M.+Aronov&title=Predictive+in+silico+modeling+for+hERG+channel+blockers&doi=10.1016%2FS1359-6446%2804%2903278-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive in silico modeling for hERG channel blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-155</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  HERG-mediated sudden death as a side effect of non-antiarrhythmic drugs has been receiving increased regulatory attention.  Perhaps owing to the unique shape of the ligand-binding site and its hydrophobic character, the hERG channel has been shown to interact with pharmaceuticals of widely varying structure.  Several in silico approaches have attempted to predict hERG channel blockade.  Some of these approaches are aimed primarily at filtering out potential hERG blockers in the context of virtual libraries, others involve understanding structure-activity relationships governing hERG-drug interactions.  This review summarizes the most recent efforts in this emerging field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDgIcgWdJQJrVg90H21EOLACvtfcHk0libUKYQgPfNmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFarsbY%253D&md5=112b79a48e3d6f5ab3e313f00cf2a4fa</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903278-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903278-7%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DPredictive%2520in%2520silico%2520modeling%2520for%2520hERG%2520channel%2520blockers%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D149%26epage%3D155%26doi%3D10.1016%2FS1359-6446%2804%2903278-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of beta-arrestin-biased dopamine D<sub>2</sub> ligands for probing signal transduction pathways essential for antipsychotic efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=22025698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+beta-arrestin-biased+dopamine+D2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span></div><div class="casAuthors">Allen, John A.; Yost, Julianne M.; Setola, Vincent; Chen, Xin; Sassano, Maria F.; Chen, Meng; Peterson, Sean; Yadav, Prem N.; Huang, Xi-Ping; Feng, Bo; Jensen, Niels H.; Che, Xin; Bai, Xu; Frye, Stephen V.; Wetsel, William C.; Caron, Marc G.; Javitch, Jonathan A.; Roth, Bryan L.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18488-18493, S18488/1-S18488/15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Elucidating the key signal transduction pathways essential for both antipsychotic efficacy and side-effect profiles is essential for developing safer and more effective therapies.  Recent work has highlighted noncanonical modes of dopamine D2 receptor (D2R) signaling via β-arrestins as being important for the therapeutic actions of both antipsychotic and antimanic agents.  We thus sought to create unique D2R agonists that display signaling bias via β-arrestinergic signaling.  Through a robust diversity-oriented modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3); and UNC9994 (4) as unprecedented β-arrestin-biased D2R ligands.  These compds. also represent unprecedented β-arrestin-biased ligands for a Gi-coupled G protein-coupled receptor (GPCR).  Significantly, UNC9975, UNC0006, and UNC9994 are simultaneously antagonists of Gi-regulated cAMP prodn. and partial agonists for D2R/β-arrestin-2 interactions.  Importantly, VNC9975 displayed potent antipsychotic-like activity without inducing motoric side effects in inbred C57BL/6 mice in vivo.  Genetic deletion of β-arrestin-2 simultaneously attenuated the antipsychotic actions of UNC9975 and transformed it into a typical antipsychotic .drug with a high propensity to induce catalepsy.  Similarly, the antipsychotic-like activity displayed by UNC9994, an extremely β-arrestin-biased D2R agonist, in wild-type mice was completely abolished in β-arrestin-2 knockout mice.  Taken together, our results suggest that β-arrestin signaling and recruitment can be simultaneously a significant contributor to antipsychotic efficacy and protective against motoric side effects.  These functionally selective, β-arrestin-biased D2R ligands represent valuable chem. probes for further investigations of D2R signaling in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr87mjP6jm447Vg90H21EOLACvtfcHk0libUKYQgPfNmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFymtLzK&md5=d5b06e4ac4d2cc4cd04fd1de760ec628</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520beta-arrestin-biased%2520dopamine%2520D2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Chitty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyyalol, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Iverson, M. T.</span><span> </span><span class="NLM_article-title">Dexamphetamine effects on prepulse inhibition (PPI) and startle in healthy volunteers</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">2327</span><span class="NLM_x">–</span> <span class="NLM_lpage">2337</span><span class="refDoi"> DOI: 10.1007/s00213-013-3395-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1007%2Fs00213-013-3395-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2014&pages=2327-2337&author=K.+Chittyauthor=M.+A.+Albrechtauthor=K.+Grahamauthor=C.+Kerrauthor=J.+W.+Y.+Leeauthor=R.+Iyyalolauthor=M.+T.+Martin-Iverson&title=Dexamphetamine+effects+on+prepulse+inhibition+%28PPI%29+and+startle+in+healthy+volunteers&doi=10.1007%2Fs00213-013-3395-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs00213-013-3395-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-013-3395-z%26sid%3Dliteratum%253Aachs%26aulast%3DChitty%26aufirst%3DK.%26aulast%3DAlbrecht%26aufirst%3DM.%2BA.%26aulast%3DGraham%26aufirst%3DK.%26aulast%3DKerr%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BW.%2BY.%26aulast%3DIyyalol%26aufirst%3DR.%26aulast%3DMartin-Iverson%26aufirst%3DM.%2BT.%26atitle%3DDexamphetamine%2520effects%2520on%2520prepulse%2520inhibition%2520%2528PPI%2529%2520and%2520startle%2520in%2520healthy%2520volunteers%26jtitle%3DPsychopharmacology%26date%3D2014%26volume%3D231%26spage%3D2327%26epage%3D2337%26doi%3D10.1007%2Fs00213-013-3395-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Ramsey, A. J.</span><span> </span><span class="NLM_article-title">NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia</span> <span class="citation_source-journal">Prog. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">179</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1016/S0079-6123(09)17906-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0079-6123%2809%2917906-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=20302817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFekt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2009&pages=51-58&author=A.+J.+Ramsey&title=NR1+knockdown+mice+as+a+representative+model+of+the+glutamate+hypothesis+of+schizophrenia&doi=10.1016%2FS0079-6123%2809%2917906-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia</span></div><div class="casAuthors">Ramsey, Amy J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Brain Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">Genetic Models of Schizophrenia</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">PBRRA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6123</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  N-Me d-aspartate (NMDA) receptor subunit NR1 knockdown (NR1-KD) mice have a global redn. of NMDA receptors, enabling their use as a genetic model to study the role of NMDA receptors in the pathophysiol. of schizophrenia.  This targeted mutation results in a spectrum of altered behaviors that are similar to those induced by NMDA receptor antagonists, which have long been used to model schizophrenia in animals.  NR1-KD mice serve as a complementary tool to pharmacol. models, providing insight into the consequences of sustained NMDA receptor dysfunction in early brain development and throughout the life of the animal.  Though in many respects the phenotype of NR1-KD mice mimics that of acute NMDA receptor antagonism, there are also notable differences.  In this chapter we highlight some of the mol., behavioral, and neurophysiol. phenotypes of NR1-KD mice and compare these to pharmacol. models of NMDA receptor dysfunction.  Through the study of these models, our improved understanding of how the brain adapts to persistent NMDA receptor hypofunction may eventually suggest new therapeutic strategies for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGC4oH7Y4IUbVg90H21EOLACvtfcHk0liCb6YUpRDvqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFekt78%253D&md5=86ed6b4271427b0a9186acb6a897e2e4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0079-6123%2809%2917906-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0079-6123%252809%252917906-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DA.%2BJ.%26atitle%3DNR1%2520knockdown%2520mice%2520as%2520a%2520representative%2520model%2520of%2520the%2520glutamate%2520hypothesis%2520of%2520schizophrenia%26jtitle%3DProg.%2520Brain%2520Res.%26date%3D2009%26volume%3D179%26spage%3D51%26epage%3D58%26doi%3D10.1016%2FS0079-6123%2809%2917906-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Danion, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidailhet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berna, F.</span><span> </span><span class="NLM_article-title">Functional mechanisms of episodic memory impairment in schizophrenia</span> <span class="citation_source-journal">Can. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18399036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ktVShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2007&pages=693-701&author=J.+M.+Danionauthor=C.+Huronauthor=P.+Vidailhetauthor=F.+Berna&title=Functional+mechanisms+of+episodic+memory+impairment+in+schizophrenia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Functional mechanisms of episodic memory impairment in schizophrenia</span></div><div class="casAuthors">Danion Jean-Marie; Huron Caroline; Vidailhet Pierre; Berna Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of psychiatry. Revue canadienne de psychiatrie</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">693-701</span>
        ISSN:<span class="NLM_cas:issn">0706-7437</span>.
    </div><div class="casAbstract">OBJECTIVE:  To achieve a better understanding of the functional mechanisms underlying episodic memory dysfunction in schizophrenia, which is a prerequisite for unravelling schizophrenia's neural correlates in neuroimaging studies and, more generally, for developing an integrated approach to the pathophysiology of schizophrenia.  It is also crucial for developing cognitive remediation.  METHOD:  This paper reviews empirical evidence of episodic memory dysfunction in schizophrenia obtained with reference to various theoretical models of episodic memory.  RESULTS:  All the studies converge to show a significant impairment of the critical feature of episodic memory: conscious recollection.  Schizophrenia is also associated with a defect of autobiographical memory.  The episodic memory dysfunction results from a predominant failure of strategic processing at encoding, although an impairment of strategic processing at retrieval cannot be ruled out.  The possibility that it is not the execution of the encoding strategies that is defective but, rather, their self-initiation by the patients is plausible.  CONCLUSIONS:  These findings may explain some behavioural abnormalities associated with schizophrenia, notably, inadequate functional outcomes in everyday life.  They may also have implications for cognitive remediation and better social and work functioning of patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFFXwl23dMcekdrW1FkXG-fW6udTcc2eY7ot-iJR7hzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ktVShug%253D%253D&md5=c0be1020e3374f820431a86ba2643b51</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanion%26aufirst%3DJ.%2BM.%26aulast%3DHuron%26aufirst%3DC.%26aulast%3DVidailhet%26aufirst%3DP.%26aulast%3DBerna%26aufirst%3DF.%26atitle%3DFunctional%2520mechanisms%2520of%2520episodic%2520memory%2520impairment%2520in%2520schizophrenia%26jtitle%3DCan.%2520J.%2520Psychiatry%26date%3D2007%26volume%3D52%26spage%3D693%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Horiguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, H. Y.</span><span> </span><span class="NLM_article-title">The role of 5-HT<sub>1A</sub> receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats</span> <span class="citation_source-journal">Psychopharmacology (Berl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">221</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1007/s00213-011-2561-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1007%2Fs00213-011-2561-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=22227609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A280%3ADC%252BC38zpvFylsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=221&publication_year=2012&pages=205-215&author=M.+Horiguchiauthor=H.+Y.+Meltzer&title=The+role+of+5-HT1A+receptors+in+phencyclidine+%28PCP%29-induced+novel+object+recognition+%28NOR%29+deficit+in+rats&doi=10.1007%2Fs00213-011-2561-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats</span></div><div class="casAuthors">Horiguchi M; Meltzer H Y</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">221</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Atypical antipsychotic drugs (APDs), many of which are direct or indirect serotonin (5-HT)(1A) agonists, and tandospirone, a 5-HT(1A) partial agonist, have been reported to improve cognition in schizophrenia.  OBJECTIVES AND METHODS:  We tested the effect of 5-HT(1A) agonism, alone, and in combination with other psychotropic agents, including the atypical APD, lurasidone, in reversing the deficit in novel object recognition (NOR) induced by subchronic treatment with the non-competitive NMDA receptor antagonist, phencyclidine (PCP) (2 mg/kg, b.i.d., for 7 days).  RESULTS:  Subchronic treatment with PCP induced a persistent NOR deficit.  Lurasidone (0.1 mg/kg), a potent 5-HT(1A) partial agonist, 5-HT(2A) antagonist, and weaker D(2) antagonist, tandospirone (0.6 mg/kg), and the selective post-synaptic 5-HT(1A) agonist, F15599 (0.16 mg/kg), ameliorated the subchronic PCP-induced-NOR deficit.  The 5-HT(1A) antagonist, WAY100635 (0.6 mg/kg), blocked the ameliorating effects of tandospirone and lurasidone.  The combination of sub-effective doses of tandospirone (0.2 mg/kg) and lurasidone (0.03 mg/kg) also reversed the PCP-induced NOR-deficit.  Buspirone, a less potent partial 5-HT(1A) agonist than tandospirone, was less effective.  Co-administration of tandospirone (0.2 mg/kg) and pimavanserin (3 mg/kg), a relatively selective 5-HT(2A) receptor inverse agonist, did not reverse the effect of sub-chronic PCP on NOR.  The D(2) antagonist, haloperidol, blocked the ameliorating effect of tandospirone on the PCP-induced deficit in NOR.  CONCLUSIONS:  These results indicate that 5-HT(1A) agonism is adequate to ameliorate the PCP-induced impairment in NOR and suggest further study of utilizing the combination of a 5-HT(1A) agonist and an atypical APD to ameliorate some types of cognitive impairment in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_kRq9BE6ZfrHHuJhbyicZfW6udTcc2eY7ot-iJR7hzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zpvFylsg%253D%253D&md5=3e92009a015042f003e926f20280090f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2Fs00213-011-2561-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-011-2561-4%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DM.%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DThe%2520role%2520of%25205-HT1A%2520receptors%2520in%2520phencyclidine%2520%2528PCP%2529-induced%2520novel%2520object%2520recognition%2520%2528NOR%2529%2520deficit%2520in%2520rats%26jtitle%3DPsychopharmacology%2520%2528Berl%2529%26date%3D2012%26volume%3D221%26spage%3D205%26epage%3D215%26doi%3D10.1007%2Fs00213-011-2561-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levesque, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wacker, D. A.</span><span> </span><span class="NLM_article-title">Position 5.46 of the serotonin 5-HT<sub>2A</sub> receptor contributes to a species-dependent variation for the 5-HT<sub>2C</sub> agonist (<i>R</i>)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1211</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1124/mol.109.059204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1124%2Fmol.109.059204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=1211-1219&author=K.+J.+Millerauthor=G.+Y.+Wuauthor=J.+G.+Varnesauthor=P.+Levesqueauthor=J.+L.+Liauthor=D.+S.+Liauthor=J.+A.+Roblauthor=K.+A.+Rossiauthor=D.+A.+Wacker&title=Position+5.46+of+the+serotonin+5-HT2A+receptor+contributes+to+a+species-dependent+variation+for+the+5-HT2C+agonist+%28R%29-9-ethyl-1%2C3%2C4%2C10b-tetrahydro-7-trifluoromethylpyrazino%5B2%2C1-a%5Disoindol-6%282H%29-one%3A+impact+on+selectivity+and+toxicological+evaluation&doi=10.1124%2Fmol.109.059204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.059204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.059204%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DLevesque%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DLi%26aufirst%3DD.%2BS.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DRossi%26aufirst%3DK.%2BA.%26aulast%3DWacker%26aufirst%3DD.%2BA.%26atitle%3DPosition%25205.46%2520of%2520the%2520serotonin%25205-HT2A%2520receptor%2520contributes%2520to%2520a%2520species-dependent%2520variation%2520for%2520the%25205-HT2C%2520agonist%2520%2528R%2529-9-ethyl-1%252C3%252C4%252C10b-tetrahydro-7-trifluoromethylpyrazino%255B2%252C1-a%255Disoindol-6%25282H%2529-one%253A%2520impact%2520on%2520selectivity%2520and%2520toxicological%2520evaluation%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D1211%26epage%3D1219%26doi%3D10.1124%2Fmol.109.059204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sipes, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, M. A.</span><span> </span><span class="NLM_article-title">DOI disrupts prepulse inhibition of startle in rats via 5-HT<sub>2A</sub> receptors in the ventral pallidum</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">761</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1016/S0006-8993(97)00316-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1016%2FS0006-8993%2897%2900316-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=9247071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADyaK2sXjslKmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=1997&pages=97-104&author=T.+E.+Sipesauthor=M.+A.+Geyer&title=DOI+disrupts+prepulse+inhibition+of+startle+in+rats+via+5-HT2A+receptors+in+the+ventral+pallidum&doi=10.1016%2FS0006-8993%2897%2900316-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum</span></div><div class="casAuthors">Sipes, Thomas E.; Geyer, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-104</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Serotonin (5-HT)2A receptors are known to be involved in prepulse inhibition of the startle response (PPI), a measure of sensorimotor inhibition that is deficient in schizophrenia, Huntington's disease, and obsessive compulsive disorder.  In the present studies, the localization of the 5-HT2A receptors responsible for modulating PPI was investigated using central injections of the hallucinogenic 5-HT2 agonist DOI and the novel 5-HT2A antagonist MDL 100,907. 5-HT2A receptors are densely localized in the nucleus accumbens (NAC) and the ventral pallidum (VP), areas known to be important components of neural circuitry that mediates the ventral forebrain modulation of PPI.  In the present studies, it was found that the infusion of DOI (0.0-5.0 μg/0.5 μl) into the VP disrupted PPI without having effects on startle reactivity.  In contrast, similar infusions into the NAC had no effect on PPI or startle reactivity.  The infusion of MDL 100,907 into the VP was found to increase PPI by itself and to attenuate the PPI-disruptive effects of systemically administered DOI.  It is concluded that 5-HT2A receptors within the VP are important for the modulation of PPI, presumably through interactions at intrinsic GABAergic or cholinergic interneurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqujK_adxkw-7Vg90H21EOLACvtfcHk0ljWy0FnsK2EVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjslKmtr4%253D&md5=570d99fc158d624abadda32ea6ab99c9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2897%2900316-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252897%252900316-8%26sid%3Dliteratum%253Aachs%26aulast%3DSipes%26aufirst%3DT.%2BE.%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DDOI%2520disrupts%2520prepulse%2520inhibition%2520of%2520startle%2520in%2520rats%2520via%25205-HT2A%2520receptors%2520in%2520the%2520ventral%2520pallidum%26jtitle%3DBrain%2520Res.%26date%3D1997%26volume%3D761%26spage%3D97%26epage%3D104%26doi%3D10.1016%2FS0006-8993%2897%2900316-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title"><i>N</i>-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT<sub>1A</sub> agonist, as a putative mediator of quetiapine’s antidepressant activity</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2303</span><span class="NLM_x">–</span> <span class="NLM_lpage">2312</span><span class="refDoi"> DOI: 10.1038/sj.npp.1301646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fsj.npp.1301646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=18059438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=2303-2312&author=N.+H.+Jensenauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=W.+C.+Wetselauthor=R.+B.+Rothmanauthor=B.+L.+Roth&title=N-Desalkylquetiapine%2C+a+potent+norepinephrine+reuptake+inhibitor+and+partial+5-HT1A+agonist%2C+as+a+putative+mediator+of+quetiapine%E2%80%99s+antidepressant+activity&doi=10.1038%2Fsj.npp.1301646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity</span></div><div class="casAuthors">Jensen, Niels H.; Rodriguiz, Ramona M.; Caron, Marc G.; Wetsel, William C.; Rothman, Richard B.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2303-2312</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quetiapine is an atypical antipsychotic drug that is also US FDA approved for treating bipolar depression, albeit by an unknown mechanism.  To discover the potential mechanism for this apparently unique action, we screened quetiapine, its metabolite N-Desalkylquetiapine, and dibenzo[b,f][1,4]thiazepine-11(10-H)-one (DBTO) against a large panel of G-protein-coupled receptors, ion channels, and neurotransmitter transporters.  DBTO was inactive at all tested mol. targets.  N-Desalkylquetiapine had a high affinity (3.4 nM) for the histamine H1 receptor and moderate affinities (10-100 nM) for the norepinephrine reuptake transporter (NET), the serotonin 5-HT1A, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT7 receptors, the α1B-adrenergic receptor, and the M1, M3, and M5 muscarinic receptors.  The compd. had low affinities (100-1000 nM) for the 5-HT1D, 5-HT2C, 5-HT3, 5-HT5, 5-HT6, α1A, α2A, α2B, α2C, H2, M2, M4, and dopamine D1, D2, D3, and D4 receptors.  N-Desalkylquetiapine potently inhibited human NE transporter with a Ki of 12 nM, about 100-fold more potent than quetiapine itself.  N-Desalkylquetiapine was also 10-fold more potent and more efficacious than quetiapine at the 5-HT1A receptor.  N-Desalkylquetiapine was an antagonist at 5-HT2A, 5-HT2B, 5-HT2C, α1A, α1D, α2A, α2C, H1, M1, M3, and M5 receptors.  In the mouse tail suspension test, N-Desalkylquetiapine displayed potent antidepressant-like activity in VMAT2 heterozygous mice at doses as low as 0.1 mg/kg.  These data strongly suggest that the antidepressant activity of quetiapine is mediated, at least in part, by its metabolite N-Desalkylquetiapine through NET inhibition and partial 5-HT1A agonism.  Possible contributions of this metabolite to the side effects of quetiapine are discussed.  Neuropsychopharmacol. (2008) 33, 2303-2312; doi:10.1038/sj.npp.1301646; published online 5 Dec. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3ZgCGV-N8xrVg90H21EOLACvtfcHk0ljWy0FnsK2EVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSisbs%253D&md5=1ed7827ed03ba02899e51cc8e2f1c554</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301646%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DN-Desalkylquetiapine%252C%2520a%2520potent%2520norepinephrine%2520reuptake%2520inhibitor%2520and%2520partial%25205-HT1A%2520agonist%252C%2520as%2520a%2520putative%2520mediator%2520of%2520quetiapine%25E2%2580%2599s%2520antidepressant%2520activity%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D2303%26epage%3D2312%26doi%3D10.1038%2Fsj.npp.1301646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Park, S. M.; Chen, M.; Schmerberg, C. M.; Dulman, R. S.; Rodriguiz, R. M.; Caron, M. G.; Jin, J.; Wetsel, W. C.</span><span> </span><span class="NLM_article-title">Effects of β-arrestin biased dopamine D<sub>2</sub> receptor ligands on schizophrenia-like behavior in hypoglutmatergic mice</span>.  <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span>in press, <span class="refDoi"> DOI: 10.1038/npp.2015.196</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+M.+Park&author=M.+Chen&author=C.+M.+Schmerberg&author=R.+S.+Dulman&author=R.+M.+Rodriguiz&author=M.+G.+Caron&author=J.+Jin&author=W.+C.+Wetsel&title=Effects+of+%CE%B2-arrestin+biased+dopamine+D2+receptor+ligands+on+schizophrenia-like+behavior+in+hypoglutmatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26atitle%3DEffects%2520of%2520%25CE%25B2-arrestin%2520biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520schizophrenia-like%2520behavior%2520in%2520hypoglutmatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Geyer, M. A.; Swerdlow, N. R.</span><span> </span><span class="NLM_article-title">Measurement of startle response, prepulse inhibition, and habituation.</span> <span class="citation_source-book">Current Protocols in Neuroscience</span>; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">; </span>Chapter 8, 8.7.1–8.7.15.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;key=10.1002%2F0471142301.ns0807s03" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=M.+A.+Geyer&author=N.+R.+Swerdlow&title=Current+Protocols+in+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2F0471142301.ns0807s03&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471142301.ns0807s03%26sid%3Dliteratum%253Aachs%26aulast%3DGeyer%26aufirst%3DM.%2BA.%26atitle%3DMeasurement%2520of%2520startle%2520response%252C%2520prepulse%2520inhibition%252C%2520and%2520habituation.%26btitle%3DCurrent%2520Protocols%2520in%2520Neuroscience%26pub%3DWiley%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01153">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43103"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01153">10.1021/acs.jmedchem.5b01153</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic procedures for compounds <b>16a</b>–<b>g</b>, <b>18a</b>–<b>g</b>, and <b>19a</b>–<b>g</b>, and characterization data of all chemical intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds (−)-<b>20a</b>–<b>g</b>, (+)-<b>20a</b>–<b>g</b>, (−)-<b>21a</b>–<b>g</b>, (+)-<b>21a</b>–<b>g</b>, (−)-<b>22a</b>–<b>g</b>, and (+)-<b>22a</b>–<b>g</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_002.pdf">jm5b01153_si_002.pdf (455.19 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01153/suppl_file/jm5b01153_si_003.csv">jm5b01153_si_003.csv (4.5 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01153&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-2%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01153%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01153" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679945df9b1423e0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
